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Platensimycin/platencin are recently discovered natural products that inhibit 
membrane formation in bacteria and cyclic diguanylic acid (c-di-GMP) is a master 
regulator of bacterial biofilm formation. The rise of bacterial antibiotic resistance and the 
dwindling pipeline of new antibiotics make these molecules of interest to the scientific 
community. This dissertation reports the design, synthesis and biological evaluation of 
analogs of platensimycin/platencin and c-di-GMP.  
Platensimycin and platencin have garnered interest from synthetic c mists due to 
the complexity of their molecular architecture, coupled with their exciting biological 
profile (inhibition of bacterial fatty acid synthases). We have developed a concise 
synthetic approach towards the platensimycin/platencin class of antibiotics. The highlight 
of our synthesis is the use of dynamic ring-closing metathesis to prepare a bicyclo 
intermediate and a tandem nucleophilic addition of organolithium to a ketone moiety, 
followed by a subsequent ring opening of a nearby epoxide to generat complex tricyclic 
framework. 
The synthesis of platensimycin or closely related analogs requires multi-steps 
(average of 17 overall steps). Using a function-oriented synthetic approach, we developed 
short syntheses of N,N-dialkyl benzoic acid derivatives of platensimycin, and we 
demonstrate that these readily prepared molecules have comparable anti iotic properties 
to the difficult-to-synthesize platensimycin/platencin. 
C-di-GMP has been dubbed the master regulator of bacterial “lifesty e” due to the 
key role that this molecule plays in bacterial biofilm formation and virulence formation. 
In order to study c-di-GMP signaling in bacteria, with the ultimate goal of using key 
insights gained from such studies to develop anti-biofilm or anti-virulence agents, we 
prepared analogs of c-di-GMP and studied their biophysical and biologica  profiles. 
Interestingly, we reveal that conservative modifications to c-di-GMP affect both the 
biophysical and biochemical properties of this molecule. We also demnstrate a concept 
called “conformational steering” as a powerful principle to selectively target different 
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Chapter  1. Introduction 
1.1  Bacterial antibiotic resistance problem 
(The majority of this section was published in ref [1].) 
The discovery of several antibiotics between the 1930s and 1960s led to effec iv  
management of previously lethal bacterial infections [2,3]. Several l thal epidemic 
diseases, caused by bacteria, were even considered extinct around 1980 in the western 
world (e.g. bubonic plague [4]). This success story did not last long, and soon multi-drug 
resistant bacteria (the so-called superbugs) emerged in hospital wards. It is hypothesized 
that the indiscriminate use of antibiotics  in both hospitals [5,6] and animal farms [7] and 
pollution of the environment with antibiotics, which are added to general household 
products [8], contribute the rise of antibiotic resistance in bacteria. 
Modern use of antibiotics probably began with the administration of sulfonamides 
(e.g. prontosil, compound 1–1 in Figure 1–1) and penicillins (e.g. penicillin G, 
compound 1–2) to patients. Penicillin was once called the “magic drug”, and it 
contributed to reducing the number of deaths among soldiers in World War II, who were 
infected with Streptococcus pneumonia [9]. After early resistance to penicillin was 
observed [10-12], a new generation of β-lactam antibiotics, such as methicillin (1–3), 
cephalothin (1–4) and imipenem (1–5), were developed [13]. In 1964, a methicillin-
resistant strain of S. aureus (MRSA) was isolated [14,15]. Sooner thereafter, other 
bacterial strains that were resistant to various antibiotics, e.g. streptomycin [16,17] (1–8), 
chloramphenicol [18] (1–9) and tetracycline [19,20] (1–6) were also identified. It is now 
widely recognized that bacteria can develop resistance to almost any antibiotic. 
2 
 
Table 1–1 lists several classical antibiotics and showcases the severity of the 
antibiotic resistance issue. With the exception of few antibiotics, e.g. vancomycin (1–14), 
bacteria developed resistance to most antibiotics within 15 years afte  their first clinical 
use. In the case of vancomycin [21], it took almost three decades, ft r the drug was first 
introduced into the US market, for scientists to observe the emergenc  of resistant 
bacteria strains (Table 1–1, Entry 7). 
In the last few decades, scientists have put tremendous efforts into researching the 
mechanisms of antibiotic resistance. The three main strategies that are used by bacteria to 
develop resistance to antibiotics are: 
1) Overexpression of enzymes that can modify the antibiotic to make it less 
effective.  
2) Mutation of the antibiotic target site so that the target (e.g. nzymes) can 
maintain its function but not bind to the antibiotic. 
3) Export of the antibiotic to the extracellular media by multidrug- esistant (MDR) 




Table 1–1. Structural classes, modes of action and antibiotic resistance mechanisms of selected antibiotics 








Prontosil (1-1) sulfonamides 1935 Inhibition of DNA/RNA synthesis (binds to dihydropteroate 
synthase ) 
1943[22] 








amphenicols 1947 Inhibition of protein synthesis (binds to the 23S site of 50S rRNA) 1950[18] 
5 Tetracycline (1-6) tetracycline 1948 Inhibition of protein synthesis (binds to the 16S site of 30S rRNA) 1963[19,20] 
6 Erythromycin (1-7) macrolides 1952 Inhibition of protein synthesis (binds to the 23S site of 50S rRNA) 1956[23] 
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Polymyxin B  
(1-17) 
polypeptides 1960s Disrupt outer and inner membranes (binds to lipopolysaccharide) 1975[24] 




quinolones 1987[a] Inhibition of DNA replication (binds to bacterial DNA gyrase) 1990[25,26] 
11 Cephalothin (1-4) β-lactams 1964 Inhibition of cell wall synthesis (binds to transpeptidase) 1965[27] 
12 
Rifampicin (1-12) rifamycins 1967 Inhibition of RNA synthesis (binds  to RNA polymerase β 
subunit) 
1968[28,29] 
13 Clindamycin (1-16) lincosamides 1969 Inhibition of protein synthesis (binds to the 23S site of 50S rRNA) 1970[30,31] 




streptogramin 1999[b] Inhibition of protein synthesis (binds to the 23S site of 50S rRNA) 1999[34,35] 
16 Linezolid (1-10) oxazolidinones 2000 Inhibition of protein synthesis (binds to the 23S site of 50S rRNA) 2001[36,37] 
17 Daptomycin (1-15) lipopeptides 2003 Depolarization of bacterial membrane 2005[38] 
[a] Other quinolones were discovered in the 1960’s; [b] other streptogramin antibiotics were developed prior to this year including v rginiamycin 




Figure 1–1. Chemical structures of antibiotics 
 
β-Lactam drugs such as penicillin G (Figure 1–1, compound 1–2), methicillin (1–
3), cephalothin (1–4) and imipenem (1–5) are mainly inactivated via the overexpression 
of β-lactamases, which hydrolyze the antibiotics [39]. For an excellent review on the 
mechanism of action of β-lactamases, see ref [40]. Resistance to β-lactams via β-
lactamase-mediated hydrolysis can be minimized when the β-lactam antibiotic is used in 
combination with β-lactamase inhibitors such as clavulanic acid [41], tazobactam[42] and 
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sulbactam [43]. Both clavulanic acid and sulbactam irreversibly inactivate β-lactamases 
[41,44]. Unfortunately there are documented cases where some bacterial strains have 
been shown to be resistant to these β-lactamase inhibitors – a very worrisome scenario 
[45,46].  
Another antibiotic class, aminoglycosides, including streptomycin (1–8, Figure 
1–1) and tobramycin, can inhibit bacterial ribosome function and hence inhibit protein 
synthesis [47,48]. Aminoglycosides are rendered ineffective by bacteria via the 
overexpression of antibiotic-modifying enzymes, such as nucleotidyltransferase or 
phosphotransferase, which transfer a monophosphate moiety from ATP to a hydroxyl on 
the ring of an aminoglycoside [49]. Other aminoglycoside modifying enzymes include N-
acetyltransferases and O-adenyltransferases. These two enzymes catalyze acetyl CoA-
dependent acetylation of the amino functionality (1–8) and ATP-dependent adenylation 
of the hydroxyl group (1–8), respectively [49]. Other protein synthesis inhibitor 
antibiotics, such as the streptogramins and oxazolidinones (e.g. linezolid), are made 
ineffective via the modification of the 23S site of 50S ribosomal RNA in bacteri  [50,51].  
 Bacteria can also use multiple pathways to inactivate an antibiotic. For example, 
resistance to vancomycin (1–14) can occur via thickening of the bacterial cell wall [52], 
changing the peptidoglycan precursor [53,54] or expression of an ‘abnormal’ ligase that 
makes the unusual Ala-lactate peptide bond [55,56].  
Efflux pump proteins such as AcrA and AcrB in E. coli [57,58], the MexA-
MexB-OprM systems in P. aeruginosa [59,60] and NorA in S. aureus [61] export 
antibiotics out of bacterial cells, thereby raising the MIC (mini um inhibitory 
concentration) values of antibiotics. Proton motive force inhibitor (or commonly referred 
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to as energy uncoupler), carbonyl cyanide m-chlorophenylhydrazone (CCCP) [62,63] and 
MDR (multidrug-resistant) efflux pump inhibitors e.g. L-phenylalanine-L-arginine-β-
naphthylamide dihydrochloride (PAβND) [64,65],  reserpine [66,67], biricodar [68] and 
timcodar [68] have been shown to potentiate the antibiotic activity of conventional 
antibiotics. The widespread use of MDR efflux inhibitors as combinatio  therapeutics is 
probably not as popular as the use of β-lactamase inhibitors, due to the dearth of effective 
but non-toxic bacterial MDR efflux pump inhibitors.  
After years of the development of second- and third-generation antibiotics, which 
ultimately suffered from bacterial resistance, two new drugs were introduced at the 
beginning of the new millennium: daptomycin (compound 1–15, Figure 1–1) [69,70] and 
linezolid (1–10) [71,72].  Linezolid (1–10) is a synthetic oxazolidinone antibiotic, which 
was initially effective against vancomycin-resistant E terococci (VRE) and MRSA [72]. 
Linezolid inhibits protein synthesis by binding to the 23S site of the 50S ribosome RNA 
[73]. Although its action is similar to the macrolides and amphenicols, no cross-resistance 
was observed [71]. Regretfully, linezolid resistance was reportd in VRE and MRSA 
only a few years after it was introduced [36,74]. Daptomycin (1–15), a natural 
lipopeptide antibiotic, was also introduced in the early 21st century. Daptomycin kills 
bacteria via a novel mode of action involving binding to the bacterial cell wall and 
depolarizing the cell membrane [75]. Again, the early excitement regarding daptomycin’s 
ability to kill MRSA and VRE was diminished upon the identification f strains of 
MRSA and VRE that were resistant to daptomycin (1–15) [76,77]. Only a handful of 
antibiotics have been approved by the United States FDA for clinical use in the past few 
years (see Table 1–2 and Figure 1–2) [78-84]. Worryingly, these newer antibiotics (with 
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the exception of retapamulin) are merely derivatives of older generation antibiotics. Since 
the newer antibiotics are acting on the same targets, which have been shown to be 
evolvable, it would be naive to think that the newly introduced antibiotics will not 
ultimately suffer from bacterial resistance.  
Retapamulin (compound 1–21, Figure 1–2), introduced in 2007, belongs to a new 
class of antibiotics called pleuromutilins. It inhibits protein biosynthesis by binding to the 
peptidyl transferase center of the 23S ribosomal RNA, which is located on the 50S 
subunit and, thus, prevents peptide bond formation [85,86]. Retapamulin (1–21) may also 
destabilize transfer RNA in the P-site of the 50S subunit [86]. However, bacteria have 
shown in the past that ribosomal targets can be modified in order to ab ogate antibiotic 
inhibition, and there is no reason to suggest that the 50S ribosome RNA is not evolvable.  
The previous discussion highlights an unsavory truth: we are in a never-ending 
battle against pathogenic bacteria. The ability of bacteria to find several pathways to 
render a bacteriocidal or bacteriostatic antibiotic ineffective, coupled with the lack of 
newer druggable targets in bacteria and the paucity of new structural classes of antibiotics, 






Figure 1–2. Chemical structures of recently approved antibiotics. 
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1.2  Fatty acid biosynthesis – untapped opportunities to develop novel antibiotics 
1.2.1  Introduction of fatty acid biosynthesis and its inhibition 
Fatty acids play a key role in bacterial cellular structures and functions. Therefore, 
fatty acid synthases (FAS) are considered promising targets for he development of new 
antibiotics to resolve the rising drug resistant problem [87-91].  
Fatty acids are key components of phospholipid and lipid A, important 
components of cell envelope in Gram-positive (e.g. S  aureus) and Gram-negative (e.g. E
coli) bacteria. Phospholipid (Figure 1–3b) is the major constituent of cellular membrane 
of almost all bacteria strains [92], whereas lipid A is mostly found in Gram-negative 
bacteria [93]. Unlike the cell wall of Gram-positive bacteria (Figure 1–3a), which mainly 
consists of peptidoglycan and teichoic acids, the cell wall of Gram-negative bacteria have 
a second membrane which contains lipopolysaccharides and lipoproteins (Figure 1–3c); 
and this lipid component is termed lipid A (Figure 1–3d). Among all the bacteria strains, 
the fatty acid biosynthesis of E. coli is the most extensively studied, and the biosynthesis 
pathways in this organism are summarized in Scheme 1–1.  
 The cell envelope (i.e. the cell membrane and cell wall) of M. tuberculosis (MTB) 
is distinct from either typical Gram-positive or -negative bacteria (Figure 1–3d). MTB 
infections are difficult to treat, and the World Health Organization reported in 2010 that 
there are still about two billion people in the world who carry MTB and that more than 
two million people die from MTB infections each year in the world [94,95]. This makes 
MTB the number one killer bacteria in the world. Fatty acids make up to approximately 
60 % of the dry weight of a MTB bacterium. Among the MTB fatty acids, long-chain 
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mycolic acid (e.g. α-mycolic acid, Figure 1–3f), which is unique to MTB, is one of the 
best studied. The biosynthesis of α-mycolic acid is well characterized (Scheme 1–2).  
In summary, the inhibition of fatty acid synthesis will disrupt bacterial cell 
envelope formation and function. The intermediates in the fatty acid biosynthesis 
pathways are also used in cellular regulation and metabolism. For example, in quorum 
sensing (bacterial communication) of V. fisheri, the signal molecule (acyl homoserine 
lactone) is synthesized from hexanoyl-ACP (ACP = acyl carrier protein) [96]. Also, lipid 
A in Gram-negative bacteria pathogens is not only used as a shield to the external 
chemical insult, but is also responsible for the toxic syndrome associ ted with bacterial 
infection by inhibiting the activation of human immune system [97]. 
The next section will focus on the mechanisms of the fatty acid biosynthesis in E. 
coli and mycolic acid biosynthesis in MTB. Some mechanisms (e.g. elongation steps) of 
FAS enzymes for many other bacteria strains (e.g. Gram-positive bacteria) are expected 
to be similar to these two strains.  
 
 
Figure 1–3. a) The cell wall structure
structure of phospholipid; c
including an outer membrane
micrograph of the cell wall structure of 
(source: National Institute of Allergy and Infectious Diseases
 
 
 for Gram-positive bacteria [98]
) the cell wall structure of a regular Gram-negative bacteri
; d) chemical structure of Kdo2-lipid A 
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Fatty acid biosynthesis can be classified into two categories, type I and type II, 
according to their genetic features. Type I fatty acid synthesis has mainly been found in 
eukaryotes (e.g. mammal, bird and yeast cell) and very rarely in prokaryotes (e.g. 
mycobacteria cell). Type II fatty acid synthesis is mainly found in prokaryotes (bacteria) 
and some plants [101]. Type I FAS in most eukaryotes are encoded by one single gene, 
and the substrate does not fall off the multifunctional enzyme before synthesis is 
completed [102,103]. For example, the whole metabolic pathway for making 16-carbon 
fatty acids in yeast is carried out by a 2.6 MDa fatty acid synthase, which contains eight 
different active sites for catalysis [104]. On the other hand, the FAS enzymes of most 
prokaryotes are encoded by discrete genes, and these enzymes belong to type II.  
MTB has both type I and type II FAS. During the biosynthesis of mycolic acid, 
type I FAS first synthesizes a 20-carbon fatty acid, and then type II FAS takes this 20-
carbon substrate and continues with the synthesis of mycolic acid (Scheme 1–2).  
Generally speaking, type I FAS is more efficient than type II, and the products of 
type I are less diverse than type II [105,106]. Type II FAS can produce various chain 
lengths, unsaturated chains, branch chains, cyclic chains and hydroxy fatty acids [107]. 
Type I FAS (mostly in eukaryotes), on the other hand, usually only produces saturated, 
straight chain 16-carbon palmitic acid [105]. Despite the fact that the overall architectures 
of type I and II FAS enzymes are different, the catalytic mehanisms for the enzymatic 
reactions or the active site architectures of the enzymes are similar. Consequently, some 
small molecules can inhibit both type I and II FAS enzymes. For example, cerulenin is a 
potent inhibitor of bacterial type II FAS and can also inhibit type I FAS enzymes in 
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mammals [108].Cerulenin is a transition-state mimetic and is bound to FAS enzymes via 
a covalent linkage [109,110]. 
Some amino acid sequences of type II FAS enzymes are highly conserved. For 
example, the His-His-Cys catalytic triad is present in all of the condensing enzymes that 
are involved in the elongation steps (FabF and FabB) [111]. The conservation of he His-
His-Cys catalytic triad in most FAS elongation enzymes presents a good opportunity to 
design small molecules that could inhibit FAS in diverse bacteria.  
 
1.2.2 Modes of action of type II fatty acid biosyntheses 
Bacterial fatty acid biosynthesis has three modules: initiation, elongation and 
termination (Scheme 1–1 outlines the fatty acid biosynthesis in E. coli). It should be 
pointed out that in most bacteria, the strategies and/or mechanisms used to elongate fatty 
acids are similar to those used in E. coli, although alternative mechanisms may exist in 




Scheme 1–1. Fatty acid biosynthesis inE. coli. During initiation step, acetyl-CoA is converted into malonyl-ACP (int 1), catalyzed by 
Acc protein and FabD. This is followed by a decarboxylative condensatio , catalyzed by FabH to give acetoacetyl-ACP (int 2). 
During the elongation phase, two carbons are added in each cycle (step a–d). When a threshold chain length is reached, an 




Scheme 1–2. Biosynthesis of α-mycolic acid. Co-existance of type I and type II FAS system in bacteria is very rarely observed but 
occurs in mycobacteria. A 20-carbon long CoA thioester, synthesized by type I FAS system, is further extended by type II FAS to give 
an unsaturated 22-carbon CoA thioester (int 3). Subsequent elongations (recurring) then afford bis-alkene (int 4), which is then acted 
upon by cyclopropanase to give monomycolate (int 5).  Monomycolate (int 5) is modified by FadD32 and a multidomain protein 
Pks13 to furnish the final product α-mycolic acid [112]. 
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In E. coli, the initiation phase of fatty acid synthesis starts with the conversion of 
acetyl-CoA into malonyl-CoA, catalyzed by acetyl-CoA carboxylases (ACC). The ACC 
reaction requires four discrete enzymes, AccA, AccB, AccC and AccD, and the overall 
reaction is a biotin-dependent carboxylation of acetyl-CoA to form malonyl-CoA [113]. 
MTB has a similar initiation phase (not shown in Scheme 1–2). ACC is considered to be 
a promising target for antibiotic discovery. For example, NCI-65828 (see Figure 1–7; a 
small molecule belonging to the NCI small molecule diversity se) has a Ki value of 13 
µM to AccD5 (i.e. β5 subunit of AccD) of MTB [114].  
One of the most abundant proteins in the bacterial cell is acyl crrier protein 
(ACP). ACP (< 9,000 Da in most cases) is a small and diffusible protein and is a 
necessary enzyme for the initiation step of fatty acid synthesis in all bacteria strains. ACP 
is converted from an inactive to an active form by ACP synthase (AcpS) from apo-ACP. 
Several inhibitors of AcpS that are effective in various bacterial str ins have been 
discovered. For example, anthranilic acid and analogs have MICs around 32 µM against S. 
aureus (MRSA) and B. subtilis (168) [115]. The activated ACP then reacts with malonyl-
CoA to form malonyl-ACP via a reaction that is catalyzed by transacylase (FabD, see 
Scheme 1–1). From this point on, the ACP will be a cofactor protein for all of the 
subsequent reactions until the acyl chain is transferred to the termination steps. For E. 
coli, malonyl-ACP can directly enter the elongation cycle by reacting with an acetyl-CoA 
catalyzed by FabH (Scheme 1–1). Whereas for MTB, malonyl-ACP first reacts with a 
20-carbon ester, catalyzed by FabH, to give a 1,3-keto thioester, which is then converted 
to a β,γ-unsaturated ACP thioester by reductase, dehydrase and isomerase enzym s (FAS-
II-A, Scheme 1–2). The mode of action of the dehydrase/isomerase in MTB FAS-II-  
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pathway is still not clear. The resulting β,γ-unsaturated ACP thioester (22-carbon) then 
enters the elongation steps (FASII, Scheme 1–2). For either E. coli or MTB, four types of 
enzymes are involved in the elongation cycle: β-ketoacyl-ACP synthases (KAS), β-
ketoacyl-ACP reductase (KR), β-hydroxyacyl-ACP dehydrase (HD) and enoyl-ACP 
reductase (ER) (Scheme 1–1). The acyl chain is elongated via the addition of two 
carbons during each cycle.  
There are three known β-ketoacyl-ACP synthases (KAS) in E. coli, FabH, FabF 
and FabB. These three KAS enzymes all belong to the thiolase superfamily [111], which 
catalyze Claisen condensation reactions. Thus the KAS enzymes are also called 
condensing enzymes or KAS I–III in various literature reports (e.g. ref [116]). In MTB 
the three enzymes are referred to as FabH, KasA and KasB. FbH only catalyzes the first 
two condensation reactions in E. coli. For the first condensation, E. coli uses acetyl-CoA 
as the primer and malonyl-ACP as the acceptor to form the acetoacetyl-ACP as the 
product. For the second elongation cycle, the 4-carbon thioester ACP is used as primer 
instead [117]. Longer chains (C6 and up) require FabF and FabB for the condensation 
reactions. FabB is not efficient at elongating intermediates with long, saturated side 
chains, whereas FabF can elongate intermediates with both saturated and unsaturated side 
chains [116]. For MTB, FabH only catalyzes the first condensation reaction before the 
elongation (FASII, Scheme 1–2). The active site of FabH (both E. coli and MTB) 
contains a His-Asn-Cys catalytic triad, whereas those of both FabF and FabB have a His-
His-Cys triad. Figure 1–4 shows the catalytic mechanism of spFabF (sp means the 
protein was from Streptococcus pneumoniae) [118]. The thiol in the active site (Cys164) 
is activated into a thiolate, and the nucleophilic thiolate then attacks the carbonyl-ACP 
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substrate and transfers the acyl group. His303 and His337 are both protonated, and they 
stabilize the negative charge on the malonyl-ACP. After decarboxylation, the formed 
carbonanion will then attack the thioester on Cys164 [118]. It is also worth-noting that 
during the second thioester transfer, the amide bonds of Cys164 and Phe396 can stabilize 
the oxyanion intermediate via two hydrogen bonds, and this oxyanion binding site is 
usually refer as to an “oxyanion hole” in literature (Figure 1–4) [111]. The basic 
mechanisms of all the condensing enzymes are the same. For FabH, one of the histidines 
at the active site is replaced by an asparagine. In E coli, FabF and FabB are homologous 
with 37 % sequence identity [87]. Consequently, FabB/F inhibitors often have similar 
structural features [87]. The best FabH and FabB/F inhibitors to Gram-positive bacteria 
discovered so far are platencin [119] and platensimycin [120] respectively.  Platencin has 
an IC50 value of 16 µM against FabH [119], and platensimycin has an IC50 value of 0.048 
µM against FabF in S. aureus [120]. In MTB, KasA and KasB are homologs of ecFabB 
and ecFabF (ec means E. coli), respectively [121].  
 
 
Figure 1–4. The catalytic mechanism of S. pneumoniae FabF [118].  
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KR (β-ketoacyl-ACP reductase, usually referred to as FabG) is a NADPH-
dependent reductase that converts β-ketoacetyl-ACP into β-hydroxyacyl-ACP [87]. 
Analysis of the X-ray crystal structure of KR (PDB code: 1Q7B) suggests that the 
hydride transfer from NADPH to the ketone carbon is probably facilit ted by a Ser-Tyr-
Lys hydrogen bonding relay (Figure 1–5). And this Ser-Tyr-Lys triad was found in 
various bacteria strains, including Streptococcus pneumonia [122], E. coli [123] and 
MTB (in MTB, KR is often referred to as MabA) [124].  
 
 
Figure 1–5. The catalytic mechanism of S. pneumoniae FabG [122].  
 
In E. coli, β-hydroxyacyl ACP is dehydrated by HD (β-hydroxyacyl-ACP 
dehydrase), which is either FabZ or FabA. FabA is a bifunctional e zyme in E. coli that 
can dehydrate/ isomerize the substrate to give unsaturated intermediates or products. It is 
worth-noting that FabA is very narrow distributed in bacteria, and has only been observed 
in Gram-negative α- and γ-proteobacteria till today [125]. It is still unclear how MTB 
isomerize the double bonds via FAS-II-A and B (Scheme 1–2). Gram-positive bacteria 
do not have the homolog of ecFabA either. In E terococcus faecalis, FabZ1 is the 
equivalent bifunctional isomerase/ dehydrase [125].  
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FabI, a NADH-dependent ER (enoyl-ACP reductase), is the last player to 
complete the elongation process of fatty acids in E. coli. Three other isoforms of ER in 
other bacteria strains, FabK, FabL and FabV, are also found [126]. Some bacteria strains 
can utilize more than one ER for fatty acid synthesis [127]. ER is a proven antibiotic 
target and isoniazid, which is an inhibitor of ER, has been used clinically to combat MTB 
since 1950’s [87].  
The catalytic mechanism of ER in MTB (referred to as InhA) is very similar to 
KR (Figure 1–5, 1–6). Instead of Ser-Tyr-Lys triad, InhA possesses a Phe-Tyr-Lys triad, 
where phenylalanine (Phe149) is probably used to direct the hydride transfer [128]. 
Studies utilizing isotopically enriched NADD (deuterated NADH) showed that Tyr158 
probably does not act as a proton donor, but rather performs the role of an electrophilic 
catalyst [129]. In E. coli, FabI has a Tyr-Tyr-Lys triad, but the replacement of one of the 
tyrosines (Tyr158) with phenylalanine has no effect on catalysis [130]. This probably 
suggests that the catalytic mechanisms of ecFabI and InhA are similar.   
 
 
Figure 1–6. Catalytic mechanism of MTB FabI homolog, InhA [128]. 
 
In typical Gram-positive or Gram-negative bacteria, the final long-chain carbon 
acyl-ACP will then react with glycerol-3-phosphate (G3P) to start he phospholipid 
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biosynthesis (see Scheme 1–1) [131]. In Gram-negative bacteria β-hydroxyacyl-ACP is 
transported into the cell inner membrane and used for lipid A biosynthesis. The 
biosyntheses of both phospholipid and lipid A are beyond the scope of this thesis, and the 
interested reader should refer to recent reviews for more information [99,132]. In MTB 
mycolic acid biosynthesis the resulting 24 carbon acyl-ACP substrate will repeat the 
FAS-II-A (referred to as FAS-II-B) and the FAS-II process for 5 cycles, followed by 
cyclopropanation of the two double bonds (Scheme 1–2). For a further reading on 
mycolic acid synthesis in MTB see ref [112].  
 
1.2.3  Type II FAS inhibitors 
Small molecule inhibitors of FAS will be discussed in four sections: fatty acid 
synthesis initiation module inhibitors, condensing enzyme (KAS) inhibitors, β-ketoacyl-
ACP reductase (KR) and β-hydroxyacyl-ACP dehydrase (HD) inhibitors, and, last but not 
least, enoyl-ACP reductase (ER) inhibitors. The antibiotic profiles of all the inhibitors are 
summarized in Table 1–3.  
 
Initiation module inhibitors 
As mentioned in the previous section 1.2.2, ACP is the one of the most abundant 
proteins in bacteria, and is an essential cofactor for quorum sensing [96]. The AcpS 
enzyme is required for the covalent attachment of 4’-phosphopantetheine (4’-PP) moiety 
to a conserved Ser36 on the apo-ACP to form the holo-ACP [133]. Apo-proteins ar  the 
proteins without a necessary cofactor bound, whereas proteins which are bound to 
cofactors are called holo-proteins. Both ACP and AcpS are essential to cellular viability. 
A high-throughput assay was devised to find inhibitors of AcpS by measuring the 
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incorporation of radio-labeled 4’-phospho-pantetheine moiety of CoA into preparations 
of apo-ACP [134].  
 
 
Figure 1–7. The inhibitors of fatty acid biosynthesis initiation phase. 
 
The first small molecule inhibitor of AspS, Sch-538415 (Figure 1–7), was found 
in 2003 [134]. The IC50 value for Sch 538415 inhibition of the incorporation of radio-
labeled 4’-phosphopantetheine (4’-PP) into AcpS is 4.2 µM. Sch 538415 was also found 
to inhibit bacterial growth (determined using a cell-based agar diffusion assay) [134]. 
Anthranilate 4H-oxazol-5-one derivatives (Figure 1–7) were synthesized as AspS 
inhibitors [135]. Although anthranilate 4H-oxazol-5-ones were found to inhibit AcpS in 
vitro (Table 1–3), these molecules were not effective at killing bacteria. Anthra ilic acid 
derivatives (Figure 1–7) were also found to be inhibitors of AspS, and these analogs 
were cytotoxic to bacteria with MIC values of 32–64 µM to a number of Gram-positive 




Plants also have type II FAS, and many widely used herbicides target plant ACC 
(acetyl-CoA carboxylase) [136], validating ACC as a good antibacteri l target [137]. 
Moiramide B (Figure 1–7) and andrimid were discovered in 1987 [138], and the first 
asymmetric synthesis of moiramide B was achieved in 1998 [139].  The mode of action 
of these pseudopeptide pyrrolidine dione antibiotics was not elucidated un il 2004 [140]. 
Moiramide B is a selective inhibitor (nanomolar) of ACC of both Gram-positive and 
Gram-negative bacteria (see Table 1–3), but has an IC50 of > 100 µM for eukaryotic 
acetyl-CoA carboxylase from rat liver [140]. Abundance of mycolic acids, a class of long 
fatty acids that usually contain 60–80 carbons (see Figure 1–3f), and multi-methyl-
branched fatty acids are uniquely found in the cell envelope of all strin  of mycobacteria 
[141]. Approximately 10 % of the genomes of mycobacteria are devoted to fatty acid 
biosynthesis [142]. NCI-65828 (see Figure 1–7), a lead compound that was originally 
identified via in silico inhibitor screening against AccD5 (one of the six known AccD in 
MTB), has a Ki value of 13 µM [143]. Further research also showed that NCI-172033 
(see Figure 1–7), an analog of NCI-65828 (see Figure 1–7), has a Ki value of 1.8 µM to 
AccD6 from MTB [144,145].  
To the best of our knowledge, the only FabD (MCAT; malonyl-CoA: acyl carrier 
protein transacylase) inhibitor discovered so far is corytuberine (Figure 1–7), which has 
an IC50 of 33 µM to the FabD of Helicobacter pylori. MCAT enzymatic assay also 






Table 1–3. The antibiotic activities of type II FAS inhibitors 
protein inhibitor IC50 (µM)/ enzymatic 
assay 
MIC (µM)/ strain name References 
AcpS Sch-538415 4.2/ AcpS (. aureus) -- [134] 
4H-oxazol-5-one 1.3/ AcpS (B. subtilis) > 200/ B. subtilis [135] 
anthranilic acid 2.8/ AcpS (B. subtilis) 32/ S. aureus (MRSA) 
32/ B. subtilis (168) 
[115] 
ACC moiramide B 0.015/ ACC (E.coli) 
0.096/ ACC (S. aureus) 
70/ E. coli (Neumann) 
18/ S. aureus (133) 
[140] 
NCI 65828 13 (Ki)/ AccD5 (MTB) -- [143] 





5.7/ FabH (E. coli) 
1.9/ FabH (S. aureus) 
17/ E. coli 
38/ S. aureus (MRSA) 
[147,148] 
YKAF02 0.042 (Kd)/ FabH (E. coli) 16/ E. coli 
32/ S. aureus (MRSA) 
[149] 
YKAs3003 0.02 (Kd)/ FabH (E. coli) 584/ E. coli 
584/ S. aureus (MRSA) 
[150] 
SB418001 1.2/ FabH (E. coli) 
0.016/ FabH 




0.004/ FabH (E. faecalis) 
3.8/ FabH (S. aureus) 
>106/ E. faecalis 




52/ FASII[a] (E.coli) 
21/ FASII (S. aureus) 
>388/ E.coli (wild-type) 
21/ S. aureus (wild-type) 
[153] 
platencin (FabH/F) 4.6/ FabH (S. aureus) 
9.2/ FabF (S. aureus) 
2.4/ S. aureus (MRSA) 
>150/ E.coli (wild-type) 
[119] 
FabB/F Cerulenin 3/ FabB (Kd, E.coli) 
20/ FabF (Kd,E.coli)  
700/ FabH (Kd,E.coli) 
4.5/ FASII (E.coli) 
6.7/ FASII (S. aureus) 
425/ E.coli (wild-type) 
287-573/ S. aureus 
[154-156] 
Thiolactomycin 26/ FabB (Kd,E.coli) 
60/ FabF (Kd,E.coli) 
158/ FabH (Kd,E.coli)  
61/ FASII (S. aureus) 
476/ E.coli (No-9) 
304-609/ S. aureus 
238/ B. subtilis (PCI-
219) 
[155-158] 
thiotetromycin 63/ FASII (S. aureus) 269-538/ S. aureus 
26/ Bacteroides fragilis 
(ATCC 23745) 
[159] 
BABX 69/ FASII (E.coli) 
21/ FASII (S. aureus) 
>460/ E.coli (wild-type) 





0.16/ FabF (E.coli) 
0.048/ FabF (S. aureus) 
67/ FabH (S. aureus) 
0.5/ FASII (S. aureus) 
>145/ E.coli (wild-type) 




5/ FabG (E.coli) 
15/ FabI (E.coli) 
>200/ E.coli [160] 
FabA 3-decynoyl-NAC 
& Allenic acids 
(thioesters) 
-- 10/ E.coli [161,162] 
FabZ NAS-91, NAS-21 0.6/ FabZ (Kd, P. 
falciparum, NAS-91) 
-- [163] 
FabI isoniazid (INH- 0.00075/ FabI (Ki,  MTB) 0.12/ MTB (wild-type) [164-166] 
26 
 
NAD) >3,600/ E.coli 
thionamides 
(ethionamide) 




triclosan 2.0/ FabI (E. coli) 1.7/ E. coli (wild-type) [169] 
5-octyl-2-
phenoxyphenol 
0.005/ FabI (MTB) 6.7/ MTB (TN587) [170] 
diazoborine 
(benzodiazaborine) 
-- 83/ E. coli (wild-type) 






<0.06/ FabI (E. coli) 
0.05/ FabI (S. aureus) 
0.13/ FabI (H. influenzae) 
3.0/ FabK (S. 
pneumoniae) 
1.3/ E.coli (120AcrAB) 
0.04/ S. aureus 
(WCUH29) 
2.6/ H. influenzae (Q1) 
43/ S. pneumoniae 
(1629) 
[173,174] 
[a] The high through-put FASII inhibitory assay. 
 
Condensing enzyme inhibitors 
Cerulenin (CER) is a fungal mycotoxin, and was the first potent condensing 
enzyme inhibitor discovered [154]. The molecule is an irreversible inhibitor and mimics 
the transition state of the FabF/B catalyzed reaction (Figure 1–9a). FabH (the initiation 
condensing enzyme) is generally insensitive to cerulenin [155]. FabF is a homodimer, 
and Cys163 is located at the bottom of a mainly hydrophobic pocket at the dimer 
interface. Cerulenin is covalently attached to Cys163 via the opening of the epoxide ring 
by the Cys163 residue (Figure 1–9a). The amide carbonyl oxygen of cerulenin interacts 
with His340 and His303, and the hydroxyl group at C3 forms a hydrogen bond to the NH 
of Phe400 (Figure 1–9a) [175]. Cerulenin also inhibits the type I FAS. For example, it 
has IC50 of 4.5 µM to yeast KAS [176]. It is also worth-noting that cerulenin cannot be 
used for antibiotic therapy because it also inhibits human KAS. An analog of cerulenin 
C75 (Figure 1–8), however, has some clinical potential and was found to be cytotoxic to 
some human cancer cells [177].  
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Bacteria have developed resistance mechanisms to cerulenin [178]. Two 
resistance mechanisms to the action of cerulenin in B. subtilis have been reported: i) up-
regulation of transcription of the fabF gene increases 8-fold in response to cerulenin; ii) 




Figure 1–8. Structures of condensing enzyme inhibitors 
 
Thiolactomycin (TLM, Figure 1–8) is a natural product isolated from a Nocardia 
strain in 1982 [157]. Unlike cerulenin (CER), the toxicity of TLM is weak in animal 
experiments, and it has a broad-spectrum antibiotic activity against both Gram-negative 
and Gram-positive bacteria n vitro and in vivo [179]. Several thiolactomycin analogs, 
such as thiotetramycin (Figure 1–8) [159], were isolated from Streptomyces. The 
variables of these analogs are limited on the alkyl substituents. Both CER and TLM have 
high affinities to FabB [155], whereas the binding affinity with FabH is very weak [155]. 
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By changing the catalytic triad in FabB (His-His-Cys) into the His-Asn-Cys triad found 
in FabH, the mutated FabB showed significant resistance to both CER and TLM [155]. 
  A Merck group designed a high through-put FASII inhibitory assay in 2005 by 
using an antisense silencing technology and changing the conventional substrates, acetyl-
CoA and malonyl-CoA, into long-chain acyl-CoA (octanoyl-CoA or lauroyl-CoA) [156]. 
Using this method the inhibitors of the elongation steps in fatty acid synthesis were 
discovered [156]. Four potent FabB/F/H inhibitors were found by this modified FASII 
inhibitory assay, namely BABX [156], phomallenic acid C [153], platensimycin [120] 
and platencin [119] (see Figure 1–8 and Table 1–3). All four compounds showed 
antibiotic activities in vivo only to Gram-positive but not Gram-negative bacteria. It was 
suggested that the action of efflux pumps in Gram-negative bacteria accounted for the 
poor activities of these compounds against Gram-negative bacteria.  E. coli lpxC or tolC 
strains that did not have the efflux pumps could be inhibited with these n w FAS 
inhibitors [120]. Platensimycin, isolated from Streptomyces platensis, is the best FabF 
inhibitor discovered so far, with an IC50 of 48 and 160 nM for FabF of S. aureus and E. 
coli, respectively. The compound also showed a weak inhibition of S. aureus FabH, with 
an IC50 of 67 µM [120]. Furthermore, platensimycin showed no toxicity issue to the 
human cell-line and no antibiotic cross-resistance to MRSA (methicillin-resistant S. 
aureus) and VRE (vancomycin-resistant Enterococcus) strains.  
As previously mentioned, the FabF and FabB inhibitors usually share the sam  
structural motifs because the binding sites these FabF/B inhibitors contain similar amino 
acids. Figure 1–9 depicts the X-ray crystal structures of FabF/B and shows the binding 
modes of CER, TLM [155] and platensimycin [120] to FabF/B. A carbonyl group in all 
 
three compounds plays an important role in their binding by interacting with
histidines (His333 and His298 in 
1–9c and 1–9d; His311 and His345 in 
the nucleophilic addition of cysteine residue to the epoxide moiety on CER, the binding 
patterns of CER (Figure 1
(Figure 1–9d) in the active sites of the condensing enzymes are similar
[155]. 
 
Figure 1–9. Co-crystal structure of FabF/B proteins with their inhibitors. a) Cerulenin 
(CER) binding site of ecFabB (PDB code 1FJ8); b) thiolactomycin (TLM) binding site of 
ecFabB (PDB code 1FJ4); c) CER binding site of ecFabF (PDB code 1B3N); d) 
platensimycin binding site of ecFabF (C163Q) (PDB code2GFX); e) TLM binding site of 
MTB KasA, a FabF homolog
bound to the proteins (CER, TLM or platensimycin
atoms are colored blue, red and gold, respectively.
Figure 1–9a and 1–9b; His303 and His340 in 
Figure 1–9e) in the His-His-Cys triad. Apart 
–9a, 1–9c), TLM (Figure 1–9b, 1–9e) and platensimycin 
 (PDB code 2WGG). Amino acid residues 
: green); nitrogen, oxygen
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Figure 
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 (Figure 1–9) 
 
(yellow); ligands 
 and sulfur 
30 
 
Besides FabF and FabB (or KasA and KasB in MTB), FabH is also a highly 
conserved protein. The amino acid sequence of FabH for S. aureus has 57, 40, and 34% 
sequence identity with the FabH of B. subtilis, E. coli, and M. tuberculosis, respectively 
[147]. Benzoylaminobenzoic acids (Figure 1–8) were discovered as FabH inhibitor in a 
structure-based drug design approach [152]. Many analogs of this clas  of compounds 
showed nanomolar inhibition activity against both Gram-positive and Gram-negative 
bacteria FabH [152]. Di- or tri- hydroxy benzene derivatives (e.g. YKAs3003, YKAF04; 
see Figure 1–8), which were discovered in silico, showed nanomolar inhibition to FabH 
[149,150]. However, the MIC values of these compounds are too high (16–584 µM) to be 
clinically useful (Table 1–3). Platencin, also isolated from S. platensis by the Merck 
group, is structurally similar to platensimycin with the only difference found in the 
tetracyclic moiety (Figure 1–8). Like platensimycin, platencin also has a broad-spectrum 
antibiotic activity against Gram-positive bacteria with no toxicity issue or antibiotic 
cross-resistance problem. However, platencin is 14-fold more active against FabH than 
platensimycin and maintains a similar inhibition activity to Fab , thus platencin is a dual 
FabF/H inhibitor. Also similar to platensimycin, platencin inhibited phospholipid 
biosynthesis in the whole-cell labeling experiments in S. aureus with IC50 values of 0.45 
µM [119].  
 
β-Ketoacyl-ACP reductase (KR) and β-hydroxyacyl-ACP dehydrase (HD) inhibitors 
KR of E. coli, or FabG is a NAD(P)-dependant reductase. Only a handful of FabG 
inhibitors are currently known. Epigallocatechin gallate (EGCG) is the major component 
of green tea extracts. EGCG and other polyphenol green tea extracts, which contain the 
galloyl moiety, showed a potent dual inhibition of FabG and FabI, but a moderate in vivo 
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MIC value [160]. Other plant polyphenols were screened, and some of them had good 
FabG inhibition and antibacterial activities, but the mode of action of i hibition of both 
of the NAD(P)-dependant reductases is still unknown [160].  
Little attention has been paid to the discovery of FabA inhibitors because not 
many bacterial strains have FabA as their β-hydroxyacyl-ACP dehydrase (e.g. C. 
acetobutylicum and C. difficile) [87]. The 3-decynoyl-N-acetylcysteamine, and its analogs, 
2,3-decadienoyl-N-acetylcysteamine and 2,3-decadienoic acid were shown to inhibit β-




Figure 1–10. The structures of KR and HD inhibitors 
 
The only FabZ (HD) inhibitors reported so far are two synthetic compounds, 
NAS-91 (Figure 1–10) and NAS-21. These two compounds showed binding constants 
(Kb) of 1.6 × 10
6 and 1.2 × 106 M-1 to FabZ, respectively [163].  
 
 Enoyl-ACP reductase (ER) inhibitors 
Enoyl-ACP reductases, FabI/K/L/V (called InhA in MTB) are also validated 
antibiotic targets. At least four classes of ER inhibitors have be n discovered so far: 
isoniazid (INH) [164], triclosan [169], diazoborine [171,172] and indole 
naphthyridinones [173,174] (see Figure 1–11 for structures).  
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Isoniazid has been used as an anti-MTB drug since 1950’s, and it still remains as 
the first-line antibiotic for MTB infections. Because of the drug- esistant problem, 
standard chemotherapy to treat MTB consists of at least four drugs: isoniazid, rifampin, 
ethambutol, and pyrazinamide. Although isoniazid has a very simple substituted pyridine 
structure (Figure 1–11), the mode of action of this pro-drug is complicated. It has been 
suggested that INH (isoniazid) is activated by KatG (catalaseperoxidase) and forms an 
adduct with NAD, and this INH-NAD adduct inhibits InhA (Figure 1–12) [180]. 
Inhibition of InhA results in the reduced synthesis of mycolic acid, which is required for 
the synthesis of Mycobacteria cell wall [180]. It should be pointed out that although it has 
became a common knowledge that isoniazid is a InhA inhibitor of MTB, there is still 
some evidence to suggest that there are more than one target of INH inside the MTB cell 
[181-183]. Bacterial resistance towards isoniazid is probably caused by mutations within 
the katG and inhA genes [180,184].  
 
 
Figure 1–11. Structures of FabI/K inhibitors.  
 
 
Figure 1–12. a) Co-crystal structure
benzodiazoborine-NAD and ec
ecFabI (PDB code 1QG6
proteins (isoniazid, diazaborine or triclosan
phosphorous atoms are colored 
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2’-OH of the nicotinamide ribose and a boron atom in the drugs to generat  a tightly 
bound adduct [186,190]. Mutational studies revealed that diazoborine binding to E. coli
ER requires the presence of a glycine residue at position 93. Any other amino acid, other 
than glycine, at this position dramatically affected diazaborine binding to ER [191]. 
Triclosan (Figure 1–11) inhibits the ER with a dissociation constant of 7.1 pM 
[187]. Analysis of the co-crystal structure of triclosan and ER-NAD complex revealed 
that both triclosan and diazaborine inhibitors bind to the same site (Figure 1–12) [187]. 
Resistance to triclosan occurs via mutations to ER enzymes, such a  FabI, akin to how 
mutations in INHA confer resistance to INH in MTB [169]. It should a so be noted that 
many strains of bacteria do not possess FabI or have more than one ER. For such bacteria, 
triclosan is not a very effective antibiotic [127]. Additionally, the overexpression of the 
multidrug efflux pump locus acrAB, marA or soxS decreased susceptibility to triclosan 
in bacteria [192]. A detailed structure-activity relationship study of triclosan has been 
done by the Tonge group [170,193]. And they showed that many diphenyl ether analogs 
of triclosan (e.g. 5-octyl-2-phenoxyphenol) have similar or higher activity han triclosan 
to various bacteria, including E. coli and MTB [189].  
Indole naphthyridinones (Figure 1–11) were discovered as ER inhibitors in 2003 
[173]. This class of compounds showed potent antibiotic activity to various Gram-
positive bacteria and some Gram-negative pathogens, including some multi-drug resistant 
pathogens (Table 1–3) [173]. Extensive SAR studies showed that some of the analogs 
have a dual inhibition of both FabI and FabK, and they have a promising oral in vivo 




1.2.4 Other considerations when developing new antibiotics 
As early as 1977, researchers noticed that in the presence of an inhibitory 
concentration of cerulenin, cells of S. aureus can resume growth when supplemented with 
either a saturated or an unsaturated fatty acid [194]. A very recent paper claimed that type 
II FAS is not a suitable antibiotic target for Gram-positive pathogens [195]. The uptake 
of exogenous fatty acids, which can be found in the human serum, would allow the 
bacteria to fully bypass the inhibition of the type II FAS process. Therefore the antibiotic 
activities of type II FAS inhibitors may be sensitive to the in vivo environment of the 
bacteria. It is therefore critical for the drug-developer to consider different scenarios 
whereby a therapeutic regimen will not work, when developing new antibiotics to solve 
the never-ending resistance problem. 
 
1.3  Biofilm formation – another important antibiotic target 
1.3.1  Introduction of c-di-GMP signaling 
Biofilm is an aggregation of micro-organisms in bio-matrix on living and 
nonliving surfaces [1]. It has been noted that bacteria in biofilms are more resistant to 
antibiotics than free-living (planktonic) ones, and hence diseases related with biofilm-
forming bacteria are usually chronic and difficult to treat [196]. Biofilm-forming bacteria 
have been implicated in several serious diseases, such as endocarditis, cystitis, cystic 
fibrosis pulmonary infections, and the infections of prosthetic devices [196]. Thus small 
molecules that can attenuate biofilm formation have the potential to solve the bacteria 
resistance problem. It is now known that a dinucleotide, cyclic diguanylic acid (c-di-
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GMP, Figure 1–13a), appears to be a master regulator of several processes related to 
biofilm in various bacteria strains [197,198]. 
C-di-GMP was first discovered as a cellulose synthase activator in 
Gluconacetobacter xylinus (formally known as Acetobactor xylinum) by the Benziman 
group over two decades ago [199]. It was proposed by Benziman that c-di-GMP was 
synthesized by a membrane-bound protein diguanylate cyclase (DGC) from two 
molecules of GTP in the presence of Mg2+ (Figure 1–13b). C-di-GMP was shown to 
activate cellulose production in bacteria by binding to a cellulose synthase that is also a 
membrane protein. The degradation of c-di-GMP is catalyzed by phosphodiesterase A 
and B (PDE A/B), initially into pGpG by PDEA and then the pGpG is cleaved into two 
molecules of GMP by PDEB (Figure 1–13b).  
Mg2+ is required for c-di-GMP degradation but Ca2+ can strongly inhibit 
hydrolysis [199]. DGCs are characterized by the GGDEF [200,201], whereas PDEs are 
characterized by the EAL domain [202]. These two domains have now been shown to be 
the most abundant in bacterial genomes [203]. The first identified receptor for c-di-GMP 
was the BcsB β-subunit of cellulose synthase [204,205]. However, after some debate 
about whether the BcsB β-subunit of cellulose synthase was indeed a c-di-GMP binding 
domain [206,207], Amikam and Galperin clarified that PilZ domain in the sequence of 
cellulose synthase was in fact the long-sought after c-di-GMP binding protein [208].   
 
 
Figure 1–13. a) Chemical structure of c
proposed mechanism for 
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Figure 1–14. Structure of c
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that it regulates 
[214,215]. 
Legionella 











diesterases (PDEs). pGpG can be further degraded into two GMPs [199].  Some of the 
well characterized DGCs are WspR [200] and PleD [201]. These DGCs all contain a 
GGDEF domain [200,201] but the exact role played by this domain in DGC catalysis is 
not fully understood. Researchers have, however, postulated that the mec anism utilized 
by DGCs to make c-di-GMP from GTP could be similar to that of adenylyl cyclase 
[218,219]. PDE (e.g. FimX, RocR) contains an EAL domain [203]. Recent study howed 
that EAL domain can use one, two or three Mg2+ for catalysis but only one cation is 
essential [220]. Using RocR protein (from Pseudomonas aeruginosa) s a model, Liang’s 
group further proposed that this key Mg2+ coordinates and polarizes the P–O bond of c-
di-GMP, and lowers the pKa of the coordinated water to generate the nucleophilic 
hydroxide anion, with the assistance of Glu352 via a general acid/base mechanism 
(Figure 1–15) [220]. Proteins containing EAL domain specifically produce 5’-pGpG 




Figure 1–15. Proposed catalytic mechanism for EAL domain-containing PDE.  
  
 In the last few years, tremendous progress has been made towards identifying and 
understanding c-di-GMP metabolism proteins (PDEs and DGCs). However, very little is 
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known about the downstream proteins that bind to c-di-GMP and transmit the binding 
event into a biological response (the so-called adaptor proteins). Table 1–4 shows known 
proteins that bind to c-di-GMP.  
 
Table 1–4. Known c-di-GMP adaptor proteins and RNAs (modified from refs[213]). 














Flagellar activity [222] 








Escherichia coli and 
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Flagella activity [223] 
FleQ FleQ P. aeruginosa 
Flagella expression 
and Pel synthesis 
[224] 
PelD PelE P. aeruginosa Pel synthesis [225] 




















Cd1 Clostridium difficile Flagella synthesis 
c-di-GMP-II 
riboswitches 
84 Cd Clostridium difficile Bacterial virulence [217] 
 
1.3.2  Polymorphism of c-di-GMP 
An interesting property of c-di-GMP is its ability to readily form dimers, 
tetraplexes and higher aggregates in the presence of cations at millimolar or even high 
micromolar concentration (Figure 1–16) [226,227]. Structural data analyses of proteins 
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that bind to c-di-GMP reveal that these proteins bind to either monomer (PDB code: 
3HV8 [228]) and dimer c-di-GMP (PDB code: 3KYF [229]; Figure 1–17). Cations such 
as those of magnesium, sodium, lithium and ammonium promote dimer formation in c-di-
GMP, whereas potassium ion promotes the formation of tetraplexes and octaplexes in c-
di-GMP [226,227]. Recently the Sintim group also showed that higher aggregates of c-di-
GMP, such as tetraplexes and octaplexes, can also form at physiological concentration 
(0–10 µM) in the presence of aromatic intercalators [230]. 
This propensity of c-di-GMP to form tetraplexes or octaplexes (G-quadruplexes) 
at micromolar concentrations in the presence of cations (such as t at of potassium) is 
intriguing because simple nucleotides (such as cGMP, GTP or pGpG) do not readily form 
G-quadruplex structures at micromolar concentrations. G-quadruplexes are formed by 
four guanine groups linked by eight H-bonds (Figure 1–16). In c-di-GMP, the near-
planar G-quardruplex floors can stack with each other, stabilized by a face-face π–π 
stacking [227]. Not all bacterial c-di-GMP binding enzymes bind to the same c-di-GMP 
polymorphism. For example, P4397 (PilZ domain) binds to dimeric c-di-GMP (Figure 
1–17a), whereas FimX (EAL domain) prefers monomeric c-di-GMP (Figure 1–17b). 
Therefore, the polymorphism of c-di-GMP should have biological implications. Plausibly, 
the facile interconversion of c-di-GMP into different aggregation state  (especially in the 
presence of cations) could be a means whereby bacteria regulate biofilm formation in the 
presence of different metals. 
 
 
Figure 1–16. Polymorphism of c
magnesium cations; b) potassium and aromatic intercalators. G
in tetramolecular and octamolecular c
 
Figure 1–17. Co-crystal structures of 
(PDB 3KYF); b) FimX (EAL domain) with monomeric c
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respectively; yellow represents the cartoon structure of the adaptor protein
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Chapter 2. The synthesis and antibiotic activities of oxazinidinyl 
platensimycin 
2.1  Syntheses of novel FAS inhibitors, platensimycin and platencin 
In 2006, Merck reported a novel potent inhibitor of FabF, called platensimycin 
(Figure 2–1) [120], from a soil sample of Streptomyces platensis (MA7327) collected in 
South Africa. The yield of this natural product after extraction and HPLC purification 
was 0.6–1.3 mg/liter of the crude fermentation broth [120]. One year later, the same 
Merck team reported another compound called platencin (Figure 2–1), which is a good 
inhibitor of FabH, from a different strain of Streptomyces platensis (MA7339) from a soil 
sample collected in Spain with a similar purification method used for platensimycin 
discovery. Platencin was obtained in a yield of 1 mg/liter [119].  
 
 
 Figure 2–1. The structures of platensimycin and platencin. 
 
Platensimycin (compound 2–1, Figure 2–1) and platencin (compound 2–2) both 
show a broad-spectrum Gram-positive activity in vitro and in vivo [119,120]. Single-
enzyme catalytic assays showed that platensimycin is a superior inhibitor of saFabF (sa = 
S. aureus) with an IC50 of 0.048 µM but a weak inhibitor of saFabH with an IC50 of 67 
µM [120], whereas platencin is a dual inhibitor of saFabF and saFabH with an IC50 of 
0.11 and 16 µM, respectively [119]. In vivo, platensimycin and platencin both showed an 
MIC (minimum inhibitory concentration) value range of 0.5–8 µg/mL. These values 
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represent about 32-fold more antibiotic potency when compared to the commercial 
antibacterial drug, linezolid, on various antibiotic-resistant bacteri l strains. Interestingly, 
both platensimycin and platencin do not exhibit significant cyto-toxicity (Table 2–1) 
[119,120].  
FabH and FabF are condensing enzymes that are both necessary for the 
biosynthesis of the fatty acid component of bacterial cellular membrane, phospholipid. 
Thus a bacterium deficient in any of these two essential enzymes cannot survive [87]. 
Platensimycin and platencin are the most potent inhibitors of FabF/H reported to date, 
and because their modes of action are distinct from any current antibiotics, such as β-
lactams, macrolides or oxazolidinones (e.g. linezolid), it was expected that platensimycin 
or platencin will not exhibit cross-resistance issue to these drugs (Table 2–1) [119,120]. 
 
Table 2–1. Microbiological and toxicity profiles of platensimycin, platencin and linezolid 
(adopted from ref [120] and [119]) 
Organism (genotype and description) Platensimycin Platencin Linezolid 
Antibacterial activity (MIC, µg/ml) 
S. aureus (MSSA, sensitive to methicilin) 0.5 0.5 4 
S. aureus + serum 2 8 4 
S. aureus (MRSA, resistant to methicilin) 0.5 1 2 
S. aureus (MRSA, resistant to macrolide)  0.5 1 2 
S. aureus (MRSA, resistant to linezolid) 1 1 32 
S. aureus (VISA, resistant to vancomycin)  0.5 0.5 2 
E. faecalis (resistant to macrolide) 1 2 1 
E. faecium (VRE, resistant to vancomycin) 0.1 <0.06 2 
S. pneumoniae 1 4 1 
E. coli (wild-type) >64 >64 >64 
E. coli (tolC) 16 2 32 
Toxicity (µg/ml) 
HeLa MTT (IC50)  >1,000 >100 >100 
Candida albicans (MIC) >64 >64 >64 
Whole-cell activity (IC50, µg/ml) 
Fatty acid synthesis (S. aureus) 0.1 0.19 ND 
Fatty acid synthesis (S. pneumonia) 0.8 2.7 ND 
 
It is worth-noting that although platensimycin and platencin showed superior 
antibacterial activities to various commercial antibiotics against several antibiotic
resistant bacterial strains in 
profiles and did not display good 
enzymes in the human serum.
 
2.1.1  KAS inhibition by
The crystal structure of a FabF mutant (C163Q), in complex with platensimycin, 
was disclosed in 2006 (Figure 2
key hydrogen bonding interactions that are postulated to be vital for binding. 
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[155]. The benzoic acid ring of platensimycin stacks with Phe400 of the FabF enzyme in 
an edge-to-face pattern of the FabF open conformation. Phe400 is the gatekeeper
that separates the malonyl
closed conformation, Phe400 would sterically clash with the benzoic acid ring of 
platensimycin, and would not be able to make as favorable a stacking interacti
inhibitor. This explains why platensimycin binds selectively to the acyl
intermediate [120]. The hydroxyl group 
water-mediated hydrogen bonds to protein residue Asp265, which is part of the malonyl 
subsite (Figure 2–3a) [120]
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The amide-linked, tetracyclic core of platensimycin is positioned i  the mouth of 
the active site and is partly exposed to solvent (Figure 2–2) [120]. The amide linker 
makes two hydrogen bonds to the protein; the carbonyl oxygen hydrogen-bonds to the 
Thr307 side chain, and the amide nitrogen interacts with the backbone carbonyl of 
Thr270. The enone carbonyl oxygen of platensimycin makes a hydrogen bond to the 
backbone amide of Ala309, and the ether oxygen makes a hydrogen bond to the side-
chain hydroxyl group of Thr270 (Figure 2–3b) [120].  
More recent structural studies [231,232] showed that the binding modes of 
platencin, platensimycin A1 (a hydroxy congener of platensimycin, Figure 2–4; 
compound 2–3) and platencin A1 (a hydroxy congener of platencin, compound 2–4) are 
similar to platensimycin (Figure 2–5). The IC50 values of platensimycin A1 and platencin 
A1 are also similar to that of platensimycin and platencin in cell-free FASII assays, 
respectively [231,232]. For platensimycin A1, the hydroxylated tetracyclic core is slightly 
rotated and shifted compared to platensimycin in the binding site (Figure 2–5) [231]. For 
platencin and platencin A1, the terpenoid ring of the tricyclic core lacks the ether oxygen 
atom found in platensimycin and therefore, both compounds cannot form a direct 
hydrogen bond to Thr270 (Figure 2–3b). This missing hydrogen bond probably accounts 
for the 6-fold weaker binding affinity to FabF compared to platensimycin [232]. However, 
the benzoic acid moieties and the amide linker are bound to the protein almost exactly the 
same way in all the cases. The hydrogenation product of platensimycin, whereby the 
enone moiety of the tetracyclic core is reduced, dihydroplatensimycin (compound 2–5, 
Figure 2–4), binds to FabF with an affinity that is only 4-fold less than the natural 
platensimycin. The lower binding affinity of dihydroplatensimycin (compound 2–5) to 
 
FabF however suggests that the cyclohexenone ring 
of platensimycin to FabF by orienting the C
bonding interaction with Ala
observations make us conclude that because the core structure does not directly inhibit 
the His-His-Cys triad (around 10 Å away), interactions between the core structure of 
these inhibitors and the protein residues probably do not contribute as much to the 
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2.1.2  Previous total syntheses of platensimcyin and platencin 
In only four years since the seminal report [120] by the Merck group, over 20 
groups worldwide have reported the total syntheses of platensimycin [182,234-246] and 
platencin [247-257], or the enzymatic syntheses of platencimycin [258,259]. Additionally, 
several papers demonstrated various strategies to make analogs of these molecules 
[231,232,260-277], and the biological evaluations of these analogs [231,232,262-
264,266-268,271-277] have also been reported. Several review articles [278-282] on 
these molecules have also been published, establishing the platensimyci  family of 
antibiotics as one of the most intensely studied bioactive molecules in the last decade. 
Despite the intense research efforts directed at discovering newer analogs of 
platensimycin and family, the majority of the reported syntheses of platensimycin or 
analogs typically involve close to twenty total steps, with the shortest linear steps being 
around nine [256]. Most total syntheses of platensimycin or platencin have produced only 
a few milligrams of material. As most antibiotic pills used in the clinics typically contain 
from one to two hundred milligrams of active substances, the current ch mical syntheses 
of platensimycin or analogs reported so far would not be economically viable. 
Nicolaou’s group first reported the total synthesis of platensimycin in 2006 [234] 
and platencin in 2008 [250]. Nicolaou’s first platensimycin synthesis included 10 steps 
towards the core structure. The key step in Nicolaou’s strategy is a ketyl radical 





Scheme 2–1. Nicolaou’s first total synthesis of platensimycin 
 
Snider reported a 7-step synthesis of the core structure 2–9 of platensimycin 
(Scheme 2–2) [241], the major drawback of this approach is that many steps are low 
yielding and result in mixtures of undesired products. Therefore, f practical purposes, 
Snider’s strategy is not ideal (Scheme 2–2). Yamamoto reported a 10-step asymmetric 
synthesis towards the core structure 2–9 of platensimycin in 2007 [237]. Yamamoto’s 
synthesis started with an asymmetric Diels-Alder reaction, a d ended with a 




























cis : trans = 1:4
2-11 2-12 2-13
 





Scheme 2–3. Yamamoto’s synthetic strategy towards the core structure of platensimycin 
 
The core structure of platencin is less complicated than platensimycin. Instead of 
a tetracyclic moiety, the tricyclic moiety makes the platencin synthesis generally shorter 
than platensimycin. The shortest total synthesis of platencin so far is Tiefenbacher and 
Mulzer’s synthesis reported in 2009 [256]. The synthesis started with a commercially 
available compound perillaldehyde. After the key ring-closing metath sis/ Diels-Alder 
cascade reaction, the tricyclic structure was readily formed in only three steps (Scheme 
2–4). The total number of steps of Tiefenbacher and Mulzer’s synthesis is nine, with an 
overall yield of 9.6 % [256].   
 
 
Scheme 2–4. Tiefenbacher and Mulzer’s total synthesis of platencin. 
 
2.2  Design, syntheses and antibiotic activities of first generation platensimycin 
analog – oxazinidinyl platensimycin 
(The majority of this section was published in ref [273]) 
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2.2.1  The design of oxazinidinyl platensimycin 
Although platensimycin shows an excellent antibacterial activity, there are still 
some issues that must be addressed:  
i) Platensimycin is 4-fold less effective in serum than that is in bacterial growth 
medium (Table 2–1). The instability of platensimycin in serum might be due to the 
hydrolysis of the amide group. Replacement of the amide moiety with stable isosteric 
groups might lead to a longer lasting drug.  
ii) Practical chemical synthesis of platensimycin for mass u age is currently not 
feasible with the synthetic strategies reported so far.  
Since the benzoic acid moiety is important, SAR studies of platensimycin have 
mainly been focused on the tetracyclic core structure of platensimycin, and any attempts 
to modify the benzoic acid moiety rendered the molecule inactive (Table 2–2). 
Interestingly, although the tetracyclic moiety of platensimycin is distal from the active 
site in FabF, modifications on the core does not always give an active compound (Table 
2–2).  
 
Table 2–2. MIC values of platensimycin/ platencin analogs against S. aureus.  (Unless 
otherwise shown, analogs contain the benzoic acid moiety found in platensimycin) 
 active analogs inactive analogs 


























































































[a] The molecule was synthesized and reported by Sintim group [273] and will be 
discussed in this dissertation.  
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Herein, we report the total synthesis and biological testing of oxazinidinyl 
platensimycin (2-30, Scheme 2–6) and a simplified oxazinidinyl analog (2-57, Scheme 
2-17). This limited set of analogues was designed to answer two questions: a) Could the 
enone moiety of platensimycin be replaced with the oxazinidinyl rig to create a potential 
bioisostere compound 2? b) Could the tetracyclic core structure of platensimycin be 
replaced with other motifs that are synthetically easier to access? 
The choice of the oxazinidinyl moiety to replace the enone moiety was dictated 
by the observation by the Merck group that the enone functionality does n t play a 
significant role in platensimycin inhibition of FabF [120]. Additionally, the replacement 
of the C4 atom (Scheme 2–5) with nitrogen will open up the possibility of synthesizing 
platensimycin analogs via reductive amination. Reductive amination reactions (Scheme 
2–5), with sodium cyanoborohydride, do not require stringent inert or anyhydrous 
conditions and are generally high yielding. Therefore the reaction is amenable for high-
throughput synthesis; enabling the rapid syntheses of platensimycin analogs via the 
coupling of the aryl side chain with readily available 1,3-hydroxyketones to generate a 




Scheme 2–5. Synthetic strategy towards platensimycin analogs. 
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2.2.2  Synthesis of oxazinidinyl platensimycin 
Scheme 2–6 outlines our retrosynthetic analysis for the core structure of 
platensimycin analogues. For the synthesis of the core structure of oxazolidinyl 
platensimycin 2–30, bis-alkene 2–34 was chosen as a key intermediate that could be ring-
closed with Grubb’s metathesis catalyst. Epoxidation of the resulting cyclic alkene would 
give compound 2–32, after a nucleophilic addition to the ketone moiety.  
 
 
Scheme 2–6. Retro-synthetic analysis of oxazinidinyl platensimycin. 
 
We reasoned that because the lone pairs of the hydroxyl oxygen anion of 2-32 
overlapped with the π* of the epoxide’s C-O bond, a facile 6-exo-tet ring closure should 
ensue to provide the tricyclic structure 2-36 (Scheme 2–7). Of concern was the 
possibility of obtaining the alternative diastereomer 2- 37 via a 5-exo-tet ring closure. 
 
 
Scheme 2–7. 6-exo-tet (pathway a) vs 5-exo-tet cyclization (pathway b). 
 
DFT calculations, using the Gaussian 03 program, indicated that the activation 
energy of pathway a via the transition state structure TS-a was 9.8 kcal/mol lower than 
 
that of pathway b via TS-
b (Scheme 2–8). Diastereomer 
energy of 2–37 is 14.0 kcal/mol higher compared to 
optimized ground state geometry of compound 
nucleophile and C1 atom (
3.7 Å away from C2. Taken together, these analyses gave us the confidence that our key 
step towards the synthesis of oxazin
 
Scheme 2–8. The energy surfaces o
reaction 
 
Initially, we set out to make
closing metathesis reaction. Treatment of commercially available vinylagous ester 
with anion 2–39, generated f
b. This suggests that pathway a is more favorable than pathway 
2–37 contains a boat conformation and the ground state 
2–36 (Scheme 2–
2–32, the distance between the oxygen 
Scheme 2–8) was 3.2 Å whereas the oxygen nucleophile was 
 
idinyl platensimycin was viable and worth pursuing.
 
f pathway a and b for the epoxide ring
 bis-alkene 2–34, the requisite substrate for the ring
rom a stannane precursor via a lithium-tin exchange gave 
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enone 2–40 in good yield (84 %). The next step involved the allylation of enone 2–40 
with an allyl halide. Allyl bromide only gave the desired product 2–41 in a meagre 34% 
yield accompanied by a substantial amount of diallylated product 2–42 (44 % yield). 
Interestingly, changing the allylation reagent to allyl iodide improved the yield to 62 % 
and the formation of the diallylated product was suppressed to 25 %. A conjugate 
addition of vinyllithium to enone 2–41, in the presence of BF3·Et2O resulted in a 1 : 3.5 
mixture of cis-bis-alkene 2–34 and trans-bis-alkene 2–34 respectively. Unfortunately, the 
major product (trans-2–42) was not suitable for the subsequent ring-closing metathesis 
because the alkene moieties were trans- to each other (Scheme 2–9). The low overall 
yield of the desired cis-bis-alkene 2–34 led us to investigate the epimerization of 
compound trans-2–34 to give cis-2–34 (Scheme 2–10). Subjecting compound trans-2-34 
to 30 mol% DBU in toluene yielded an epimeric mixture of trans-2–34: cis-2–34 in an 11: 
9 ratio after 23 h (Scheme 2–10). It therefore appears that the undesired cis-bis-alkene 2–
34 is both the kinetic and thermodynamic product.  
Under the experimental condition, cis-2–34 and trans-2–34 may reach 70 % of 
their equilibrium in about 6 hours (see Appendix I). We wondered if we could perform 
the ring-closing metathesis in the presence of DBU. Should the ruthenim catalyst be 
compatible with the amine base, then a dynamic ring-closing resolution should ensue and 
both diastereomers cis-2–34 and trans-2–34 would be suitable for the ring closing 
reaction. To the best of our knowledge, a dynamic ring-closing metathesis has not been 
reported in the literature. For the successful implementation of the dynamic ring-closing 
strategy, the ruthenium catalyst will have to survive the amine base for over 24 h at reflux 













Scheme 2–9. Reaction conditions: 
LDA, HMPA, allyl iodide, THF, 
material); c) Sn(CHCH2)4
 
Scheme 2–10. Stacked NMR spectra of epimerization reaction of comp und 
and trans-2–34 under the condition: 30 mol% DBU, 0.02 M substrate (pure 
alkene 2–34), 100 °C in d















a) LiCH2OBn, THF, –78 °C  RT,
–78 °C  RT, 12 h, 62 % (67 % based on the starting 
, n-BuLi, CuCN, BF3·Et2O, –78 °C  RT, 12 h, 85 %. 
8-toluene. The reaction was carried in a 5 mm NMR tube with 
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Scheme 2–11. Dynamic ring-closing metathesis. Reaction conditions: Hoveyda-Grubbs 
II catalyst (2 % x 5), 50 % DDQ, 30% DBU, toluene, 0.02 M compound 2–34, reflux, 6 h 
each loading, 69 % (83 % based on the starting material). See App ndix II for more 
information.  
 
Pleasingly, subjecting an epimeric mixture of compounds cis-2–34: trans-2–34 
(ration of 1:3.5) to Hoveyda-Grubbs II catalyst in the presence of DBU and benzoquinone 
afforded the ring-closed product in 69 % yield (83 % based on the starting material, 
Scheme 2–11). In contrast, in the absence of DBU, the desired product could be obtained 
in a meager 20% yield. The benzoquinone additive was important for minimizi g the 
formation of the enone by-product 2–43 [283]. For this protocol to work, it was important 
to add the ruthenium catalysts in 2 mol% portions five times over a 24 h period. The 
portion-wise addition of the catalyst was necessary because even though the catalyst was 
tolerant of the amine base to some extent, the ruthenium catalyst w s decomposed under 
the experiment condition in a period of approximately one hour [284]. More reaction 
conditions screened for the dynamic ring-closing metathesis refer to Appendix II.  
 
 
Scheme 2–12. Reaction conditions: a) m-CPBA, dichloromethane, 0 °C  RT, 12 h, 
64 %; b) MeLi, THF, –78 °C  RT, 5 h, 70%; c) Dess-Martin reagent, CH2 l2, RT, 12 h, 




With bicyclic compound 2–33 in hand, in gram quantities, we proceeded with the 
epoxidation reaction using m-CPBA. The epoxide 2–35, obtained in 64 % yield, was then 
subjected to a tandem nucleophilic MeLi addition followed by a subsequent epoxide ring-
opening to afford tricycle 2–36 in 70 % yield (Scheme 2–13). In line with our 
expectation, the 5-exo-tet pathway b product 2–37 was not observed (Schemes 2–8 and 
2–13). Treatment of 2–32 with KOt-Bu (1.5 eq) in d6-DMSO resulted in epoxide ring-
opening product 2–36 within 5 minutes quantitatively (Scheme 2–14). Oxidation of 
compound 2–36 with Dess-Martin periodinane was followed by debenzylation with 
Pd/H2 to afford 2–44 without any incident.  
 
 
Entry Temperature Reaction time (h) 
Product distribution 
2–32 : 2–36 : 2–37  (overall yield) 
1 –78  –10 °C 2 0.7 : 1 : 0 (87 %) 
2 –78  rt 6 0 : 1 : 0 (70 %) 
 
Scheme 2–13. The product distribution of epoxide ring-opening reaction. 
 
 
Scheme 2–14. Epoxide ring
mixture in d6-DMSO; b) e














Scheme 2–15. a) NIS, TFA,
97 %; c) CNCO2Me, PhMgBr, 
CH2Cl2, RT, 12 h, 78 %; e) H
50 °C, 5 h, 95%; g) K2CO
-opening reaction and the stacked NMR spectra of 
poxide ring-opening product 2–36 in CDCl3; c) e
























 RT, 12 h, 100 %; b) MOMCl, Hunig base, CH
-78 °C  RT, THF, 12h, 78 %; d) MOMCl, Hünig base, 
2, 10 mol% Pd/C, MeOH, 69%; f) pyridine, benzene,





2Cl2, RT, 12 h, 
 RT  
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The aromatic side chain of compound 5 was synthesized following the strategy 
shown in Scheme 2–15. The stage was now set to couple the aromatic side chain 2–50 
with the tricyclic ring core 2–44. The reductive amination intermediate 31 has two 
sterically similar faces (shown as faces A and B in Figure 2–6), and it appeared at first 
glance that a mixture of diastereomers would be obtained during the reductive amination 
step. We, however, postulated that because one face (face B) contained oxygen, subtle 
stereoelectronic factors could swing the selectivity towards the desired product. The 
Felkin-Anh model [285-287] is not suitable to interpret the stereoselctivity of this 
reaction. In Felkin-Anh model, the addition of nucleophiles to iminium 2–51 favors 
addition from face A (Figure 2–6) due to favorable interactions between the nucleophile 
and the low lying σ*C–O bond. However, literature examples [288-291] indicated that, for 
tricyclic systems such as 2–51, a Cieplak model [292,293] would be a more appropriate 
predictor for product distribution: A hydride approach from face B would lead to two σ C-
C interacting favorably with the developing σ C-H bond whereas a hydride approach from 
face A will only lead to one σ C-C interacting favorably with the developing σ*  C-H bond. σ 
C-O bonds are low lying and not expected to make any significant hyperconjugative 
contribution. Additionally, transition-state dipole minimization between the C–O bond 
and the forming C–N bond dictates that approach from face B should predominate [294].  
Together, these arguments strengthened our conviction that the desired product would be 
obtained via reductive amination. Model studies using a simplified side chain confirmed 





Figure 2–6. The origin of the facial selectivity of reductive amination of c mpound 2–44 
and 2–50. In Felkin-Anh model, the s orbital of the hydride is stabilized by interaction 
with the σ* orbital of the C–O bond. In Cieplak model, the hyperconjugation of the 
forming σ*C–H and the two σ C–C orbitals favors the nucleophilic addition from the B face. 
The dipole moment is also minimized in the transition state of B face addition.  
 
 
Scheme 2–16. Facial selectivity of reductive amination for a model reaction. 
 
The end game of our synthesis proceeded smoothly. Reacting compounds 2-50 
and 2-44 in methanol in the presence of sodium cyanohydride gave compound 2-54; 
which was not purified but subjected to carbonyldiimidazole cyclization to afford 2-55 in 
76% yield. Deprotection of the methyl ester and the MOM groups led to oxazinidinyl 
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platensimycin (2-30) in 80% yield over two steps. Oxazinidinyl cyclohexaplatensimyc n 
(2-57) was synthesized following the strategy outlined in Scheme 2-18. 
 
 
Scheme 2–17. a) NaB(CN)H3, MeOH, pH 4, RT, 5 h, 75%; b) carbonyl diimidazole, 20 
mol % DMAP, benzene, 50 °C, 12 h, 76%; c) 1 N LiOH, MeOH: H2O = 2:1, RT, 12 h, 




Scheme 2–18. a) NaB(CN)H3, MeOH, pH 4, RT, 5 h; then, carbonyl diimidazole, 20 mol% 
DMAP, benzene, 50 oC, 12 h, 70 %; b) 1 N LiOH, MeOH: H2O = 2:1, RT, 12 h, then, 2N 
HCl, MeOH: H2O = 2:1, RT, 24 h, 85 %.  
 
2.2.3  The biological evaluation 
Oxazinidinyl platensinmycin (2-30) inhibited the growth of Staphylococcus 
aureus (Newman), Streptococcus agalactiae (2603V/R), and Bacillus subtilis (3160) at 
micromolar concentration (90 µg/mL). Despite its structural mimicry of platensimycin, 
oxazinidinyl platensinmycin (2-30) is two orders of magnitude less potent. 
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Carbaplatensimycin (see Table 2–2), an analog that has the ethereal oxygen of 
platensimycin replaced with carbon, has an MIC of 3–4 µM (MRSA), which is close to 
that of the parent compound. It appears that the enone moiety of platensimycin is more 
important than the ethereal oxygen with regard to antibiotic activity. Oxazinidinyl 
platensinmycin methyl ester (2-56) did not inhibit bacterial growth at micromolar 
concentrations. We conclude, based on this work and others’ [274] that bacterial esterases 





Chapter 3. Syntheses and antibiotic activities of N,N-dialkylamino 
benzoic acids – second generation design of the platensimycin analogs  
(The majority of the work was published in ref [295]) 
3.1  The design of dialkylamino benzoic acid analogs 
Studies have shown that modifications on the 2,4-dihydroxybenzoic acid moiety 
of platensimycin diminish most of the antibiotic activity [264]. This is in agreement with 
the proposed mechanism whereby the dihydroxybenzoic acid subunit engages the Hi -
His-Cys catalytic triad of the condensing enzymes (FabF/H) [120]. It therefore appears 
that efforts aimed at discovering simpler platensimycin analogs have a higher chance of 
success if the essential dihydroxybenzoic acid moiety is keptintact or minimally 
modified (Table 2–2). 
Recently, several groups have focused their attention on the replacement of the 
“difficult-to-synthesize” tetracyclic core of platensimycin or platencin with moieties that 
are relatively easy to chemically prepare. For example the Metzler-Nolte group reported 
the synthesis and biological evaluation of a bioorganometallic analogs f 
platensimycin/platencin whereby the tetracyclic/tricyclic core of these antibiotics were 
replaced with a η6-arylCr(CO)3 moiety [271]. Although the synthesis of the 
organometallic analogs of platensimycin took a total of nine linear steps, which was 
significantly shorter than the chemical synthesis of the parent platensimycin antibiotic, 
the MIC of these analogs were close to two orders of magnitude higher than 
platensimycin. Recently, Mulzer has reported a new analog that took only 7 total steps to 
make and which show antibiotic activity profile that is similar to those of platensimycin 
or platencin [276]. 
 
We rationalized that since FAS enzymes utilize substrates with long alkyl chains 
to make fatty acids [87] there ought to be a hydrophobic pocket at or near the active site 
of these enzymes. It is also known that dihydroxybenzoic acids bind to the catalytic triad 
in FAS enzymes [120]
thiolactomycin [91] or alkyl disulfide
side chains. Therefore we wondered if a combinatorial strategy whereby 
dihydroxybenzoic was coupled to a variety of commercially available alkyl 
yield an active analog of platensimycin












Scheme 3–1. A general pathway to generate bis
analogs. 
 
3.2 Synthesis and biological evaluation
En route to our reported synthesis of 
demonstrated the facile synthesis of amine 
dihydroxybenzoic acid ester with a terminal amino gr up 
gram-scale. A simple reductive amination with commercially available aldehydes 
. In fact, other FAS inhibitors such as cerulenin
 [296] analogs contain hydrophobic alkyl or alkenyl 
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(Scheme 3–3) or reaction with acid chlorides or sulfonyl chlorides would then fur ish 
myriads of easily accessible platensimycin/platencin analogs (see Figures 3–2 and 3–3).  
 
 
 Figure 3–2. Synthesized analogs for the initial screening. 
 
Table 3–1. MIC value of compounds 3–6 to 3–22. 
Compounds 
MIC (µg/mL) 
B. subtilis (3160) E. coli K12 (1655) 
platensimycin (1) 2 >32 
3–6 >256 >256 
3–7 128 >256 
3–8 4 >256 
3–9 >256 >256 
3–10 >256 >256 
3–11 >256 >256 
3–12 >256 >256 
3–13 >256 >256 
3–14 >256 >256 
3–15 >256 >256 
3–16 >256 >256 
3–17 >256 >256 
3–18 8 >256 
3–19 128 >256 
3–20 2 >256 
3–21 4 >256 
3–22 >256 >256 
 
Initial screening of analogs (Table 3–1), compounds 3–6 to 3–13, revealed that 
compound 3–8 (a myrtenal derivative) had the most potency amongst the molecules 
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tested with MIC values of 4, 16 and 8 µg/mL against B. subtilis (3160), methicillin-
resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) respectively 
(Table 3–1, 3–2). The MIC of compound 3–8 against B. subtilis (4 µg/mL) compared 
favorably with the MIC of platensimycin against B. subtilis (2 µg/mL). The other bis-
alkylamino analogs in Figure 3–2 were inactive and shows that the antibiotic activity of 
compound 3–8 is not just due to “greasiness”. Of note, compounds 3–10 and 3–11 which 
are structurally similar to compound 3–8 were found to be inactive. In line with earlier 
observation by the Merck group that platensimycin/platencin were ineffective against 
gram-negative bacteria [119,120], our new analog 8 was also ineffective against E. coli 
K12 (1655) (Table 3–1).  
 
Table 3–2. MIC values of compounds 3–8, 3–20 and 3–21. 
compounds 
MIC, µg/mL 
MRSA VRE E. coli + PAβND 
platensimycin (1) 0.5[120] 0.1[120] >32 
3–8 16 8 4 
3–20 32 32 2 




Figure 3–3. Second set of analogs and probes derived from (–)-myrtemycin. 
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We chose compound 3–8 as the lead structure and we designed a second set of 
structurally related compounds (Figure 3–3; compounds 3–16 to 3–22). Compounds 3–
16 and 3–17 tested the importance of the carboxylic acid moiety by either deleting or 
modifying as the methyl ester. Methyl esters can usually hydrolyze in vivo to produce 
carboxylic acids but we and others have previously shown that methyl esters of 
platensimycin are not good pro-drugs and do not hydrolyze into carboxylic acids under in 
vivo conditions [231,273,274]. This is not surprising because the presence of two 
phenolic hydroxyls on the benzoic acid core of platensimycin is expected to reduce the 
reactivity of the ester carbonyl towards hydrolysis. Compound 3–18 had one extra 
methylene group in the linker region between the benzoic acid core and the myrtenyl 
moiety and was designed to test the importance of the length of te linker unit. 
Compound 3–19 was designed to test if the benzoic acid moiety was as important in our 
analog as it is in the natural antibiotic. Compound 3–20 synthesized from saturated 
myrtanal, was designed to probe the importance of the alkene unit for b ological activity. 
Compound 3–21 is the enantiomer of the lead compound 3–8 whereas compound 3–22 
had only one (–)-myrtenyl group and was designed to test if both alkyl groups on 
nitrogen were needed for biological activity. The MIC values of the second-generation 
compounds 3–16 to 3–20 against S. aureus and B. subtilis are summarized in Table 3–1. 
From these results, we conclude that both carboxylic acid moiety and the di-
myrtenyl/myrtyl groups are important for the antibiotic activity of compound 3–8. 
Interestingly, the antibiotic activities of enantiomers (–)-3 8 and (+)-3–21 or the 
saturated form of (–)-3–8, compound (–)-3–20 are similar (see Table 3–1, 3–2). Adding 
one carbon length between the benzoic acid moiety and the di-myrtenyl amino moiety 
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didn’t change the MIC value significantly. However, analog 3–22 which had only one 
myrtenyl group attached to the nitrogen atom was inactive. The ineffectiveness of 
platensimycin/platencin against gram negative bacteria has been ascribed to efflux pumps 
in gram negatives that reduce the intracellular concentrations of this class of antibiotics 
[297]. Consequently, co-administration of efflux pump inhibitor, Phe-Arg-β-
naphthylamide dihydrochloride (PAβND), potentiated the effects of our new analogs on 
E.coli. In the presence of PAβND at 128 µg/mL, the MICs of compound 8 and analogs 
were 2–8 µg/mL. Interesting, these MICs were even lower than that of platensimycin in 
the presence of PAβND (see Table 3–2). 
In summary, we illustrate that biological function can be replicated with moieties 
that are easier to install but which would not have been predicted based on structure 
homology design. Significantly, we report a new set of analogs, which are exceptionally 
simple to make (three linear steps from commercial materials) yet they maintain 
biological activities that are comparable to the natural compounds which are typically 
synthesized in over 15 linear steps. Ongoing work in our laboratory is currently focused 
on investigating if these new platensimycin analogs target the same biological targets as 




Chapter 4. C-di-GMP mediated biofilm formation in bacteria and 
efforts towards anti-biofilm agents. 
4.1 Endo-S-c-di-GMP, a conservative change to the phosphate moiety of c-di-GMP 
4.1.1 Introduction 
C-di-GMP signaling has become of interest in the development of anti-biofilm or 
anti-virulence drugs because it has recently been shown that it regulates diverse 
phenotypes in bacteria including biofilm formation [203]. Despite the central role that c-
di-GMP plays in bacterial “lifestyle”, several aspects of this signaling molecule remain 
far from being understood. For example, the so-called adaptor proteins that bind to c-di-
GMP and transmit this binding event into processes, which lead to biofilm formation, are 
poorly characterized. Most of the c-di-GMP adaptor proteins, which have been found so 
far (for example the PilZ family) do not have any enzymatic activities of their own, 
suggesting that they probably relay the c-di-GMP binding event into allosteric 
modulation of other enzymes that they associate with. However, these as ociated 
enzymes or factors of c-di-GMP adaptor proteins have largely not been found. An 
interesting property of c-di-GMP is its ability to readily form dimers, tetraplexes and 
higher aggregates in the presence of cations [226,227]. Divalent cations such as 
magnesium promote dimer formation in c-di-GMP whereas monovalent cations such as 
potassium promote the formation of tetraplexes and octaplexes in c-di-GMP [226,227]. 
This propensity of c-di-GMP to form tetraplexes or octaplexes (G-quadruplexes) at 
micromolar concentrations in the presence of cations (such as magnesium and potassium) 
is intriguing because simple nucleotides (such as cGMP, GTP or pGpG) do not readily 
form G-quadruplex structures at micromolar concentrations. Plausibly, the facile 
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readily achieved when the dinucleotide pGpG does not so readily form intermolecular G-
quadruplexes. As both c-di-GMP and pGpG contain guanine bases, which are requir d 
for the formation of the G-tetrad plane found in G-quadruplexes, it is rea onable to 
assume that other structural features found in c-di-GMP, but not in the linear pGpG, are 
responsible for the enhancement of G-quadruplex formation. Herein, we reveal that small 
changes to the phosphodiester backbone of c-di-GMP (0.92 Å increase in the 
circumference of the backbone ring; Figure 4–1a) remarkably decrease the propensity to 
form G-quadruplexes. We show that a c-di-GMP analog which has one of th xygens in 
the 5’-bridging phosphodiester linkages replaced by sulfur (endo-S-c-di-GMP (4–2), 
Figure 4–1b) has altered biophysical and biochemical properties, distinct from th se of 
c-di-GMP.  
One general strategy that is typically used by drug developers to discover 
antagonists of signaling molecules is to modify the signaling molecule to afford analogs 
[299] that still maintain the ability to bind to the receptors that e signaling molecule 
binds to but unable to activate the receptors for biological function. In order to develop 
effective c-di-GMP analogs, which will be used to antagonize the actions of c-di-GMP, it 
is of interest to determine which functionalities on c-di-GMP could be modified to 
maintain binding to c-di-GMP processing proteins, without triggering processes that lead 
to biofilm formation. The aggregation of a c-di-GMP antagonist into higher aggregates 
would reduce its effective molarity. Therefore, we initiated a program to determine which 
moieties on c-di-GMP facilitate aggregate formation. C-di-GMP is a twelve-membered 
ring with limited conformational flexibility. The crystal structure of c-di-GMP reveals 
that the torsion angles found in this macrocycle are similar to those found in standard 
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linear RNAs, implying that the ring structure imposes little to no torsional stress to this 
molecule [300]. 
The ability of c-di-GMP but not linear pGpG, to readily form dimers and G-
quadruplexes at micromolar concentrations prompted us to hypothesize that the l ck of 
conformational flexibility in c-di-GMP, coupled with the low torsional stress in the 
macrocycle poise this molecule to make aggregates, such as G-quadruplexes or dimers 
(Figure 1–16). As a starting point to determine if the 12-membered ring of c-di-GMP is 
critical to its biophysical (aggregate formation) as well as biochemical (binding to 
receptors) properties, we chose to study a very close analog of c-di-GMP, referred in this 
thesis as endo-S-c-di-GMP (4–2). 
The replacement of oxygen at the bridging positions in phosphate linkages in 
nucleic acids can be considered conservative; Kool has shown that the thermal stabilities 
of DNAs containing phosphodiester linkages have similar thermal stabilities as native 
DNAs [301]. Enzymes, such as Klenow DNA polymerase or T7 RNA polymerase, can 
utilize templates containing phosphothioates as effectively as those c ntaining native 
phosphodiester linkages and no pauses were observed at the phosphothioester sites when 
these replicative enzymes were used [301]. 
 
4.1.2 Synthesis of endo-S-c-di-GMP.  
The synthesis of endo-S-c-di-GMP (4–2) is summarized in Scheme 4–1 (22% 
overall yield from commercially available phosphoramidite 4–3). The key step for the 
synthesis of 4–2 is the phosphothioate–iodide macro-ring closure, developed by Kool 
[302]. It has been shown by several researchers that the “bridging” positions in the 
phosphate linkages of both DNA [303-307] and RNA [308-311] can be replaced by sulfur 
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to give phosphothioester linkages. In DNA, 5’-phosphorothioester linkages are tabl  
[301] whereas for RNAs, 5’-phosphorothioesters are about six fold more labil than the 
natural phosphodiester linkages at pH 7 [308]. Although endo-S-c-di-GMP (4–2) also 
contains 2’–OH (the functionality that is responsible for facilitatng hydrolysis in RNA) it 
is stable at neutral pH because the cyclic structure position  he phosphate moiety more 
than 3.3 Å away from the 2’–OH, making it impossible for the 2’–OH in endo-S-c-di-
GMP to participate in an in-line cleavage reaction [312]. 
 
 
Scheme 4–1. Synthesis of endo-S-c-di-GMP (4–2). Conditions: a) cyanoethyl alcohol 
(5.0 eq.), imidazolium perchlorate (3.6 eq.), 6 h, then Beacauge reagent (2.5 eq.), 1 h, 
MeCN, RT; b) dichloroacetic acid (11–14 eq.), CH2 l2, 10 min, 60 % over two steps; c) 
phosphoramidite 4–3 (1.5 eq.), imidazolium perchlorate (4.7 eq.), then t-BuOOH (9.3 
eq.), MeCN, RT, 6 h; d) Me(PhO)3P
+I– (5.3 eq.), 2,6-lutidine (20 eq.), DMF, RT, 1 h, 61 
% over three steps; e) ammonia, RT, 24 h; f) NEt3
.3HF (20 eq.), MeCN, RT, 12 h, 59 % 
over two steps. DMF = dimethylformamide.  
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4.1.3 Polymorphism of c-di-GMP and endo-S-c-di-GMP 
C-di-GMP can exist in myriads of conformations. These conformations can be 
generally categorized as “closed” (the two guanine bases are on the same face) or “open” 
(the two guanines are on opposite faces). Calculations using Gaussian 09 software with 
HF/6-31G(d) basis set revealed that the ground state conformer of c-di-GMP is an open 
conformer whereby the C5s of the two guanines are 13.5 Å apart. The “closed” 
conformer of c-di-GMP, where the two guanines are parallel and separated by 6.8 Å, is 
biologically relevant and found in the active site of many c-di-GMP binding proteins (for 
recent examples see protein databank (PDB) crystal structures 3KYF [229], 3KLO [313] 
and 3I5A [314]). Computational studies revealed that the torsion angle [300] of endo-S-c-
d-GMP is different from that of the native c-di-GMP (Table 4–1). From these 
computational studies, we predicted that the aggregative behavior of endo-S-c- i-GMP 
would be different from that of c-di-GMP. 
 




α β γ δ ε ζ 
c-di-GMPa 
opend 72.3 –163.9 50.4 96.1 –161.5 63.6 
closede 79.7 –151.9 55.1 83.2 –179.4 64.9 
endo-S-c-di-GMPb 
openf 63.9 –146.6 58.9 94.3 –164.1 64.8 
closede 68.5 –137.6 64.5 80.6 –179.9 65.9 
linear RNAc 73.8 –168.2 62.2 81.6 –147.1 63.9 
The dihedral angular notations are determined as follows: a) O3’     P  α  O5’  β  C5’  γ  
C4’  δ  C3’  ε  O3’  ζ  P     O5’; b) O3’     P  α  S  β  C5’  γ  C4’  δ  C3’  ε  O3’  ζ  P     O5’; c) These are 
average values, taken from PDB 3MXH; d) C5–C5 of the guanines are 13.5 Å apart; e) 
C5–C5 of the guanines are 6.8 Å apart; f) C5–C5 of the guanines are 11.7 Å apart as the 
most stable conformer. 
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It is expected that the “closed conformer” of c-di-GMP (4–1) or endo-S-c-di-
GMP (4–2) would more readily form dimers or G-quadruplexes than the open conformers 
of c-di-GMP and endo-S-c-di-GMP (Figure 1–16). This is because in the closed 
conformation of both c-di-GMP and endo-S-c-di-GMP, the two guanines are uitably 
positioned for mutual intercalation (dimer, Figure 1–16) or for forming G-quadruplexes 
(Figure 1–16). One can therefore reliably predict the relative aggregative property of a c-
di-GMP analog by comparing the relative energy difference between the “closed” and 
“open” conformers of an analog to that of c-di-GMP. 
Computational studies done on both c-di-GMP and endo-S-c-di- GMP (both gas 
phase and using a solvent model) revealed that c-di-GMP is more likely (~ three times) to 
form a “closed” conformer than endo-S-c-di-GMP (see Table 2). Thisprediction was 
verified experimentally; the 1HNMR spectra of triethylammonium c-di-GMP and endo-S-
c-di-GMP show that both compounds exist as monomeric forms at 20 °C in the absence 
of monovalent cations such as K+ (see Figure 4–2c and 4–3c). The 1HNMR spectrum of 
c-di-GMP (which is C2 symmetric) shows two singlets at 5.87 and 7.96 ppm, assigned to 
the anomeric H1’ and guanine H8 protons, respectively (Figure 4–2c). Endo-S-c-di-GMP 
is not C2 symmetric, due to the presence of one “bridging” sulfur atom in the 
phosphothioate moiety and therefore the two anomeric H1’ as well as the two guanine H8 
in endo-S-c-di-GMP are chemically non-equivalent and have different chemical shifts 
(Figure 4–3c). The guanine H8 in endo-S-c-di-GMP appears as two singlets of equal 
intensities at 7.90 and 8.02 ppm, and the anomeric H1’ in endo-S-c-di-GMP appears as a 
singlet at 5.95 and a doublet at 5.85 ppm (Figure 4–3c). Upon the addition of 100 mM 
K+ to c-di-GMP, the intensities of the peaks at 7.96 and 5.87 ppm are reduced and other 
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peaks appear around 7.96 and 5.87 ppm (Figure 4–2b). These peaks are attributed to the 
different aggregates of c-di-GMP because upon heating the sample to 60 oC (which will 
break all aggregates), the multiple peaks disappear and new singlet peaks at 8.39 and 6. 0 
ppm appear (corresponding to the guanine H8 and the anomeric H on c-di-GMP 
respectively, Figure 4–2a). The shift in ppm values for monomeric c-di-GMP is expected 
as temperature affects ppm values [315]. Based on integration of the peaks in the 1HNMR
spectrum of c-di-GMP in a buffer containing 100 mM potassium cations at 20 oC, we 
estimate that only 14 % of c-di-GMP exists in the monomeric form under this condition 
(Figure 4–2b). On the other hand, upon the addition of 100 mM K+ to endo-S-c-di-GMP, 
43 % of the monomeric form still remains in the solution (compare Figures 4–2 and 4–
3).  It therefore appears that c-di-GMP has a higher propensity to form aggregates than 
endo-S-c-di-GMP and it is remarkable that a single conservative substitution in the 
phosphate moiety can result in such drastic consequences.  
 







ratio (open : closed)c 
gas phase solution phase 
c-di-GMP –1.9 1.9 24: 1 1: 25 
endo-S-c-
di-GMP 
–2.8 1.3 113: 1 1: 9 
a) The electronic energy (in the gas phase) was computed with Gaussian 09 
software [298] with HF/6-31G(d) basis set; b) The solvent effect in H2O was calculated 
with Onsager’s model in a self-consistent reaction field (seeSupporting Information for 
details); c) the ratio was determined from the equilibrium constant K, obtained from the 
equation ∆E = –RT lnK (T = 298 K).  
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In order to determine the nature of the aggregation states of both c-di-GMP and 
endo-S-c-di-GMP, DOSY experiments were conducted (see Appendix II for a brief 
introduction). Following literature precedent, the diffusion constants of he various c-di-
GMP/endo-S-c-di-GMP aggregates were obtained via analysis of T1/T2 relaxation [316]. 
According to the Stokes-Einstein equation, the hydrodynamic frictional coefficients or 
the diffusion constant D = k T / (6 π η R), where k is the Boltzmann constant, T is the 
temperature, η is the solvent viscosity and R is the radius of the molecular sphere. It 
therefore follows that the diffusion constant is inversely proportional to the radius of the 
molecule (or aggregate). The diffusion constants of c-di-GMP and endo-S-c-di-GMP in 
their monomeric forms can be obtained via DOSY experiments, in the absence of added 
metal cations (Figures 4–2c, 4–2d, 4–3c and 4–3d). Based on the obtained diffusion 
constant for monomeric c-di-GMP or endo-S-c-di-GMP, the diffusion constants for the 
dimeric, tetrameric and octameric forms can be predicted, using calculated radii of these 
aggregates (Figures 4–2d, 4–3d and Section 6.5.2). The monomer, dimer, tetramer and 
octamer of c-di-GMP or endo-S-c-di-GMP are denoted as M, B (Bimolecular, consistent 
with previous report ref [227]), T and O, respectively in F gures 4–2b and 4–3b. For c-
di-GMP, the majority of the aggregates in the presence of K+ are tetrameric (T) and 
octameric (O) [227], with predicted diffusion constants at 2.01 x 10–10 and 1.62 x 10–10 
m2/s; the experimental diffusion constants of the tetramer and octamer forms of c-di-
GMP (obtained from the DOSY experiment) are 1.91 x 10–10 and 1.60 x 10–10 m2/s, 
respectively. For endo-S-c-di-GMP, the only identified aggregate st in the presence of 
K+ was dimers (B), with the predicted and experimental diffusion constants at 2.07 x 10–





Figure 4–2. 1HNMR stacked spectra of 1.0 mM c-di-GMP in D2O. Conditions: a) 100 
mM KCl, 60 oC; b) 100 mM KCl, 20 oC; the peaks were assigned based on T1/T2 
relaxation analysis and ref 18; c) no metal cation, 20 oC; d) T1/T2 relaxation analysis 
(from DOSY experiments) with 3 mM c-di-GMP in D2O in 100 mM KCl (blue) or no 





Figure 4–3. 1HNMR stacked spectra of 1.0 mM endo-S-c-di-GMP in D2O. Conditions: a) 
100 mM KCl, 60 oC; b) 100 mM KCl, 20 oC; the peaks were assigned based on T1/T2 
relaxation analysis and NOE experiments (see Supporting Informati n); c) no metal 
cation, 20 oC; d) T1/T2 relaxation analysis (from DOSY experiments) with 3 mM endo-S-




The relative conformations of the guanine H8 and anomeric H1’ were determined, 
following previous reported method [227]. Guanine H8 and anomeric H1, in the syn 
conformation, are expected to exhibit strong positive NOE effects; whereas guanine H8, 
in the anti conformation, is expected to show a much weaker NOE effect with the 
anomeric H1 (Section 6.6.1). The syn or anti relation was denoted as “s” or “a” in 
Figures 4–2b and 4–3b, respectively. For example, Ba represents a dimeric endo-S-c-di-
GMP with the H1’ and H8 in an anti conformation in Figure 4–3b.  
Circular dichroism (CD) is a powerful tool for identifying the aggregation state of 
nucleic acids [227,317,318]. Although CD cannot give detailed molecular structure of G-
quadruplex (tetramolecular or octamolecular complexes), it can be used to qualitatively 
determine if a G-quadruplex is present in solution. Jones has shown tat a positive CD 
peak at around 310 nm is indicative of tetramolecular or octamolecular omplex 
formation by c-di-GMP [227]. This CD signature which indicates the presence of c-di-
GMP tetramolecular or octamolecular complexes was corroborated wi h NMR studies by 
Jones group. 
The CD (circular dichroism) spectra of c-di-GMP (under different conditions) are 
also remarkably different from that of endo-S-c-di-GMP (Figure 4–4). In the presence of 
potassium cation, c-di-GMP (100 µM) forms G-quadruplexes (a positive CD peak around 
310 nm is indicative of G-quadruplex formation in c-di-GMP, see Figure 4–4a and also 
reference [227]). However, the CD spectra of endo-S-c-di-GMP (100 µM) in the 
presence of various monovalent cations (Na+, K+, Li+) do not show any sign of G-
quadruplex formation (no positive peak around 310 nm, see Figure 4–4b). Even when 
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Figure 4–4. CD spectra of c
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nucleobase moieties of c-di-GMP. For example, the phosphate moieties of c-di-GMP 
interact with Arg479 and Gln596 of the EAL domain of FimX [202,228] (from 
Pseudomonas aeruginosa, nd binds monomeric c-di-GMP, Figure 4–5c) The majority 
of c-di-GMP binding proteins, whose crystal structures have been deposited in the protein 
databank (pdb), bind to dimeric c-di-GMP. In the majority of these structures, the protein 
residues interact with the phosphate moiety of c-di-GMP. The crystal structure of dimeric 
c-di-GMP bound to VpsT [313,319] (a transcriptional regulator from V. cholerae) reveal 
that Thr133 and Arg134 as well as other residues make specific interactions with the 
phosphate groups of c-di-GMP. Similarly, Arg123 and Asn124 of P4397 (a c-di-GMP 
“adaptor” protein containing the PilZ domain [209,229]) interact with the phosphate 
moiety in dimeric c-di-GMP (Figure 4–5b). Most diguanylate cyclases contain an 
inhibitory site (I-site) that allosterically modulates the synthesis of c-di-GMP [320]. 
WspR, a DGC from Pseudomonas aeruginosa also contains the I-site and analysis of a 
crystal structure of WspR bound to dimeric c-di-GMP (Figure 4–5a) [314] reveals 
specific interactions between the protein and the phosphate group found in c- i-GMP 
(Figure 4–5d) [321]. 
 
 
Figure 4–5. a) Dimeric c
c-di-GMP, bound to P4397 (PilZ domain) (PDB 
bound to FimX (EAL domain) (PDB 
TBD1265 (EAL domain) (PDB 
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from the catalytic site to inhibit the diguanylate cyclase ctivity. RocR is a potent PDE 
that has been shown to inhibit the expression of chaperone-usher pili that participate in 
biofilm formation [324]. Alg44 is a gene encoded in the alg operon that binds c-di-GMP 
and this binding is required for the production of the alginate polysaccharide. The 
interaction of Alg44 to c-di-GMP is well studied through isothermal c lorimetry and 
filter binding assays [221]. To assess the effect of endo-S-c-di-GMP, the compound was 
tested for its ability to inhibit the DGC activity of WspR, to c mpete for cleavage by the 
PDE activity of RocR and to compete for binding to Alg44 by thin layer chromatography 
(TLC) or filter binding assay. The effect of endo-S-c-di-GMP was compared to c-di-
GMP, which blocks all three protein activities, and cGMP, which does nt affect any of 
the proteins. In the presence of endo-S-c-di-GMP (1 mM), WspR (5 µM) in Tris buffer 
converted 70 % of GTP (8 nM) into c-di-GMP. 1 mM of c-di-GMP was however able to 
inhibit WspR from converting GTP into c-di-GMP (Figure 4–6). Similarly endo-S-c-di-
GMP failed to displace radio-labeled c-di-GMP from Alg44 whereas c-di-GMP was able 
to displace radio-labeled c-di-GMP from Alg44 (Figure 4–7). Endo-S-c-di-GMP did 
however bind to RocR, evident by the inhibition of RocR cleavage of radio-lbeled c-di-
GMP in the presence of endo-S-c-di-GMP (Figure 4–8). In the case of RocR, endo-S-c-
di-GMP was almost as effective at competing with radio-labeled c-di-GMP as c-di-GMP. 
In the presence of Ca2+ [199], PDEs do not cleave c-di-GMP. Therefore, to determine the 
binding constant for c-di-GMP/endo-S-c-di-GMP and RocR, we added Ca2+ (5 mM) to 
the binding buffer. Unlabeled c-di-GMP could compete with radio-labeled c-di-GMP (5 
nM) binding to RocR (5 µM) with an IC50 of 236 nM, whereas endo-S-c-di-GMP 
competed with radio-labeled c-di-GMP with an IC50 of 431 nM (Figure 4–8a). The 
 
cleavage site of endo-S-c
not the endo-S-phosphothioate bridge 
the RocR enzymatic cleavage occurred also proves that the binding of endo
with RocR protein.  
 
Figure 4–6. Inhibition 
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Figure 4–7. Displacement of radio
GMP, endo-S-c-di-GMP or cGMP. The value of 
proportional to the binding affinity for Alg44.
Figure 4–8. a) Binding assays of RocR 
presence of Ca2+; b) RocR enzymatic cleavage reactions o
GMP (see Section 6.4.2) 
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The studies presented herein reveal that proteins that bind to c-di-GMP utilize the 
phosphate moiety of c-di-GMP as an important recognition element. The crystal structure 
of c-di-GMP bound to the EAL domain of FimX shows the dinucleotide bound in the 
“open” conformer (Figure 6c and d) whereas c-di-GMP is bound to most DGCs and PilZ 
proteins in the “closed” conformer (see Figure 6a and b). RocR has been crystallized but 
its structure not solved [325]. However, Rao et al. have computed the structure of RocR 
and shown that the computed structure binds to monomeric c-di-GMP, which is in the 
“open” conformer [326] Interestingly, endo-S-c-di-GMP (4–2) (which has a lower 
propensity to form a “closed” conformer) could only inhibit an EAL containing protein, 
RocR, and not DGC or PilZ containing proteins (WspR and Alg44 respectively). 
 
4.1.5 Conclusion 
C-di-GMP analogs that can selectively inhibit c-di-GMP metabolism or “adaptor” 
proteins will become useful tools for modulating c-di-GMP signaling i  bacteria. To 
readily cross the bacterial cell membrane, it is desirable that such analogs are not 
charged. In this work, a conservative modification of one of the phosphate moieties in c-
di-GMP (by replacing only one of the “bridging” oxygens in the phosphate linkages in c-
di-GMP with sulfur) gives an analog, endo-S-c-di-GMP, which is remarkably different 
(biophysically and biochemically) from c-di-GMP. This suggests that the phosphate 
moieties in c-di-GMP play important roles in aggregate formation as well as the binding 
of c-di-GMP to metabolism and processing proteins. It appears tht the interactions 
between proteins’ residues and the phosphate moieties in c-di-GMP are important for 
binding. Therefore, it is tempting to speculate that the amino acids that contact the 
phosphate moieties are partial determinants of c-di-GMP binding to the so-called adaptor 
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proteins. Future directions are aimed at mutating these residues in c-di-GMP proteins to 
determine if they are indeed determinants of c-di-GMP binding to adaptor proteins. These 
experiments are beyond the scope of this current Ph.D work. Adaptor proteins that bind 
to c-di-GMP are poorly characterized but they are thought of as mediators of c-di-GMP 
action. Understanding the determinants of c-di-GMP binding to proteins will aid in the 
prediction of c-di-GMP binding proteins as well as providing design pri ci les for the 
construction of c-di-GMP antagonists. 
C-di-GMP interacts with numerous proteins and has pleiotropic effets on the 
bacterial cell. The effect of endo-S-c-di-GMP allows selectiv  inhibition of proteins that 
bind the open form of c-di-GMP. This provides the basis for rationale design of small 
molecular inhibitors that only act on specific proteins in the c-di-GMP pathway. Future 
studies may also reveal selective inhibition of the proteins that bind the closed form of c-
di-GMP. 
 
4.2 Design and syntheses of c-di-GMP analogs  
4.2.1  The design of the c-di-GMP analogs 
 The previous section highlighted that conservative changes to the phosphate 
moiety of c-di-GMP remarkably affect structure and biological profile. To gain more 
insights into which of the functionalities in c-di-GMP are important for binding to c-di-
GMP signaling proteins, we extended our studies to look at how modifications to the 2’-
OH of c-di-GMP could affect the structure and biological profile of these analogs. Four 
sugar puckering conformations of ribose and deoxyribose can exist in equ librium 
(Figure 4–9, [327]). The ribose unit in c-di-GMP adopts a 3’-endo, 2’-exo puckering; the 
3’-carbon and the nucleobase lie on the same face, whereas the 2’-carbon lies in the 
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opposite face [328]. The electronic properties and the size of the 2’-functionalities have a 
great effect on the sugar puckering modes [329]. The 2’-OH can also p rtake in hydrogen 
bonding interactions with the macromolecular receptor that binds to c-di-GMP (e.g. PDB 
code: 3HV8). Six analogs (4-52 to 4-57) were synthesized following Jones’ protocol 
(Figure 4–10) [330].  
 In compounds 4–52 and 4–53, the 2’-OH group in c-di-GMP is replaced with 2’-
OMe and 2’-H, respectively. 4-52 is expected to adopt a 3’-endo, 2’-exo puckering 
(similar to c-di-GMP) but the OMe group can only act as a hydrogen bond acceptor and 
not donor (unlike c-di-GMP, for which the 2’-OH can act as a hydrogen bond acceptor or 
donor). Also the 2’-OMe group is bigger than the native 2’-OH. Consequently a alog 4-
52 is ideal for probing the effect of the 2’OH group in c-di-GMP. In compound 4-53, the 
2’-OH is replaced with a 2’-H. It was expected that 4-53 would adopt all puckering 
modes available to it (similar to the puckering modes in 2’deoxynucleotides [329]). 
Compound 4-53 would, therefore, be ideal for investigating how the sugar puckering 
mode affects the biophysics as well as the biology of c-di-GMP. We have already 
mentioned that the conservative substitution of the phosphate moiety of c-di-GMP 
affords an analog that has a lower propensity to form aggregates (Section 4.1). To arrive 
at c-di-GMP sugar analogs that also have a lower propensity to form aggregates, we 
designed compounds 4–54 to 4–57 in which both the 2’-OH and one of the bridging 









































































































































































endo-S-c-di-GMP analogs with phosphothioate linkage
c-di-GMP analogs with phosphate linkage





endo-c-di-GMP (4-2) 4-54 4-55
4-56 4-57
 
Figure 4–10. Chemical structures of designed c-di-GMP and endo-S-c-di-GMP analogs. 
  
4.2.2 Previous syntheses of c-di-GMP 
 The synthesis of c-di-GMP is non-trivial. The first preparative synthesis of c-di-
GMP was probably reported by Dennis and Jones groups in 1985 with a phosphotrie ter 
strategy [331]. Dennis and Jones prepared cyclic di-UMP (Scheme 4–2), cyclic di-AMP 
and cyclic UMP-AMP and investigated their inhibitory activity against RNA synthesis 
[331]. The highlight of their synthesis is a sulfonyl chloride (TPSCl) mediated coupling 
of an alcohol and a phosphate. This was followed by deprotection of the cyanoethyl 
group on phosphate with Et3N and a cyclization step, utilizing the same TPSCl for an 
intramolecular reaction of a 3’-phosphate with a 5’-OH of a dinucleotid  to afford a 
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cyclized product (4–12). After global deprotections with 2-nitrobenaldoxime (NBO) and 
ammonia, cyclic dinucleotides (such as 4-13) were obtained. Later, in 1987, the 
Benziman et al. adapted this chemical synthetic strategy for synthesizing cyclic di-GMP, 
and they published a modified c-di-GMP chemical synthesis method using a different 
cyclization reagent (triisopropylbenzenesulfonyl nitrotriazole) and protecting groups 
[332]. In the following decades, Hayakawa [333], Jones [330], Sintim [334] and others 
all contributed to a better chemical synthesis of c-di-GMP. Recently an enzymatic 
synthesis of c-di-GMP using DGC from E. coli also reported [335].  
 
 
Scheme 4–2. Cyclic di-UMP synthesis by Dennis and Jones [331]. Conditions: a) TPSCl 
(3 eq), tetrazole (9 eq) in pyridine, RT, 2 h; b) NEt3, pyridine, RT, 2 h; c) BSA (2 %), 
CHCl3: MeOH (7: 3), 0 °C , 20 min; d) TPSCl (6 eq), tetrazole (18 eq), RT, 5 h; e) 
tetramethylguanidine (TMG), p-nitrobenzaldoxime (NBO), in dioxane: H2O (1: 1), RT, 
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12 h, then, ammonia (37 %, aq), RT50 °C , 12 h; f) TBAF in pyridine, RT, 3 h, then 
pyridinium Dowex 50-X8, RT, 1 h.  
 Hayakawa’s synthesis was a modified procedure of the Dennis and Jo es’ 
strategy. The yield of the cyclization step was claimed to improve,  up to 75 %, by 
changing the protecting groups on the phosphate [333]. We and others have howe r not 
managed to obtain a high yield in the cyclization step [336]. Jones’ group also introduced 
an H-phosphonate strategy [226] (Scheme 4–3). Firstly, guanosine phosphoramidite 4–15 
and phosphonate 4–16 were prepared by coupling a common starting material 4–14 with 
phosphoramidite and phosphorochloridite, respectively. The resulting phosphoramidite 
(4–15) and H-phosphonate (4–16) were then coupled and oxidized, followed by 
cyclization with an acid chloride (4–18). The final product (4–19) was achieved by 
removal of the TBS group with NEt3•3HF and global deprotection of the iso-butyrate and 
the cyanoethyl groups on the nucleobase and phosphate groups respectively with 
ammonia. Recently, the Jones’ group reported a gram scale synthesis of c-di-GMP and 
phosphothioate analog by using a modified H-phosphonate strategy that was originally 





   
Scheme 4–3. Jones’ H-phosphonate strategy for c-di-GMP synthesis. Conditions: a) 
bis(diisopropylamino)cyanoethyl phosphoramidite, pyridinium trifluoroacetate; b) 2-
chloro-4H-1,3,2-benzodioxaphosphorin-4-one; c) pyridinium trifluoroacetate; d) tert-
butylhydroperoxide; e) sulfonic acid resin; f) adamantoylcarbonyl chloride; g) NBS, 
MeOH; h) pyridine: ammonia (37 %, aq) (1:1); i) NEt3•3HF. 
   
Taking advantage of solid-support synthesis, Sintim group proposed a miniscale 
synthesis of c-di-GMP synthesis (Scheme 4–4) [334]. The synthesis is programmed 
(steps a–d, Scheme 4–4) by DNA/RNA synthesizer and can be achieved automatically 
before the macro-ring is closed. The DNA/RNA synthesizer can perform four standard 
commands: detritylation with an acid, coupling reaction with a phosphoramidite (4–22), 
capping the trace amount of unreacted hydroxyl groups with an acid anhydride, and an 
oxidation reaction to convert phosphines into phosphates (Scheme 4–4). The synthesis 
start from an ODMT modified CPG bead 4–20 (for synthesis see Section 6.1), and after 
two complete cycles of synthesis with DMT-off mode (a–b–c–d–a–b–c–d–a, Scheme 4–4; 
DMT-off mode means the product is DMT deprotected when the programmed cycles 
finish), a 5’-OH diguanosine (4–28) was produced on the CPG beads.  After the CPG 
linker was cleaved by Et3N, the ring was cyclized with a sulfonyltriazole (1-
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mesitylenesulfonyl-3-nitro-1,2,4-triazole) followed by a global deprotection with 














































































































































































































































Scheme 4–4. Sintim’s solid support synthesis of c-di-GMP. Steps a–d were conducted on 
the DNA/RNA synthesizer with a standard program. Reaction conditions: a) detritylation: 
6 % dichloroacetic acid in CH2Cl2, RT, 45 s; b) coupling: phosphoramidite (0.1 g/mL), 
ETT (0.25 M) in CH3CN, RT, 90 s; c) capping: Ac2O (10 v%), 2,6-lutidine (10 v%) in 
THF (Cap A solution), then N-methylimidazole (10 v%) in THF (Cap B solution), RT, 30 
s; d) oxidation: I2 (0.02 M) in water: pyridine: THF (1: 2: 7), RT, 30 s; e) TEA in 
acetonitrile, then 1-mesitylenesulfonyl-3-nitro-1,2,4-triazole (0.1 M) in pyridine, RT, 48 
h, then filtered; g) NH4OH (28 %), RT or 40 °C , 14 h, then filtered; h) NEt3•3HF (20 eq.) 




4.2.3 The synthesis of the designed c-di-GMP analogs 
 We choose the solid-supported strategy [334] for synthesizing endo-S-c-di-GMP 
analogs (see Scheme 4–5) and solution phase strategy [330] for synthesizing natural c-di-
GMP analogs. The advantages of preparing c-di-GMP analogs on a solid-support are 
numerous: i) the intermediate can be simply purified by washing off unreacted reagents 
with organic solvents, rather than by using tedious column chromatography or HPLC 
purification; and ii) most reactions can be pre-programmed in a DNA/R A synthesizer 
and, hence, easier to execute. For the synthesis of endo-S-c-di-GMP analogs, 
sulfurization was achieved using Beaucage reagent. The mechanism for phosphothioate 
using Beaucage reagent, or 3H-1,2-benzodithiole-3-one 1,1-dioxide is illustrated in 
Scheme 4–6b [337]. 
 In summary, eight c-di-GMP analogs (including the natural c-di-GMP, Figure 4–
9) were synthesized without incident. The characterization of the c-di-GMP analogs are 
referred to Section 6.4. The ongoing work by a new Ph.D student in the Sintim laboratory 
is to characterize the synthesized c-di-GMP analogs, using both biphysical and 
biochemical techniques. These experiments are expected to provide more insights 
regarding the pharmacophore units on c-di-GMP that are important for binding to the 





Scheme 4–5. Solid-support synthesis of dinucleotides and cyclization in solution phase. 
Steps a–e were conducted on the DNA/RNA synthesizer with a standard program. 
Reaction conditions: a) detritylation: 6 % dichloroacetic acid in CH2Cl2, RT, 45 s; b) 
coupling: phosphoramidite (0.1 g/mL), ETT (0.25 M) in CH3 N, RT, 90 s; c) capping: 
Ac2O (10 v%), 2,6-lutidine (10 v%) in THF (Cap A solution), then N-methylimidazole 
(10 v%) in THF (Cap B solution), RT, 30 s; d) sulfurization: Beaucage reagent (10 
mg/mL) in CH3CN, RT, 15 min; e) oxidation: I2 (0.02 M) in water: pyridine: THF (1: 2: 
7), RT, 30 s; f) methyltriphenoxyphosphonium iodide (20 eq.) in DMF, RT, 45 min, the  
filtered; g) NH4OH (37 %), RT or 40 °C , 14 h, then filtered; h) NEt3•3HF (20 eq.) in 





Scheme 4–6. a) Cleavage of nucleotide from CPG support, deprotection of cyanoethyl 
group and cyclization to afford endo-S-c-di-GMP analogs; b) the mechanism of 
sulfurization, using the Beaucage reagent.   
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Chapter 5. Conclusions and future directions 
5.1 FAS inhibitors 
In this dissertation we have highlighted an unsavory truth that we are in a never-
ending battle with bacterial pathogens. Solving this bacterial resistance problem demands 
the combination of several disciplines, from synthetic organic chemistry to biochemical 
characterization of ligand protein interactions and then to microbiology. Fatty acids are 
important building units in both human and bacterial cells. However the enzym s that are 
responsible for fatty acids in humans are different from those found in bacteria, 
presenting a great opportunity to target FAS enzymes for antibiotic development. 
Platensimycin and platencin are newly discovered potent bacterial FAS inhibitors. In the 
early part of this dissertation, we demonstrated concise synthetic strategies to access 
platensimycin-like molecules (such as compound 5–2, Figure 5–1) and showed that 
although the tetracyclic core of platensimycin was initially thought of as not been 
important for the drug’s action, conservative modifications to this ring can sometimes 
abrogate the drug’s affinity for the FabF enzyme.  Interestingly, using function-oriented 
synthetic approach [338-343], we also demonstrate that analogs whereby the tetracyclic 
core unit of platensimycin is drastically altered (such as compound 5–3, Figure 5–1) can 
also have good antibiotic profile. We have therefore identified a new class of antibiotic 






Figure 5–1. Structures of platensimycin (5–1), oxazinidinyl platensimycin (5–2) and 
myrtemycin (5–3).  
 
5.2  Development of dynamic ring-closing metathesis 
En route to making platensimycin-like compounds, we uncovered conditions that 
allowed for ring-closing metathesis, under dynamic conditions. The dynamic ring-closing 
metathesis is a one-pot reaction in the presence of both ruthenium and a compatible base. 
The dynamic ring-closing metathesis (RCM) permitted the use of ither diastereomers 
cis-2–34 or trans-2–34 to be used for a ring-closing reaction. Normally RCM requires 
that both alkenes on cyclic structures to be on the same side, but a dynamic RCM 
combines epimerization and the ring-closing reaction in one pot and thereby obviating the 
need to have both alkenes on cyclic structures to be on the same side, see Scheme 2–11). 
The product obtained from our dynamic RCM procedure, 2–33, contains a bicyclo[3.2.1] 
moiety that is not only found in platensimycin but also in many other biologically active 
molecules (Figure 5–2). Thus the dynamic ring-closing metathesis would be a general 
way to construct these molecules. Future development of the dynamic RCM to shorten 
the reaction time as well as reduce the catalyst loading will make this methodology 





Figure 5–2. Selected natural products that carry a bicyclo[3.2.1] moiety.  
 
5.3  Biofilm formation in bacteria 
C-di-GMP, dubbed a master regulator in bacteria is critical for several processes, 
including biofilm formation. As bacterial biofilms are known to confer greater antibiotic 
resistance, when compared to bacteria in the planktonic state, it is natural that the 
scientific community is now focused on finding means to interrupt c-di-GMP signaling in 
bacteria. Despite years of active research in the c-di-GMP field, very little is known about 
the functionalities on this important molecule that could be altered to achieve specificity 
in c-di-GMP binding to the different binding proteins. In this dissertation, we provide a 
general solution to this long-standing problem by demonstrating that one can use 
conformational steering to design c-di-GMP analogs that can specifically inhibit one 
class of binding proteins and not others. This is a first in the field, to the best of our 
knowledge and lays down the foundations to design other c-di-GMP analogs to alter the 
biofilm phenotype. The challenge now is to design analogs that will preferentially form c-
di-GMP dimers and only inhibit DGCs and PilZ-type adaptor proteins that are involved 
in the production of biofilm-related matrix. Future work in the Sintim group will examine 
the biophysical as well as biological properties of the c-di-GMP analogs, 4–52 to 4–57, 
that were prepared during this PhD project.  
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Chapter 6. Experimental Section 
6.1  General procedure 
6.1.1  General reaction conditions 
Air and moisture sensitive reactions are explicitly indicated in the reaction 
procedures. Reactions were carried out in oven-dried glassware and se le  with rubber 
septa under a positive pressure of anhydrous argon or nitrogen. All solution phase 
reactions were all stirred with teflon-coated magnetic stir bars. Elevated temperatures 
were obtained using silicone oil baths and monitored by a thermometer. Low 
temperatures were obtained by ice bath or by solid CO2 (dry ice) mixed with organic 
solvents such as acetone and acetonitrile. Organic solutions were all concentrated using a 
Büchi rotary evaporator with an aspirator pump. Trace amount of solvent or high boiling 
point solvent was removed by treatment under high vacuum for 0.5–5 hours.  
6.1.2  Preparation of the solvents 
Anhydrous tetrahydrofuran was obtained by distillation over metallic sodium or 
using a PureSolvent™ system prior to use. Dry dichloromethane, toluene and pyridine 
were distilled from CaH2 prior to use. Acetonitrile was first distilled over CaH2 and then 
dried overnight with activated molecular sieves (4Å). DMF was distilled over CaCl2 
under a reduced pressure before stored with activated molecular sieves (4Å) overnight. 
Anhydrous benzene was purchased from Sigma-Aldrich and used “as is”. Degassed 
solvent was obtained by bubbling argon through the solvent (5–10 bubbles per second) 
and venting with a needle for 30 min (Figure 6–1).  
 
 
Figure 6–1. The apparatus for solvent degassing. 
 
6.1.3  Reagents 
Hoveyda-Grubbs II catalyst and a
was purchased from Sigma
sieves overnight prior to use. 
America. Phosphoramidites and Beacauge reagent 
or Azco Biotech. Sulfonylethyl
reported procedure [344]
(Scheme 6–1). Solvents for silica
grade) were purchased from VWR. Other reagents were all purchased from Sigma











Scheme 6–1. Chemical synthes
 
 
nhydrous Hünig’s base (diisopropylethylamine) 
-Aldrich. Triethylamine was dried over activated molecular 
Chloro(methoxy)methane was purchased from TCI 
were purchased from Glen Research 
-ODMT modified CPG beads were synthesized by 
 from the inexpensive 3-aminopropyl CPG on a


















i  of sulfonylethyl-ODMT beads [344].  
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6.1.4  Instrument 
Thin-layer chromatography (TLC) was performed on Merck Kieselgel 60 F254 
plates with a 365 nm fluorescent indicator. The TLC was visualized by UV light, KMnO4 
stain or acidic p-anisaldehyde stain followed by gentle heating. The crude reaction 
mixtures were purified by flash chromatography on silica gel (230-400 mesh) with slow 
elution of a mixture of organic solvents, or by HPLC. A Varian 210 system was used 
with a UV detector for all HPLC analysis and purification. The samples were all filtered 
by a 0.2 µm syringe filter (PVDF or PTFE) prior to the injection.  
 NMR spectra were measured on Bruker AV-400, Bruker DRX-400, Bruker 
DRX-500 or Bruker AVIII-600. Data for 1H-NMR spectra are reported as follows: 
chemical shift (ppm, relative to residual solvent peaks or indicated external standards; s = 
singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, td = triplet of 
doublets, dt = doublet of triplets, ddd = doublet of doublet of doublets, tdd = triplet of 
doublet of doublets, dddd = doublet of doublet of doublet of doublets, m = multiplet), 
coupling constant (Hz), and integration. Coupling constants were rounded to 0.5 Hz. Data 
for 13C-NMR are reported in terms of chemical shift (ppm) relative o residual solvent 
peak. HSQC (Heteronuclear Single Quantum Coherence), COSY (COrrelation 
SpectroscopY) and selective NOE (Nuclear Overhauser effect) wre also reported for the 
structural elucidation purpose. DOSY (Diffusion Ordered Spectroscopy) experiment 
conditions refer to Section 6.6.1.  
Mass spectra (MS) were recorded by JEOL AccuTOF-CS (ESIpositive and 
negative modes) or Varian GC-MS (EI, 70 eV). High resolution mass spectra (HRMS) 
for ESI spectrometer were calibrated with an aqueous solution of CsI. The aggregated 
 
cation [Cs2I]
+ and anion [CsI
negative mode, respectively. 
UV absorbance spectra were obtained on a JASCO V
1 cm path length cuvette, and CD experiments were performed on a JASCO J
spectropolarimeter with 1 cm path length cuvette. The co
of c-di-GMP and endo-S
260 nm for c-di-GMP and endo
coefficient for both compounds.
 
Figure 6–2. a) A real 
Nakayama). 1 – synthesis columns (up to four columns can be installed); 2 
panel; 3 – phosphoramidites; 4 
Cap A solution (Ac2O (10 v%), 
methylimidazole (10 v%) in THF); 7 
6 % dichloroacetic acid in CH
b) detail illustration of a synthesis column. The column contains two separate p rts 10 
and 11, and each part contains a fritted glass support that can hold the CPG beads and 
allow the liquid reagents to pass through. Around 0.1 g CPG beads can be loaded in 
between the two fritted glass supports
(The figure is modified from 
2]
– peaks were used as standard for ESI positive and 
 
-630 spectrophotometer with 
ncentration of a stock solution 
-c-di-GMP was determined by the measuring of absorbance at 
-S-c-di-GMP, using 21,600 M-1cm-1 as a molar extinction 
 
photo of DNA/RNA synthesizer (photo credit: Dr. Shizuka 
– ETT (0.25 M) in CH3CN with 4 Å molecular sieves; 5 
2,6-lutidine (10 v%) in THF); 6 – Cap B solution (
– I2 (0.02 M) in water: pyridine: THF (1: 2: 7); 8 
2Cl2; 9 – anhydrous acetonitrile (with 4 Å molecular sieves). 













DNA/RNA synthesizer (ABI Applied Biosynthesis 392) was used to conduct the 
pre-programmed synthesis of nucleotides (Figure 6–2). Regular 1.0 µmol synthesis 
program was used for all CPG-supported reactions.  
 
6.2  Synthetic protocols for compounds in Chapter 2 
3-(Benzyloxymethyl)cyclopent-2-enone (2–39) 
 
(Benzyloxymethyl)tributylstannane was prepared (50 g scale) using the reported 
literature method [345]. This reaction was air and moisture sensitive. To a solution of 
(benzyloxymethyl)tributylstannane (13.0 g, 31.6 mmol) in dry THF (130 mL) at –78 oC 
under argon, n-BuLi (1.6 M in hexane, 17.0 mL, 27.2 mmol) was added via syringe. 
After stirring for 15 min, 3-methoxycyclopent-2-enone 2–38 (2.20 g, 19.6 mmol) in dry 
THF (15 mL) was added dropwise within 10 min. A precipitate sometimes forms before 
addition is complete. After stirring for 1 h, the reaction mixture was allowed to warm to 
room temperature and stirred at room temperature for an additional 4 h before the mixtur
was quenched with NH4Cl (saturated aqueous solution, 50 mL). The aqueous layer was 
then extracted with EtOAc (30 mL x 3). The combined organic layer was dried over 
MgSO4 and was concentrated in vacuo. The crude material was purified by silica gel 
column chromatography (Rf = 0.35, hexane/EtOAc = 3:1) to afford product 2–39 (3.35 g, 
84 %) as a pale yellow crystal. Product 2–39 showed black on TLC after staining with p-
anisaldehyde followed by gentle heating.  
109 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.52-7.15 (m, 5H), 6.17 (m, 1H), 4.56 (s, 2H) , 4.28 
(s, 2H), 2.61-2.46 (m, 2H), 2.40-2.35 (m, 2H). 13C NMR (100 MHz, CDCl3) δ ppm 
208.7, 177.7, 137.1, 128.7, 128.1, 127.5, 127.2, 72.7, 69.0, 34.4, 28.0. GCMS (EI): 202 
(M+), 173, 107, 91. IR (cm–1): 3072 (w), 2852 (w), 1699 (s), 1677 (s), 1625 (m), 1498 
(w), 1437 (m), 1402 (w), 1265 (s), 1240 (w), 1143 (s), 1105 (m), 1024 (m), 971 (w), 868 
(w), 735 (s), 699 (s), 628 (w).  
(±)-5-Allyl-3-(benzyloxymethyl)cyclopent-2-enone (2–40) 
 
This reaction was air and moisture sensitive. To a solution of diisopropylamine 
(2.0 mL, 15 mmol) in dry THF (50 mL) at –78 °C under argon, n-BuLi (1.6 M in hexane, 
8.2 mL, 13 mmol) was added dropwise within 10 min. After stirring for 30 min, the 
reaction mixture was allowed to warm to 0 °C. After stirring for another 1 h, dry HMPA 
(1.5 mL, 8.6 mmol) was added via syringe, and the reaction mixture was cooled to –78 
°C. Enone 2–39 (2.44 g, 12.1 mmol) in dry THF (10 mL) was added dropwise within 5 
min. The reaction mixture was stirred for 1 h at –78 °C before allyl iodide (1.4 mL, 15 
mmol) in dry THF (10 mL) was added dropwise within 30 min. After stir ing for another 
30 min, the reaction mixture was allowed to warm to room temperature overnight. The 
reaction mixture was quenched with NH4Cl (saturated aqueous solution, 30 mL), the 
water layer was extracted with EtOAc (20 mL x 3). The combined organic layer was 
dried over MgSO4 and was concentrated in vacuo. The crude material was purified by 
silica gel column chromatography (Rf = 0.40, hexane/EtOAc = 5:1) to afford product 2–
40 (1.83 g, 62 %) as a colorless oil. Some starting material enone 2–39 was recovered 
110 
 
(0.15 g, 8 %). The product 2–40 showed black on TLC after staining with p-anisaldehyde 
followed by gentle heating. Byproduct 2–41 was obtained (~ 25 %) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ ppm 7.43-7.27 (m, 5H), 6.22-6.17 (m, 1H), 5.74 (tdd, J = 
17.0, 10.0, 7.0 Hz, 1H), 5.07 (ddd, J = 17.0, 3.0, 1.5 Hz, 1H), 5.05-5.01 (m, 1H), 4.60 (s, 
2H), 4.30 (d, J = 0.5 Hz, 2H), 2.72 (tdd, J = 19.0, 7.0, 1.0 Hz, 1H), 2.61-2.46 (m, 2H), 
2.31 (d, J = 19.0 Hz, 1H), 2.20-2.10 (m, 1H). 13C NMR (100 MHz, CDCl3) δ ppm 210.3, 
176.6, 137.3, 135.2, 128.5, 128.4, 127.9, 127.6, 116.8, 73.0, 69.3, 44.8, 35.3, 34.2. 
GCMS (EI): 242 (M+), 136, 121, 91. IR (cm–1): 1695 (s), 1627 (m), 1440 (m), 1370 (w), 




1H NMR (400 MHz, CDCl3) δ ppm 7.42-7.28 (m, 5H), 6.28 (t, J = 2.0 Hz, 1H), 5.63 
(dddd, J = 17.0, 10.0, 8.0, 7.0 Hz, 2H), 4.98-4.90 (m, 4H), 4.78 (s, 2H), 2.66 (dd, J = 
13.0, 7.0 Hz, 2H), 2.41-2.28 (m, 4H), 2.19 (m, 2H). 13C NMR (100 MHz, CDCl3) δ ppm 
222.1, 140.8, 137.3, 134.4, 128.4, 127.9, 127.3, 118.2, 117.4, 73.9, 57.0, 40.5, 39.0, 23.5. 
GCMS (EI): 281 (M-H+), 251, 214, 173, 91. IR (cm–1): 2861 (w), 1737 (s), 1641 (w), 





This reaction is air and moisture sensitive. In a 250 mL round bottom flask, CuCN 
(2.6 g, 29 mmol) was added and dried under high vacuum at 100 °C for 1 h. After the 
mixture had been cooled to room temperature, the flask was flushed with argon before 
tetravinyltin (3.5 mL, 19 mmol) in dry THF (100 mL) was added. Themixture was then 
cooled to –78 °C, and n-BuLi (18.0 mL, 1.6 M in hexane, 28.8 mmol) was added 
dropwise within 15 min. After stirring for 30 min, the reaction mixture turned greenish. 
BF3·Et2O (11.4 mL, 90.0 mmol) was then added via syringe and stirring cotinued for 10 
min before enone 2–40 (1.14 g, 4.70 mmol) in dry THF (10 mL) was added dropwise 
within 10 min. After stirring for another 1 h, the reaction mixture was allowed to warm to 
room temperature overnight, and it slowly turned black. The reaction mixture was 
quenched with NH4Cl (saturated aqueous solution, 20 mL), whereupon the black color 
disappeared to give a clear brown solution, and the water layer was extracted with EtOAc 
(15 mL x 3). The combined organic layer was dried over MgSO4 and was concentrated in 
vacuo. The crude material was purified by silica gel column chromatgr phy (Rf = 0.40, 
hexane/EtOAc = 10:1) to afford product (a mixture of cis- and trans- 2–34, 1.08 g, 85 %) 
as a colorless oil. The product 2–34 mixture showed black on TLC after staining with p-
anisaldehyde followed by gentle heating. The product ratio was determined by GCMS 
and 1H NMR. cis-2–34: trans-2–34 = 1: 3.7.  
1H NMR (400 MHz, CDCl3) δ ppm 7.40-7.23 (m, 5H for t ans, 5H for cis), 5.95 (dd, J = 
18.0, 11.0 Hz, 1H for cis), 5.9 (dd, J = 18.0, 11.0 Hz, 1H for trans), 5.79-5.66 (m, 1H for 
trans, 1H for cis), 5.15 (d, J = 11.0 Hz, 1H for trans), 5.03 (m, 3H for trans, 3H for cis), 
4.54 (s, 2H for trans), 4.51 (d, J = 7.0 Hz, 2H for cis), 3.38 (s, 2H for trans), 3.35 (dd, J 
= 24.0, 9.0 Hz, 2H for cis), 2.57-2.44 (m, 1H for trans, 1H for cis), 2.43-2.22 (m, 3H for 
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trans, 3H for cis), 2.07 (m, 2H for trans, 2H for cis), 1.77 (t, J = 12.0 Hz, 1H for trans, 
1H for cis). 13C NMR (100 MHz, CDCl3) δ ppm 218.8, 218.5, 142.7, 141.6, 138.1, 137.9, 
135.7, 135.7, 128.3, 128.3, 127.6, 127.5, 127.4, 127.3, 127.2, 116.5, 116.4, 114.5, 113.1, 
76.3, 75.9, 73.3, 73.2, 47.0, 46.8, 46.6, 45.5, 44.9, 44.4, 37.4, 36.0, 35.2, 34.0, 31.8, 29.6, 
29.6, 29.3, 27.8, 27.6, 26.8, 26.6, 22.6, 17.4, 14.1, 13.5, 13.5. GCMS (EI): 179, 149, 136, 
121, 107, 91.  
(±)-(2S,4R)-2-Allyl-4-(benzyloxymethyl)-4-vinylcyclopentanone (trans-2–34) 
 
Analytically pure 2–34 was obtained by subjecting the cis-/ trans- mixture to 
Hoveyda-Grubbs II catalyst. With this approach, only the cis-isomer ring-closed. The 
crude material was purified by flash chromatography, silica gel (Rf = 0.40, hexane/EtOAc 
= 10:1).  
1H NMR (400 MHz, CDCl3) δ ppm 7.39-7.27 (m, 5H), 5.85 (dd, J = 18.0, 11.0 Hz, 1H), 
5.73 (tdd, J = 18.0, 11.0, 7.0 Hz, 1H), 5.15 (d, J = 11.0 Hz, 1H), 5.06 (d, J = 18.0 Hz, 
1H), 5.04 (ddd, J = 18.0, 3.5, 1.5 Hz, 1H), 5.01 (tdd, J = 11.0, 2.0, 1.0 Hz, 1H), 4.54 (s, 
2H), 3.37 (s, 2H), 2.56-2.45 (m, 1H), 2.42 (dd, J = 2.0, 1.5 Hz, 1H), 2.40-2.30 (m, 2H), 
2.12-2.01 (m, 2H), 1.77 (d, J = 15.0 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ ppm 218.5, 
141.6, 138.1, 135.7, 128.3, 127.6, 127.4, 116.4, 114.5, 75.9, 73.2, 46.6, 45.5, 44.9, 36.0, 






This reaction was air sensitive. Dry toluene (250 mL) was transferred into a 500 
mL round bottom flask containing bis-alkene 2–34 (0.680 g, 2.50 mmol), 
dichlorodicyano quinone (0.11 g, 0.48 mmol), and DBU (0.17 mL, 1.14 mmol) under 
argon. The resulting black red solution was cooled to -78 °C and degassed under high 
vacuum for 1 h. The reaction mixture was heated to 100 °C and Hoveyda-Grubbs II 
catalyst (50 mg, 0.080 mmol, 3.2 mol %) in degassed dry toluene (1 mL) was added via 
syringe. A black precipitate was observed in the reaction mixture. More Hoveyda-Grubbs 
II catalyst (same quantity as previously) was added every 6 h interval. A total of 16 mol% 
of catalyst was added. 30 min after the last catalyst portion was added, the reaction 
mixture was allowed to cool to room temperature, and the solvent was removed in vacuo. 
The crude material was purified by silica gel column chromatogr phy (hexane/EtOAc = 
10:1) to afford recovered starting material bis-alkene 2–34 (Rf = 0.40, 0.120 g, 18%) and 
product 2–33 (Rf = 0.35, 0.420 g, 69 %, 83 % based on the starting material) as a 
colorless oil. The product 2–33 showed blue on TLC after staining with p-anisaldehyde 
followed by gentle heating. The major byproduct (10 %) was enone 2–43, which resulted 
from alkene migration.  
1H NMR (400 MHz, CDCl3) δ ppm 7.46-7.15 (m, 5H), 5.89 (ddd, J = 9.5, 4.0, 2.0 Hz, 
1H), 5.55 (td, J = 9.5, 3.0 Hz, 1H), 4.58 (s, 2H), 3.48 (q, J = 9.0 Hz, 2H), 2.68 (t, J = 4.5 
Hz, 1H), 2.48-2.39 (m, 1H), 2.33-2.29 (m, 2H), 2.28-2.19 (m, 1H), 2.06 (dd, J = 11.0, 5.5 
Hz, 1H), 1.94 (dd, J = 11.0, 2.5 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ ppm 220.3, 
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138.2, 135.3, 128.3, 127.6, 127.4, 124.7, 74.5, 73.3, 51.6, 46.4, 42.7, 36.4, 32.4. GCMS 
(EI): 242 (M+), 136, 91. IR (cm–1): 1722 (s), 1452 (w), 1270 (s), 1112 (m), 1025 (m), 712 
(s). 
(±) 4-(benzyloxymethyl)-2-propylidene-4-vinylcyclopentanone (2–43) 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.35-7.21 (m, 5H), 6.51 (tt, J = 7.5, 2.5 Hz, 1H), 5.88 
(dd, J = 18.0, 11.0 Hz, 1H), 5.06 (d, J = 11.0 Hz, 1H), 5.01 (d, J = 18.0 Hz, 1H), 4.49 (s, 
2H), 3.34 (s, 2H), 2.61 (dd, J = 73.0, 17.0 Hz, 2H), 2.42 (dd, J = 53.0, 18.0 Hz, 2H), 
2.15-2.05 (m, 2H), 1.02 (t, J = 7.5 Hz, 3H). GCMS (EI): 270 (M+), 240, 149, 136, 107, 
91. IR (cm–1): 2928 (w), 2857 (w), 1736 (s), 1652 (w), 1454 (w), 1407 (w), 1271 (w), 
1206 (w), 1096 (s), 735 (s), 698 (s), 1027 (m), 918 (m).  
(±) Compound 2–35 
 
To a solution of alkene 2–33 (0.388 g, 1.60 mmol) in dichloromethane (5 mL) at 0 
°C, mCPBA (0.46 g, 70 %, 2.6 mmol) was added quickly under the protection of 
nitrogen. After stirring for 1 h, the reaction mixture was allowed to warm to room 
temperature overnight. The solvent was removed in vacuo and the crude material was 
immediately purified by silica gel column chromatography (hexan /EtOAc = 3:1) to 
afford the desired product 2–35 (Rf = 0.40, 0.232 g, 64 %) and diastereomer byproduct 2–
115 
 
35b (Rf = 0.30, 0.045 g, 12 %). The products 2–35 and 2–35b showed blue on TLC after 
staining with p-anisaldehyde followed by gentle heating.  
1H NMR (500 MHz, CDCl3) δ ppm 7.39-7.21 (m, 5H), 4.62-4.51 (m, 2H), 3.65 (d, J =
9.0 Hz, 1H), 3.53 (d, J = 9.0 Hz, 1H), 3.19 (d, J = 3.0 Hz, 1H), 3.04 (t, J = 4.0 Hz, 1H), 
2.31 (s, 2H), 2.19 (t, J = 5.5 Hz, 1H), 2.09 (dd, J = 15.0, 5.5 Hz, 1H), 2.03-1.96 (m, 1H), 
1.93 (ddd, J = 16.0, 4.5, 1.5 Hz, 1H), 1.54 (dd, J = 11.0, 5.5 Hz, 1H). 13C NMR (125 
MHz, CDCl3) δ ppm 219.1, 137.9, 128.2, 127.4, 127.2, 73.6, 73.2, 56.6, 48.8, 45.4, 43.7, 
43.0, 30.0, 27.7. ESI+/MS for [C16H19O3]
+: 259 (m/z). 
(±) Compound 2–35b 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.40-7.27 (m, 5H), 4.60 (s, 2H), 3.65 (d, J = 9.0 Hz, 
1H), 3.57 (d, J = 11.0 Hz, 1H), 3.38 (d, J = 4.0 Hz, 1H), 3.10 (t, J = 3.0 Hz, 1H), 2.51 
(dd, J = 17.0, 3.0 Hz, 1H), 2.43 (d, J = 15.0 Hz, 1H), 2.28 (t, J = 5.5 Hz, 1H), 2.08 (ddd, 
J = 15.0, 6.0, 3.0 Hz, 1H), 1.81-1.77 (m, 3H). 13C NMR (125 MHz, CDCl3) δ ppm 218.4, 
137.9, 128.4, 127.7, 127.6, 74.8, 73.4, 58.8, 50.0, 44.5, 42.9, 41.6, 36.2, 33.2. ESI+/MS 
for [C16H19O3]
+: 259 (m/z). IR (cm–1): 2920 (w), 2858 (w), 1742 (s), 1455 (w), 1364 (w), 
1258 (w), 1102 (s), 1075 (m), 1012 (w), 838 (w), 750 (m), 700 (m).  




(±) Compound 2–36 
 
This reaction was air and moisture sensitive. To a solution of epoxide 2–35 (88 
mg, 0.340 mmol) in dry THF (3 mL) at –78 °C under argon, n-BuLi (0.30 mL, 1.6 M in 
hexane, 0.48 mmol) was added dropwise within 1 min via a syringe. After stirring for 1 h, 
the reaction was allowed to warm to 0 °C and stirred at 0 °C for another 2 h. The reaction 
was quenched with NH4Cl (saturated aqueous solution, 1 mL). The water layer was 
extracted with EtOAc (2 mL x 3). The combined organic layer was dried over MgSO4 
and was concentrated in vacuo. The crude material was purified by silica gel column 
chromatography (Rf = 0.25, hexane/EtOAc = 3:1) to afford product 2–36 (65 mg, 70 %) 
as a colorless oil. The product 2–36 showed purple on TLC after staining with p-
anisaldehyde followed by gentle heating. See Section 6.5.1 for the details of 
computational study of this reaction.  
1H NMR (400 MHz, CDCl3) δ ppm 7.41-7.26 (m, 5H), 4.51 (dd, J = 27.5, 12.0 Hz, 2H), 
4.21 (t, J = 4.0 Hz, 1H), 3.94 (d, J = 3.5 Hz, 1H), 3.69 (s, 1H), 3.60 (d, J = 9.0 Hz, 1H), 
3.30 (d, J = 9.0 Hz, 1H), 2.20 (t, J = 6.5 Hz, 1H), 2.10 (d, J = 11.5 Hz, 1H), 2.09 (d, J = 
11.5 Hz, 1H), 1.86-1.74 (m, 1H), 1.65 (dd, J = 11.5, 3.5 Hz, 1H), 1.38 (s, 3H), 1.35 (tdd, 
J = 11.5, 7.0, 2.0 Hz, 1H), 1.30 (d, J = 11.5 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ ppm 
137.6, 128.4, 127.7, 127.4, 85.6, 78.6, 77.2, 73.5, 73.2, 49.1, 47.3, 44.4, 39.5, 37.4, 22.6. 
ESI+/MS for [C17H23O3]




(±) Compound 2–31 
 
To a solution of alcohol 2–36 (36mg, 0.131 mmol) in wet dichloromethane [346] 
(1 mL) at 0 °C under nitrogen, Dess-Martin reagent (15 wt% in dichloromethane, 0.90 
mL, 0.20 mmol) was added dropwise within 1 min via a syringe. The reaction was 
allowed to warm to room temperature overnight. After the removal f the solvent in 
vacuo, the crude material was purified by silica gel column chromatogr phy (Rf = 0.35, 
hexane/EtOAc = 5:1) to afford product 2–31 (34 mg, 95 %) as a colorless oil. The 
product 2–31 showed black on TLC after staining with p-anisaldehyde followed by gentle 
heating. 
1H NMR (500 MHz, CDCl3) δ ppm 7.36-7.25 (m, 5H), 4.53 (d, J = 1.0 Hz, 2H), 4.24 (d, 
J = 4.5 Hz, 1H), 3.59 (dd, J = 25.0, 10.0 Hz, 2H), 2.57 (t, J = 6.0 Hz, 1H), 2.25 (tdd, J = 
11.0, 6.0, 4.5 Hz, 1H), 2.21-2.15 (m, 2H), 2.05 (d, J = 12.0 Hz, 1H), 1.85 (d, J = 12.0 
Hz, 1H), 1.58 (dd, J = 12.0, 3.5 Hz, 1H), 1.53 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 
ppm 208.5, 138.4, 128.2, 127.4, 127.4, 86.9, 83.7, 73.3, 68.6, 58.8, 51.1, 44.6, 44.2, 42.5, 
22.3. ESI+/MS for [C17H21O3]
+: 273 (m/z).  
(±) Compound 2–44 
 
This reaction was air sensitive. To a solution of benzyl protected alcohol 2–31 (27 
mg, 0.100 mmol) in MeOH (1 mL), Pd/C (5 % on activated carbon, 20 mg, 0.095 mmol) 
was added. The flask was evacuated and flushed with hydrogen, and the mixture was 
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stirred at room temperature overnight. The crude material was filtered through a pad of 
silica gel and the solvent was evaporated to afford product 2–44 (16 mg, 90 %) as a 
colorless oil. The product 2–44 showed purple on TLC after staining with p-anisaldehyde 
followed by gentle heating (Rf = 0.25, hexane/EtOAc = 1:1). 
1H NMR (500 MHz, CDCl3) δ ppm 4.24 (d, J = 4.5 Hz, 1H), 3.64 (ddd, J = 18.0, 12.0, 
5.5 Hz, 2H), 2.61 (t, J = 6.0 Hz, 1H), 2.33 (t, J = 6.5 Hz, 1H), 2.29 (dd, J = 12.0, 3.5 Hz, 
1H), 2.22-2.28 (m, 1H), 1.93 (ddd, J = 12.0, 6.5, 4.0 Hz, 1H), 1.86 (d, J = 12.0 Hz, 1H), 
1.79 (d, J = 12.0 Hz, 1H), 1.77 (dd, J = 12.0, 3.5 Hz, 1H), 1.54 (s, 3H). 13C NMR (125 
MHz, CDCl3) δ ppm 211.4, 87.1, 83.5, 64.3, 60.3, 51.5, 44.8, 44.2, 42.5, 22.2. HRMS 
(ESI+, m/z) calculated for C10H15O3 [M + H]
+ 183.1033, found 183.1040. IR (cm–1): 




To a solution of 2-nitroresorcinol 2–45 (5.36 g, 34.6 mmol) in TFA (150 mL) at 0 
°C, N-iodosuccinimide (NIS, 7.60 g, 33.8 mmol) was added in aliquots. The resulting 
solution was warmed to room temperature and stirred at 25 °C overnight. The reaction 
mixture was poured into ice-water (60 mL) and extracted with toluene (3 x 30 mL). The 
combined organic extract was washed with saturated aqueous sodium hydrosulfite and 
dried (MgSO4). The solvent was removed under reduced pressure to afford product 2–
45b (9.70 g, 99 %) as an orange crystalline.  
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1H NMR (500 MHz, CDCl3) δ ppm 11.45 (s, 1H), 10.69 (s, 1H), 7.88 (d, J = 9.0 Hz, 1H), 
6.54 (d, J = 9.0 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ ppm 156.7, 154.6, 147.5, 123.8, 
111.6, 72.5.  
1-Iodo-2,4-bis(methoxymethoxy)-3-nitrobenzene (2–46) 
 
This reaction was moisture sensitive. To a solution of 2-nitroresorcinol derivative 
2–45b (9.27 g, 33.0 mmol) in anhydrous dichloromethane (100 mL) at 0 °C, Hünig’s 
base (11.0 g, 85.1 mmol) was added. After stirring for 30 min, MOMCl (6.6 g, 82 mmol) 
was added to the resulting brown solution and stirred at 25 °C overnight. After the 
removal of the solvent in vacuo, the crude material was purified by silica gel column 
chromatography (Rf = 0.40, hexane/EtOAc = 5:1) to afford product 2–46 (11.8 mg, 97 %) 
as a yellow solid.  
1H NMR (500 MHz, CDCl3) δ ppm 7.76 (d, J = 9.0 Hz, 1H), 6.86 (d, J = 9.0 Hz, 1H), 
5.19 (s, 2H), 5.11 (s, 2H), 3.51 (s, 3H), 3.44 (s, 3H). 13C NMR (125 MHz, CDCl3) δ ppm 
149.5, 149.3, 140.3, 138.1, 113.7, 100.7, 95.0, 82.0, 57.8, 56.6. IR (cm–1): 2980 (w), 1538 
(s), 1464 (m), 1368 (m), 1259 (w), 1125 (m), 1029 (s), 937 (m), 879 (s), 807 (m).  
Methyl 2-hydroxy-4-(methoxymethoxy)-3-nitrobenzoate (2–46b) 
 
This reaction was air and moisture sensitive and the procedure was modified from 
ref [347]. To a solution of iodobenzene derivative 2–46 (4.20 g, 11.3 mmol) in anhydrous 
THF (300 mL) at –78 °C, PhMgBr (11 mL, 3.0 M, 33 mmol) was added, maintain g 
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rigorous stirring. Stirring was continued for 30 min before methyl carbonocyanidate (3.5 
mL, 40 mmol) was added dropwise to the resulting green viscous reaction mixture. After 
stirring for another 1 h at –78 °C, the reaction mixture was allowed to warm to room 
temperature overnight. The reaction mixture was quenched with NH4Cl (saturated 
aqueous solution, 60 mL) and the water layer was extracted with EtOAc (30 mL x 3). The 
combined organic layer was dried over MgSO4 and was concentrated in vacuo. The crude 
material was purified by silica gel column chromatography (Rf = 0.30, hexane/EtOAc = 
5:1) to afford product 2–46b (2.26 g, 85 %) as a yellow solid. It appears that the reaction 
or the work-up conditions lead to the deprotection of one of the MOM groups.  
1H NMR (500 MHz, CDCl3) δ ppm 11.41 (s, 1H), 7.87 (d, J = 9.0 Hz, 1H), 6.77 (d, J = 
9.0 Hz, 1H), 5.28 (s, 2H), 3.96 (s, 3H), 3.49 (s, 3H). 13C NMR (125 MHz, CDCl3) δ ppm 
169.3, 154.4, 153.9, 132.2, 131.4, 107.5, 105.7, 94.7, 56.8, 52.7.  





This reaction was air sensitive. To a solution of compound 2–46b (1.85 g, 7.20 
mmol) in anhydrous dichloromethane (50 mL) at 0 °C, Hünig’s base (1.30 g, 10.1 mmol) 
was added. The reaction mixture was warmed to room temperature and stirre  for 30 min 
before MOMCl (0.70 g, 8.7 mmol) was added. The reaction mixture was then stirred 
overnight. After the removal of the solvent i  vacuo, the crude material was purified by 
silica gel column chromatography (Rf = 0.30, hexane/EtOAc = 5:1, overlap with 2–46b) 
to afford product 2–47 (1.70 mg, 78 %) as a yellow solid. 
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1H NMR (500 MHz, CDCl3) δ ppm 7.96 (d, J = 9.0 Hz, 1H), 7.06 (d, J = 9.0 Hz, 1H), 
5.26 (s, 2H), 5.13 (s, 2H), 3.88 (s, 3H), 3.47 (s, 3H), 3.47 (s, 3H). 13C NMR (125 MHz, 
CDCl3) δ ppm 164.2, 152.2, 150.6, 138.4, 133.8, 118.0, 110.6, 102.1, 94.9, 57.7, 56.8, 
52.3. IR (cm–1): 3313 (w), 1668 (m), 1608 (w), 1503 (w), 1435 (s), 1308 (s), 1249 (m), 
1134 (s), 1041 (s), 997 (s), 920 (m), 736 (m). 
Methyl 3-amino-2,4-bis(methoxymethoxy)benzoate (2–48) 
 
This reaction was air sensitive. To a solution of nitrobenzene 2–47 (1.50 g, 4.98 
mmol) in MeOH (25 mL) and trace of toluene (0.5 mL), Pd/C (5 % on activated carbon, 
1.1 g, 0.52 mmol; wet with MeOH before adding) was added. The flask wa evacuated 
and flushed with hydrogen, and the mixture was stirred at room temperature overnight. 
After the removal of the solvent in vacuo, the crude material was purified by silica gel 
column chromatography (Rf = 0.30, hexane/EtOAc = 2:1) to afford product 2–48 (0.94 g, 
70 %) as a colorless oil. 
1H NMR (500 MHz, CDCl3) δ ppm 7.24 (d, J = 8.5 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 
5.24 (s, 2H), 5.10 (s, 2H), 4.25 (s, br, 2H), 3.86 (s, 3H), 3.61 (s, 3H), 3.49 (s, 3H). 13C 
NMR (125 MHz, CDCl3) δ ppm 166.2, 148.5, 145.4, 131.7, 120.0, 118.0, 109.5, 101.1, 
94.8, 57.6, 56.3, 51.7. HRMS (ESI+, m/z) calculated for C12H18NO6 [M + H]
+ 272.1134, 
found 272.1134. IR (cm–1): 2269 (w), 2925 (w), 1716 (m), 1595 (m), 1459 (m), 1295 (m), 




Methyl 3-(3-aminopropanamido)-2,4-bis(methoxymethoxy)benzoate (2–50) 
 
3-(2,2,2-Trifluoroacetamido)propanoic acid was prepared following literature ref 
[348]. The reaction was moisture sensitive. To a mixture of 3-(2,2,2-
trifluoroacetamido)propanoic acid (1.48 g, 8.00 mmol) and 2 drops of dry pyridine n 
anhydrous benzene (20 mL), oxalyl chloride (1.0 mL, 11.7 mmol) was added dropwise 
(effervescence was observed). After stirring at 50 °C for another 30 min, the solvent was 
removed in vacuo. The resulting viscous black oil (acid chloride 2–49) was diluted with 
anhydrous dichloromethane (10 mL) and was added into a solution of amine 2–48 (0.76 
g, 2.80 mmol) in anhydrous dichloromethane (10 mL), followed by the addition of 
pyridine (1.5 mL, 18.6 mmol). The mixture was stirred for 5 h at room temperature and 
the solvent was removed in vacuo (Rf = 0.40, hexane/EtOAc = 2: 1). MeOH (10 mL), 
H2O (3 mL) and K2CO3 (0.76 g, 5.50 mmol) was then added, and the mixture was stirred 
at room temperature for 7 h. The crude material was concentrated at r uced pressure and 
the residue was purified by silica gel column chromatography (Rf = 0.40, CHCl3: MeOH: 
28% NH4OH = 35: 7: 1) to afford product 2–50 (0.91 g, 95 %) as a colorless solid. The 
products 2–50 showed purple on TLC after staining with ninhydrin followed by gentle 
heating. 
1H NMR (500 MHz, CDCl3) δ ppm 7.70 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 8.5 Hz, 1H), 
5.16 (s, 2H), 4.99 (s, 2H), 3.80 (s, 3H), 3.47 (s, 3H), 3.41 (s, 3H), 3.05 (s, br, 2H), 2.51 (s, 
br, 2H). 13C NMR (125 MHz, CDCl3) δ ppm 170.8, 165.3, 156.6, 154.1, 130.3, 121.4, 
117.8, 110.3, 100.9, 94.5, 57.3, 56.3, 51.8, 38.3, 37.9. HRMS (ESI+, m/z) calculated for 
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C15H23N2O7 [M + H]
+ 343.1492, found 343.1485. IR(cm–1): 2952 (w), 1692 (m), 1596 
(w), 1460 (m), 1294 (m), 1199 (m), 1152 (m), 1033 (m), 994 (s), 922 (m), 750 (m).  
 (±) Compound 2–52 and 2–53 
 
To a mixture of ketone 2–31 (20 mg, 0.073 mmol) and O-benzylhydroxylamine 
(18 mg, 0.146 mmol) in MeOH (0.3 mL, pH 3, adjusted by HCl) at 0 °C, NaB(CN)H3 
(7.0 mg, 0.111 mmol) was added. After stirring for 5 h, the solvent was removed in acuo 
and the crude material was purified by silica gel column chromatography (hexane: EtOAc 
= 10:1) to afford product 2–52 (20 mg, 72%) and 2–53 (6 mg, 14 %) as colorless oil.  
2–52: 1H NMR (400 MHz,CDCl3) δ ppm 7.41-7.24 (m, 10H), 4.67 (s, 2H), 4.48 (dd, J =
12.0 Hz, 2H), 4.49-4.47 (m, 1H), 3.34-3.33 (m, 1H), 3.40 (d, J = 9.5 Hz, 1H), 3.28 (d, J
=  9.5 Hz, 1H), 2.21 (t, J = 6.5 Hz, 1H), 2.13 (d, J = 11.0 Hz, 1H), 1.83-1.79 (m, 3H), 
1.41 (s, 3H), 1.37-1.33 (m, 2H). 13C NMR (100 MHz, CHCl3) δ ppm 138.2, 137.8, 128.4, 
128.3, 128.2, 127.7, 127.4, 127.2, 86.0, 77.7, 76.5, 75.6, 73.2, 63.4, 49.4, 48.1, 44.7, 39.8, 
37.7, 22.9. ESI+/MS for [C24H30NO3]
+: 380 (m/z). IR (cm–1): 2927 (w), 2855 (w), 1454 
(w), 1270 (w), 1096 (m), 1028 (w), 914 (w), 828 (w), 734 (s), 698 (s).  
2–53: 1H NMR (400 MHz,CDCl3) δ ppm 7.39-7.27 (m, 10 H), 4.66 (s, 2H), 4.55 (d, J =
4.5 Hz, 1H), 4.48 (s, 2H), 3.60 (d, J = 9.0 Hz, 1H), 3.18 (d, J = 9.0 Hz, 1H), 3.04 (s, 1H), 
2.23 (t, J = 6.0 Hz, 1H), 2.00 (tdd, J = 8.0, 5.5, 2.0 Hz, 1H), 1.67-1.59 (m, 4H), 1.35 (s, 
3H), 1.20 (d, J = 11.0 Hz, 1H). 13C NMR (100 MHz, CHCl3) δ ppm 138.7, 138.2, 128.3, 
128.2, 128.2, 127.5, 127.3, 127.3, 86.3, 77.2, 75.9, 73.7, 73.2, 61.3, 48.7, 45.0, 44.2, 43.9, 
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39.7, 23.1. ESI+/MS for [C24H30NO3]
+: 380 (m/z). IR (cm–1): 2927 (w), 2853 (w), 1721 
(w), 1453 (w), 1269 (m), 1098 (m), 1026 (m), 965 (w), 919 (w), 735 (s), 711 (m), 697 (s). 
Stereochemistry of 2–52 and 2–53 was determined based on NOE experiments.  
(±) Compound 2–52 and 2–53 
   
(±) Compound 2–55 
 
To a mixture of ketone 2–44 (12 mg, 0.066 mmol) and amine 2–50 (90 mg, 0.26 
mmol) in MeOH (0.3 mL, pH 4, adjusted by HCl) at 0 °C, NaB(CN)H3 (7.0 mg, 0.111 
mmol) was added in 3 portions within 1 h. After stirring for another 5 h, the solvent was 
removed in vacuo and the crude material was redissolved in CHCl3: MeOH (20:1). This 
solution was then filtered through a pad of silica gel and washed with CHCl3: MeOH 
(20:1, 5 mL x 2). This procedure removes the unreacted amine starting material from the 
filtrate. The stereochemistry of crude product 2–54 was determined by NOE experiment. 




The filtrate (crude compound 2–54) was concentrated at a reduced pressure and 
then further dried under high vacuum for 2 h before it was diluted with anhydrous 
benzene (1 mL). Carbonyl diimidazole (50 mg, 0.31 mmol) and DMAP (8.0 mg, 0.066 
mmol) were sequentially added to the reaction mixture and stirred at 50 °C for 24 h. The 
reaction mixture was concentrated at reduced pressure and the residue was purified by 
silica gel column chromatography (hexane: acetone = 1:1) to afford product 2–55 (20 mg, 
56 %) as a colorless oil and as a single diastereomer. A major side reaction was the 
reduction of the ketone 2–44. Also when the concentration of ketone 2–44 was < 0.2 M, 
the yield of product 2–55 was generally low.  
1H NMR (500 MHz, CHCl3) δ ppm 7.79 (d, J = 7.5 Hz, 1H), 7.62 (s, 1H), 7.04 (d, J = 
9.0 Hz, 1H), 5.29-5.20 (m, 2H), 5.10-5.04 (m, 2H), 4.71 (s, 1H), 4.19 (d, J = 11.0 Hz, 
1H), 4.06-3.94 (m, 1H), 3.86 (s, 3H), 3.77 (d, J = 11 Hz, 1H), 3.67 (s, 1H), 3.58 (s, 3H), 
3.50 (s, 3H), 3.47-3.37 (m, 1H), 2.93-2.72 (br, 1H), 2.68-2.58 (br, 1H), 2.32 (t, J = 6.5 
Hz, 1H), 1.98 (dd, J = 12.0, 3.0 Hz, 2H), 1.80 (d, J = 11.0 Hz, 1H), 1.68 (dd, J = 11.0, 
3.5 Hz, 1H), 1.56 (dd, J = 11.0, 7.5 Hz, 1H), 1.49 (d, J = 11.0 Hz, 1H), 1.43 (s, 3H). 13C 
NMR (125 MHz, CHCl3) δ ppm 169.0 (br), 165.2, 156.8, 154.3 (br), 153.4, 130.5 (br), 
121.5, 117.8, 111.0, 101.8, 94.8, 86.8, 76.3, 72.4, 58.4, 57.4, 56.4, 51.9, 45.8, 43.8, 43.2, 
40.6, 40.1, 37.7, 34.9 (br), 22.6. HRMS (ESI+, m/z) calculated for C26H35N2O10 [M + H]
+ 
535.2291, found 535.2216.  




To a solution of compound 2–55 (10 mg, 0.0187 mmol) in MeOH (0.3 mL), 6 M 
HCl aqueous solution (0.1 mL) was added. After stirring at room temperatur  for 24 h, 
the reaction mixture was extracted with CHCl3: i-PrOH = 3: 1 (0.3 mL x 5). The organic 
layer was concentrated in vacuo and under high vacuum and the residue was purified by 
silica gel column chromatography (hexane: acetone = 1:1) to afford product 2–56 (7.8 
mg, 92 %) as a colorless solid. 
1H NMR (500 MHz, CHCl3) δ ppm 11.65 (s, 1H), 10.71 (s, 1H), 8.11 (s, 1H), 7.58 (d, J 
= 9.0 Hz, 1H), 6.52 (d, J = 9.0 Hz, 1H), 4.67 (t, J = 3.5 Hz, 1H), 4.19 (d, J = 11.0 Hz, 
1H), 3.99 (ddd, J = 14.0, 7.0, 6.0 Hz, 1H), 3.92 (s, 3H), 3.79 (d, J = 11.0 Hz, 1H), 3.64 
(d, J = 3.5 Hz, 1H), 3.46 (td, J = 14.0, 7.0 Hz, 1H), 2.99 (td, J = 15.0, 7.0 Hz, 1H), 2.78 
(td, J = 15.0, 6.5 Hz, 1H), 2.34 (t, J = 6.5 Hz, 1H), 2.03-1.95 (m, 1H), 1.99 (dd, J = 12.0, 
3.5 Hz, 1H), 1.82 (d, J = 12.0 Hz, 1H), 1.72 (dd, J = 11.0, 3.5 Hz, 1H), 1.63-1.56 (m, 
1H), 1.50 (d, J = 11.0 Hz, 1H), 1.44 (s, 3H). 13C NMR (125 MHz, CHCl3) δ ppm 171.4, 
170.6, 155.0, 153.9, 153.7, 127.7, 114.0, 111.3, 104.2, 86.9, 76.4, 72.5, 59.0, 52.2, 45.8, 
43.7, 43.3, 40.9, 40.1, 37.7, 35.1, 22.5. HRMS (ESI+, m/z) calculated for C22H27N2O8 [M 
+ H]+ 447.1777, found 447.1760.  
 (±) Compound 2–30 
 
To a solution of compound 2–55 (5.0 mg, 0.0096 mmol) in MeOH (0.3 mL), 
LiOH (1.6 M in MeOH: H2O = 3: 1, 0.2 mL) was added. HCl (4 M in MeOH: H2O, 0.3 
mL) was added before the reaction mixture was stirred for 12 h at room temperature. 
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After stirring at room temperature for another 24 h, the reaction mixture was extracted 
with CHCl3: i-PrOH = 3: 1 (0.3 mL x 5). The organic layer was concentrated in vacuo 
and under high vacuum and the residue was purified by silica gel column 
chromatography (acetone: hexane: AcOH = 1: 1: 0.1) to afford product 2–30 (3.3 mg, 80 
%) as a colorless solid. 
1H NMR (600 MHz, d4-MeOD) δ ppm 7.68 (d, J = 9.0 Hz, 1H), 6.45 (d, J = 9.0 Hz, 1H), 
4.72 (t, J = 3.0 Hz, 1H), 4.31 (d, J = 11.0 Hz, 1H), 4.05 (td, J = 13.0, 6.0 Hz, 1H), 3.88-
3.82 (m, 1H), 3.83 (d, J = 11.0 Hz, 1H), 3.44 (td, J = 15.0, 7.0 Hz, 1H), 2.89 (td, J = 
15.0, 7.0 Hz, 1H), 2.66 (td, J = 14.0, 6.5 Hz, 1H), 2.35 (t, J = 6.5 Hz, 1H), 1.98-1.94 (m, 
1H), 1.90 (dd, J = 12.0, 3.0 Hz, 1H), 1.87 (d, J = 12.0 Hz, 1H), 1.70 (dd, J = 11.0, 3.0 
Hz, 1H), 1.68-1.62 (m, 1H), 1.60 (d, J = 11.0 Hz, 1H), 1.42 (s, 3H). 13C NMR (150 MHz, 
d4-MeOD) δ ppm 176.7, 175.4, 175.2, 161.4, 157.8, 132.5, 114.8, 110.6, 108.1, 89.9, 
79.2, 75.2, 60.9, 48.0, 46.6, 45.9, 43.5, 42.3, 40.2, 36.6, 24.3. HRMS (ESI+, m/z) 
calculated for C21H25N2O8 [M + H]
+ 433.1611, found 433.1590.  
Compound 2–59 
 
To a mixture of 2-(hydroxymethyl)cyclohexanone (256 mg, 2.00 mmol) and 
amine 2–50 (342 mg, 1.00 mmol) in MeOH (5 mL, pH 3-4, adjusted by HCl) at 0 °C, 
NaB(CN)H3 (140 mg, 2.22 mmol) was added in 3 portions within 1 h. After stirring for 
another 5 h, the solvent was removed in vacuo and the crude material was redissolved in 
CHCl3: MeOH (20:1). This solution was then filtered through a pad of silica gel and 
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washed with CHCl3: MeOH (20: 1, 5 mL x 2). This procedure removes the unreacted 
amine starting material from the filtrate. The filtrate was concentrated at a reduced 
pressure and then further dried under high vacuum for 2 h before it was diluted with 
anhydrous benzene (5 mL). Carbonyl diimidazole (200 mg, 1.24 mmol) and DMAP (80 
mg, 0.66 mmol) were sequentially added to the reaction mixture and stirred at 50 °C for 
24 h. The reaction mixture was concentrated at reduced pressure and the residue was 
purified by silica gel column chromatography (hexane: acetone = 1:1) to afford product 
2–59 (336 mg, 70 %) as a colorless oil.  
1H NMR (400 MHz, CHCl3) δ ppm 7.80 (s, 1H for trans, 1H for cis), 7.71 (d, J = 9.0 Hz, 
1H for trans, 1H for cis), 6.95 (d, J = 9.0 Hz, 1H for cis), 6.94 (d, J = 9.0 Hz, 1H for 
trans), 5.16 (s, 2H for trans, 2H for cis), 4.98 (s, 2H for trans, 2H for cis), 4.32 (dd, J = 
11.0, 11.0 Hz, 1H for cis), 3.99 (dd, J = 11.0, 11.0 Hz, 1H for trans), 3.98 (dd, J = 11.0, 
11.0 Hz, 1H for cis), 3.79 (dd, J = 11.0, 11.0 Hz, 1H for trans), 3.78 (s, 3H for trans, 3H 
for cis), 3.75-3.57 (m, 2H for trans, 1H for cis), 3.51 (s, 3H for cis), 3.50 (s, 3H for 
trans), 3.41 (s, 3H for cis), 3.40 (s, 3H for trans), 3.40-3.30 (m, 2H for cis), 3.01 (t, J = 
8.5 Hz, 1H for trans), 2.94-2.71 (m, 1H for trans, 1H for cis), 2.70-2.60 (m, br, 1H for 
cis), 2.58-2.46 (m, br, 1H for trans), 2.45-2.38 (m, br, 1H for cis), 2.34-2.21 (m, 1H for 
trans, 1H for cis), 1.94 (d, J = 12.0 Hz, 1H for cis), 1.81 (d, J = 8.0 Hz, 1H for trans), 
1.76-1.51 (m, 3H for trans, 3H for cis), 1.51-1.31 (m, 2H for cis), 1.30-1.10 (m, 2H for 
trans, 3H for cis), 1.10 (dd, J = 14.0, 8.5 Hz, 1H for trans), 0.94 (ddd, J = 13.0, 3.5, 3.5 
Hz, 1H for trans). 13C NMR (100 MHz, CHCl3) δ ppm 169.3 (br, trans / cis), 165.1 
(trans / cis), 156.6 (trans), 156.5 (cis), 154.5 (br, trans / cis), 153.7 (trans), 153.0 (cis), 
130.5 (br, trans / cis), 121.3 (trans / cis), 117.7 (cis), 117.6 (trans), 110.5 (cis), 110.4 
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(trans), 101.3 (cis), 101.2 (trans), 94.5 (trans / cis), 70.0 (trans), 66.7 (cis), 59.5 (cis), 
57.1 (trans), 56.3 (cis), 56.2 (trans), 51.7 (trans / cis), 44.0 (br, cis), 40.4 (br, trans), 38.6 
(trans / cis), 35.2 (br, trans), 34.9 (br, cis), 31.3 (trans), 30.6 (cis), 30.2 (trans), 27.6 
(cis), 25.9 (trans), 25.1 (cis), 24.3 (trans), 24.1 (trans), 23.5 (cis), 20.8 (cis). HRMS 
(ESI+, m/z) calculated for C23H33N2O9 [M + H]
+ 481.2189, found 481.2169.  
Compound 2–57 
 
To a solution of compound 2–59 (240 mg, 0.50 mmol) in MeOH (1 mL), LiOH 
(1.6 M in MeOH: H2O = 3: 1, 0.8 mL) was added. HCl (4 M in MeOH: H2O, 1.6 mL) 
was added before the reaction mixture was stirred for 12 h at room temperature. After 
stirring at room temperature for another 24 h, the reaction mixture was extracted with 
CHCl3: i-PrOH = 3: 1 (2 mL x 5). The organic layer was concentrated in vacuo and under 
high vacuum and the residue was purified by silica gel column chromatography (acetone: 
hexane: AcOH = 1: 1: 0.1) to afford product 2–57 (161 mg, 85 %) as a colorless solid. 
The ratio of cis-4 and trans-4 is 2:3, determined by 1H NMR. The stereochemistry of 
product 2–57 was determined by NOE experiment. 
1H NMR (500 MHz, d4-MeOD) δ ppm 7.63 (d, J = 8.5 Hz, 1H for cis, 1H for trans), 6.41 
(d, J = 8.5 Hz, 1H for cis, 1H for trans), 4.43 (dd, J = 11.0, 11.0 Hz, 1H for cis), 4.07 
(dd, J = 11.0, 11.0 Hz, 1H for cis), 4.06 (dd, J = 11.0, 11.0 Hz, 1H for trans),  3.92 (dd, J 
=  11.0, 11.0 Hz, 1H for trans), 3.90-3.78 (m, 1H for cis, 1H for trans), 3.72-3.58 (m, 1H, 
trans), 3.59-3.50 (m, 1H, cis), 3.46 (td, J = 14.0, 6.5 Hz, 1H, cis), 3.22 (t, J = 9.5 Hz, 1H, 
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trans), 2.88-2.74 (m, 1H for cis, 1H for trans), 2.69-2.48 (m, 1H for cis, 1H for trans), 
2.40-2.26 (m, 1H for cis, 1H for trans), 1.99 (d, J = 12.0 Hz, 1H, cis), 1.84 (d, J = 5.5 
Hz, 1H, trans), 1.78-1.58 (m, 3H for trans, 3H for cis), 1.53 (dd, J = 23.0, 12.0 Hz, 1H, 
cis), 1.50-1.36 (m, 1H, cis), 1.42-1.22 (m, 2H for cis, 2H for trans), 1.17 (dd, J = 23.0, 
13.0 Hz, 1H, trans), 1.03 (dd, J = 21.0, 12.0 Hz, 1H, trans). 13C NMR (125 MHz, d4-
MeOD) δ ppm 173.9 (cis), 173.8 (trans), 173.6 (cis / trans), 159.9 (cis), 159.8 (trans), 
156.7 (cis / trans), 156.0 (cis / trans), 130.9 (cis / trans), 113.4 (trans), 113.4 (cis), 109.2 
(trans), 109.2 (cis), 106.5 (cis / trans), 71.6 (trans), 68.6 (cis), 60.5 (trans), 57.4 (cis), 
45.3 (cis), 41.6 (trans), 40.1 (trans), 35.9 (trans), 35.7 (cis), 33.0 (cis), 31.3 (trans), 28.6 
(cis), 27.2 (trans), 26.3 (cis), 25.7 (trans), 25.5 (trans), 24.9 (cis), 22.1 (cis). HRMS 
(ESI+, m/z) calculated for C18H23N2O7 [M + H]
+ 379.1505, found 379.1525.  




6.3  Synthetic protocols for compounds in Chapter 3. 
6.3.1  Synthetic strategies 
All the analogs in Chapter 3 are generated from four methods (Scheme 6–2) 





Experimental details for the synthesis of compound 6–1 refer to Section 6.2 
(compound 2–50). The reactions were performed at 1.0–10 mmol scale. Amine 6–1 (1.0 
eq.), acetic acid (3.0 eq.) and aldehyde/ ketone (3.0 eq.) were stirred in MeOH ([6–1] = 
0.2 M) at RT for 15 min. Sodium cyanoborohydride (1.5 eq.) was added in five aliquots 
over 1 h. The reaction mixture was stirred at RT for another 2 h and then quenched with 1 
M NaOH. The mixture was extracted with CHCl3 (x 3) and then concentrated under 
vacuum. The crude product was purified on silica-gel with hexane: EtOAc to give pure 
product 6–2 in up to 85% yield.  
Intermediate 6–2 was stirred with NaOH (5.0 eq.) in MeOH: H2O (3: 1, [6–2] = 
0.2 M) for 5–14 h, at which point the starting material disappeared on TLC. HCl (6 M in 
H2O, 20.0 eq.) was then added to the cloudy reaction mixture to form a clear solution at 
RT. The reaction was heated to 40 °C and stirred overnight before quenching with 
saturated NaHCO3. The mixture was extracted with CHCl3: i-PrOH (3: 1) three times. 
The crude product was concentrated under vacuum and purified on silica-gel with CHCl3: 
MeOH (5% NH4OH), or using HPLC C18 reverse phase column (Nacalai tesque 5C18-
MS II column) to give product 6–3 in up to 69% yield. The product displayed a 
distinctive blue color under UV light (365 nm) on TLC (F254). For gram-scale syntheses, 
the products can be recrystallized with 2:1 MeOH: 2 M HCl aqueous solution.  
Method B 
The procedure was the same as method A with the only exception being the use of 





Sulfonyl chloride (2.0 eq.) was added to a solution of amine 6–1 (1.0 eq.) and 
NEt3 (2.5 eq.) in anhydrous CH2Cl2 and the reaction was stirred at RT for overnight. The 
crude product was concentrated under vacuum and purified on silica-gel (hexane: EtOAc) 
to give the product 6–6 in 57% yield.  
 
 
Scheme 6–2. General synthesis of platensimycin analogs: a) synthesis of N-di-alkyl 
analogs; b) synthesis of N-mono-alkyl analogs; c) synthesis of N-sulfonyl analogs; d) 






For experimental details for the synthesis of compound 6–8, refer to Section 6.2 
(compound 2–48). This reaction is moisture sensitive. The acid chloride (1.5 eq.) was 
added to a solution of 6–8 (1.0 eq.) and NEt3 (2.0 eq.) in CH2Cl2 and the reaction was 
stirred at RT for 1 h. The reaction mixture was washed with saturated NaHCO3 and the 
aqueous layer was extracted with CHCl3 (x 2). The crude product was concentrated under 
vacuum and purified on silica-gel (hexane: EtOAc) to give the product S9 in up to 90% 
yield. 
 
6.3.2  Physical data of the analogs 
3-(3-(Bis(cyclopropylmethyl)amino)propanamido)-2,4-dihydroxybenzoic acid (3–6) 
 
The compound was synthesized with an overall yield of 13% from 2–50 and 10 
mg material was obtained. Rf = 0.30, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 1/7/55. 
1H NMR (500 MHz, MeOD) δ 7.68 (d, J = 8.5 Hz, 1H), 6.36 (d, J = 8.5 Hz, 1H), 3.70 (t, 
J = 6.5 Hz, 2H), 3.20 (t, br, J = 6.5 Hz, 4H), 3.01 (t, J = 6.5 Hz, 2H), 1.29 – 1.13 (m, 2H), 
0.87 – 0.71 (m, 4H), 0.56 – 0.44 (m, 4H). 13C NMR (125 MHz, MeOD) δ 175.8, 172.2, 
159.8, 157.4, 132.2, 131.1, 112.6, 107.3, 59.6, 50.0, 30.5, 6.9, 5.2. HRMS (ESI+, m/z) 
calculated for C18H25N2O5 [M + H]
+ 349.1763, found 349.1758. 




The compound was synthesized with an overall yield of 13% from 2–50 and 14 
mg material was obtained. The major byproduct is the benzoic acid methyl ester (50%). 
Rf = 0.35, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 1/7/55. 
1H NMR (500 MHz, CDCl3) δ 9.14 (s, br, 1H), 7.62 (d, J = 9.0 Hz, 1H), 6.39 (d, J = 9.0 
Hz, 1H), 3.45 – 3.39 (m, 2H), 3.05 – 3.00 (m, 6H), 1.75 – 1.68 (m, 4H), 1.40 (q, J = 7.5 
Hz, 4H), 0.98 (t, J = 7.5 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 174.9, 170.1, 155.8, 
153.2, 128.9, 113.7, 110.8, 108.8, 52.5, 49.7, 32.3, 25.4, 20.4, 13.8. HRMS (ESI+, m/z) 
calculated for C18H29N2O5 [M + H]
+ 353.2076, found 353.2069. 
(–)-Myrtemycin (3–8) 
 
The compound was synthesized with an overall yield of 68% from 2–50 and 18 
mg material was obtained. Rf = 0.40, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 1/7/55. 
[α]D
20 = –10.6° (c = 1.0 in MeOH). 1H NMR (600 MHz, [D5] pyridine) δ 10.84 (s, 1H), 
8.12 (d, J = 8.5 Hz, 1H), 6.88 (d, J = 8.5 Hz, 1H), 5.56 (s, 2H), 3.42 (d, J = 12.5 Hz, 2H), 
3.35 – 3.25 (m, br, 1H), 3.23 – 3.08 (m, 4H), 3.08 – 2.90 (m, br, 1H), 2.64 (s, 2H), 2.36 
(dt, J = 8.5, 5.5 Hz, 2H), 2.24 (d, J = 17.5 Hz, 1H), 2.15 (d, J = 17.5 Hz, 1H), 1.96 (s, 
2H), 1.24 (s, 6H), 1.20 (d, J = 8.5 Hz, 2H), 0.85 (s, 6H). 13C NMR (126 MHz, [D5] 
pyridine) δ 175.8, 174.5, 159.0, 158.8, 146.2, 130.4, 123.9, 116.3, 111.2, 108.1, 61.0, 
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51.4, 45.8, 42.1, 39.1, 34.6, 33.2, 32.9, 27.4, 22.3. HRMS (ESI+, m/z) calculated for 
C30H41N2O5 [M + H]
+ 509.3015, found 509.3014.  
Compound 3–9 
 
The compound was synthesized with an overall yield of 21% from 2–50 and 23 
mg material was obtained. Rf = 0.40, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 1/7/55. 
1H NMR (500 MHz, MeOD) δ 7.48 (d, J = 8.5 Hz, 1H), 6.22 (dd, J = 8.5, 1.5 Hz, 1H), 
5.75 – 5.42 (m, 4H), 3.14 – 2.93 (m, 5H), 2.93 – 2.67 (m, 4H), 2.57 (d, J = 37.5 Hz, 1H), 
2.49 – 2.18 (m, 5H), 2.18 – 1.99 (m, 1H), 1.99 – 1.74 (m, 2H). 13C NMR (125 MHz, 
MeOD) δ 173.8, 171.5, 156.0, 153.9, 133.6, 130.7, 128.9, 113.7, 109.4, 108.2, 63.7, 57.3, 
46.2, 42.5, 41.0, 40.0, 39.2. HRMS (ESI+, m/z) calculated for C24H29N2O5 [M + H]
+ 
425.2076, found 425.2066. 
Compound 3–10 
 
The compound was synthesized with an overall yield of 40% from 2–50and 8 mg 
material was obtained. Rf = 0.35, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 1/7/55. 
1H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 8.5 Hz, 1H), 6.33 (d, J = 8.5 Hz, 1H), 5.69 (s, 
2H), 3.16 (s, br, 4H), 3.05 (s, br, 2H), 2.85 (s, br, 2H), 2.06 – 1.86 (m, br, 8H), 1.60 – 
1.40 (m, br, 8H). 13C NMR (125 MHz, CDCl3) δ 174.4, 172.1, 156.0, 154.2, 131.8, 130.3, 
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129.1, 113.3, 110.0, 108.7, 61.1, 50.1, 31.6, 27.5, 25.8, 22.7, 22.2. HRMS (ESI+, m/z) 
calculated for C24H33N2O5 [M + H]
+ 429.2389, found 429.2383. 
Compound 3–11 
 
The compound was synthesized with an overall yield of 58% from S1 and 13 mg 
material was obtained. Rf = 0.40, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 1/7/55. 
1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 8.5 Hz, 1H), 6.39 (d, J = 8.5 Hz, 1H), 6.17 (s, 
2H), 5.95 (s, 2H), 3.53 – 3.12 (m, 2H), 3.12 – 2.87 (m, 2H), 2.87-2.79 (m, 4H), 2.70 – 
2.50 (m, 2H), 2.55-2.35 (m, 4H), 1.98 (s, br, 2H), 1.55 – 1.36 (m, 2H), 1.34 – 1.23 (m, 
2H), 0.63 (dd, J = 23.0, 12.0 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ 174.4, 170.9, 
155.7, 153.7, 139.0, 131.7, 129.1, 113.4, 109.9, 108.9, 58.4, 50.3, 50.0 (covered by the 
solvent peak), 45.9, 42.8, 34.9, 34.6, 32.6. HRMS (ESI+, m/z) calculated for C26H33N2O5 
[M + H]+ 453.2389, found 453.2402. 
2,4-Dihydroxy-3-(3-(adamantylamino)propanamido)benzoic acid (3–12) 
 
The compound was synthesized with an overall yield of 46% from S1 and 27 mg 
material was obtained. Rf = 0.30, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 1/7/55. 
1H NMR (500 MHz, MeOD) δ 7.69 (d, J = 8.5 Hz, 1H), 6.39 (d, J = 8.5 Hz, 1H), 3.48 – 
3.42 (m, 3H), 3.10 – 3.00 (m, 2H), 2.26 (s, br, 2H), 2.08 – 1.98 (m, 4H), 1.96 – 1.86 (m, 
4H), 1.84 (s, br, 2H), 1.77 (d, J = 8.0 Hz, 2H). 13C NMR (125 MHz, MeOD) δ 175.8 (br), 
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172.0, 159.0, 157.1, 130.4, 111.6, 106.7, 63.5, 42.5, 37.4, 37.0, 31.0, 30.1, 27.4. HRMS 
(ESI+, m/z) calculated for C20H27N2O5 [M + H]
+ 375.1920, found 375.1900. 
Compound 3–13 
 
The compound was synthesized with an overall yield of 20% from S1 and 12 mg 
material was obtained. Rf = 0.40, MeOH/ CHCl3 = 1/10. 
1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 9.0 Hz, 1H), 6.43 (d, J = 9.0 Hz, 1H), 3.49 
(qd, J = 13.5, 7.0 Hz, 2H), 3.42 (d, J = 15.0 Hz, 1H), 2.88 (d, J = 15.0 Hz, 1H), 2.79 (t, J
= 6.0 Hz, 2H), 2.32 (ddd, J = 18.5, 7.5, 7.5 Hz, 1H), 2.25 (ddd, J = 14.5, 12.0, 3.5 Hz, 
1H), 2.06 (t, J = 4.5 Hz, 1H), 2.03 – 1.92 (m, 1H), 1.87 (d, J = 18.5 Hz, 1H), 1.77 (ddd, J 
= 14.0, 9.5, 4.5 Hz, 1H), 1.38 (ddd, J = 13.0, 9.5, 4.0 Hz, 1H), 0.98 (s, 3H), 0.82 (s, 4H). 
13C NMR (126 MHz, CDCl3) δ 216.8, 174.0, 171.9, 155.3, 155.1, 128.8, 113.7, 110.5, 
104.9, 58.9, 49.6, 42.8 (2 carbons), 39.5, 36.8, 27.0, 25.8, 19.7, 19.5. HRMS (ESI+, m/z) 
calculated for C20H27N2O8S [M + H]
+ 455.1488, found 455.1502. 
3-Hexanamido-2,4-dihydroxybenzoic acid (3–14) 
 
The compound was synthesized with an overall yield of 41% from 2–48 and 14 
mg material was obtained.  
1H NMR (500 MHz, Acetone) δ 7.65 (d, J = 9.0 Hz, 1H), 6.49 (d, J = 9.0 Hz, 1H), 2.64 
(t, J = 7.5 Hz, 2H), 1.83 – 1.64 (m, 2H), 1.45 – 1.31 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H). 13C 
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NMR (126 MHz, Acetone) δ 175.8, 172.7 (br), 156.8, 156.3, 129.0, 115.4, 111.3, 105.2, 
30.3, 30.1, 26.3, 23.1, 14.2. HRMS (ESI+, m/z) calculated for C13H18NO5 [M + H]
+ 
268.1185, found 268.1197. 
2,4-Dihydroxy-3-(2-methylbutanamido)benzoic acid (3–15) 
 
The compound was synthesized with an overall yield of 54% from 2–48 and 15 
mg material was obtained.  
1H NMR (500 MHz, CDCl3) δ 11.55 (s, br, 1H), 11.35 (s, br, 1H), 7.97 (s, 1H), 7.66 (d, J
= 9.0 Hz, 1H), 6.58 (d, J = 9.0 Hz, 1H), 2.61 – 2.43 (m, 1H), 1.90 – 1.70 (m, 1H), 1.70 – 
1.52 (m, 1H), 1.31 (d, J = 7.0 Hz, 3H), 1.02 (t, J = 7.5 Hz, 3H). 13C NMR (125 MHz, 
CDCl3) δ 177.7, 174.2, 156.1, 154.5, 128.6, 114.6, 112.0, 103.1, 43.8, 27.7, 17.7, 11.9. 
HRMS (ESI+, m/z) calculated for C12H16NO5 [M + H]
+ 254.1028, found 254.1020. 
 
 






The reaction procedure refers to Section 6.2 (compound 2–46). The compound 
was synthesized with an overall yield of 83% from 2-nitroresorcinol a d 0.16 g material 
was obtained.  
1H NMR (400 MHz, CDCl3) δ 6.79 (d, J = 8.5 Hz, 2H), 6.64 (AA’BB’, J = 8.5, 7.5 Hz, 
1H), 5.20 (s, 4H), 3.95 (s, br, 2H), 3.51 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 145.2, 
127.4, 116.9, 109.0, 95.2, 56.0. HRMS (ESI+, m/z) calculated for C10H16NO4 [M + H]
+ 
214.1079, found 214.1079. 
Compound 3–16 
 
The compound was synthesized with an overall yield of 17% from 6–11 and 26 
mg material was obtained.  
[α]D
22 = –13.5° (c = 0.5 in MeOH: CHCl3 = 1 : 20). 
1H NMR (500 MHz, CDCl3) δ 10.32 
(s, 1H), 6.96 (t, J = 8.0 Hz, 1H), 6.51 (d, J = 8.0 Hz, 2H), 5.44 (s, 2H), 3.21 (dd, J = 13.5, 
1.5 Hz, 2H), 3.06 – 2.96 (m, 1H), 2.85 (d, J = 13.5 Hz, 2H), 2.76 – 2.64 (m, 1H), 2.64 – 
2.50 (m, 2H), 2.42 – 2.10 (m, 8H), 2.03 (s, br, 2H), 1.16 (s, 6H), 1.05 (d, J = 8.5 Hz, 2H), 
0.81 (d, J = 4.0 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 173.4, 149.7, 145.1, 126.8, 
122.4, 115.5, 109.8, 60.2, 49.8, 44.8, 40.8, 38.0, 33.3, 31.8 (2 carbons), 26.4, 21.2. 
HRMS (ESI+, m/z) calculated for C29H41N2O3 [M + H]
+ 465.3117, found 465.3109.  
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(–)-Myrtemycin methyl ester (3–17) 
 
The compound was synthesized with an overall yield of 65% from 2–50 and 15 
mg material was obtained. Rf = 0.40,  MeOH/ CHCl3 = 1:10. 
[α]D
22 = –9.4° (c = 0.5 in MeOH: CHCl3 = 1 : 20).
1H NMR (500 MHz, CDCl3) δ 11.59 (s, 
1H), 10.75 (s, 1H), 10.52 (s, 1H), 7.61 (d, J = 9.0 Hz, 1H), 6.53 (d, J = 9.0 Hz, 1H), 5.43 
(s, 2H), 3.94 (s, 3H), 3.23 (d, J = 12.5 Hz, 2H), 3.10 – 2.92 (m, 1H), 2.80 (d, J = 13.0 Hz, 
2H), 2.75 – 2.63 (m, 1H), 2.63 – 2.46 (m, 2H), 2.28 (dd, J = 11.5, 5.0 Hz, 4H), 2.20 (dd, J 
= 18.0, 2.5 Hz, 2H), 2.14 (dt, J = 8.5, 5.5 Hz, 2H), 2.09 – 1.94 (m, 2H), 1.14 (s, 6H), 1.04 
(d, J = 8.5 Hz, 2H), 0.80 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 173.8, 171.1, 156.0, 
155.1, 145.3, 127.7, 122.3, 115.1, 111.5, 104.2, 60.4, 52.3, 50.0, 44.6, 40.7, 37.9, 33.3, 
31.7 (2 carbons), 26.2, 21.2. HRMS (ESI+, m/z) calculated for C31H43N2O5 [M + H]
+ 
523.3172, found 523.3172.  
(–)-Homo-myrtemycin (3–18) 
 
The compound was synthesized with an overall yield of 45% from 2–50 and 25 
mg material was obtained. Rf = 0.45, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 1/7/55. 
[α]D
22 = –7.4° (c = 0.5 in MeOH: CHCl3 = 1 : 20). 
1H NMR (600 MHz, CDCl3/MeOD = 
20/1) δ 7.65 (d, J = 8.5 Hz, 1H), 6.33 (d, J = 8.5 Hz, 1H), 5.73 (s, 2H), 3.48 (d, br, J = 
11.5 Hz, 2H), 3.41 – 3.21 (m, covered by the solvent residue peak, 2H), 3.05 (s, br, 1H), 
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2.88 (s, br, 1H), 2.74 – 2.55 (m, 2H), 2.45 (dt, J = 9.0, 5.5 Hz, 2H), 2.42 – 2.19 (m, 6H), 
2.19 – 1.97 (m, 4H), 1.26 (s, 6H), 1.14 (d, J = 9.0 Hz, 2H), 0.83 (s, 6H). 13C NMR (150 
MHz, CDCl3/MeOD = 20/1) δ 176.0 (br), 175.3, 159.0, 156.6, 142.3 (br), 130.6, 128.6 
(br), 113.4, 112.5, 107.8, 71.5, 60.1, 54.4, 45.7, 41.8, 39.1, 34.9, 32.7 (2 carbons), 26.6, 
21.6. HRMS (ESI+, m/z) calculated for C31H43N2O5 [M + H]
+ 523.3172, found 523.3164.  
Compound 3–19 
 
The compound was synthesized with an overall yield of 67% from β-alanine and 
(–)-myrtenal and 0.30 g material was obtained.  
[α]D
27 = –8.3° (c = 3.0 in MeOH: CHCl3 = 1 : 20). 
1H NMR (400 MHz, CDCl3) δ 5.52 (s, 
2H), 3.24 (d, J = 12.0 Hz, 2H), 3.08 – 2.94 (m, 1H), 2.89 (d, J = 13.0 Hz, 2H), 2.67 – 
2.45 (m, 3H), 2.42 (dt, J = 9.0, 5.5 Hz, 2H), 2.29 (d, br, J = 18.0 Hz, 2H), 2.21 (dd, br, J 
= 18.0, 2.5 Hz, 2H), 2.14 (t, br, J = 5.0 Hz, 2H), 2.16 – 1.98 (m, 2H), 1.25 (s, 6H), 1.06 
(d, J = 9.0 Hz, 2H), 0.78 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 174.0, 142.3, 125.1, 
58.9, 48.9, 44.3, 40.3, 38.0, 31.7, 31.6, 29.4, 26.1, 21.1. HRMS (ESI+, m/z) calculated 
for C23H36NO2 [M + H]
+ 358.2746, found 358.2743. IR (cm–1): 2916 (s), 1718 (s), 1383 





 (–)-Myrtanal was prepared by Corey-Kim oxidation [349] from (1S,2S,5S)-(–)-
myrtanol (99 % ee). And the crude material was used for pathway 1 without further 
purification. The compound (3–20) was synthesized with an overall yield of 63% from 2–
50 and 0.40 g material was obtained. Rf = 0.35, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 
1/7/55. 
 [α]D
21 = –9.6° (c = 0.6 in MeOH: CHCl3 = 1 : 20). 
1H NMR (500 MHz, [D5] pyridine) δ 
8.25 (d, J = 8.5 Hz, 1H), 6.80 (d, J = 8.5 Hz, 1H), 3.05 – 2.88 (m, 1H), 2.87 – 2.65 (m, 
3H), 2.22 – 2.12 (m, 4H), 2.11 – 2.02 (m, 4H), 1.85 – 1.65 (m, 6H), 1.63 (d, J = 6.5 Hz, 
2H), 1.62 – 1.50 (m, 2H), 1.36 – 1.26 (m, 4H), 1.22 (s, 6H), 0.83 (s, 6H). 13C NMR (126 
MHz, [D5] pyridine) δ 175.9, 174.4, 158.9, 155.5, 129.6, 123.8, 115.9, 109.2, 61.2, 53.4, 
44.5, 42.2, 40.0, 34.0, 31.2, 27.6, 25.5, 24.3, 21.5, 20.9. HRMS (ESI+, m/z) calculated 
for C30H45N2O5 [M + H]
+ 513.3328, found 513.3326. IR(cm–1): 2916 (m), 1556 (m), 
1384 (s), 1266 (m), 736 (s).  
(+)-Myrtemycin (3–21) 
 
The compound was synthesized with an overall yield of 69% from 2–50 and 0.75 g 
material was obtained. (+)-Myrtenal was synthesized by literature method [350] from 
(+)-pinene (99 % ee). Rf = 0.40, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 1/7/55.  
[α]D
20 = +10.8° (c = 1.0 in MeOH). 1H NMR (600 MHz, [D5] pyridine) δ 10.84 (s, 1H), 
8.12 (d, J = 8.5 Hz, 1H), 6.88 (d, J = 9.0 Hz, 1H), 5.56 (s, 2H), 3.42 (d, J = 12.4 Hz, 2H), 
3.35 – 3.25 (M, BR, 1H), 3.23 – 3.08 (m, 4H), 3.08 – 2.90 (m, br, 1H), 2.64 (s, 2H), 2.36 
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(dt, J = 8.5, 5.5 Hz, 2H), 2.20 (dd, J = 50.0, 17.5 Hz, 4H), 1.96 (s, 2H), 1.24 (s, 6H), 1.20 
(d, J = 8.5 Hz, 2H), 0.85 (s, 6H). 13C NMR (126 MHz, [D5] pyridine) δ 175.8, 174.5, 
159.0, 158.8, 146.2, 130.4, 123.9, 116.3, 111.2, 108.1, 61.0, 51.4, 45.8, 42.1, 39.1, 34.6, 
33.2, 32.9, 27.4, 22.3.  HRMS (ESI+, m/z) calculated for C30H41N2O5 [M + H]
+ 
509.3015, found 509.3015. IR(cm–1): 2917 (s), 1654 (s), 1447 (m), 1366 (m), 1312 (s), 
1181 (s), 1051 (s), 891 (m), 792 (s).  
Compound 3–22 
 
The compound was synthesized with an overall yield of 20% from 2–50 and 26 
mg material was obtained. Rf = 0.30, NH3•H2O (28% aq.)/ MeOH/ CHCl3 = 1/7/55. 
1H NMR (600 MHz, MeOD) δ 7.65 (d, J = 8.5 Hz, 1H), 6.34 (d, J = 8.5 Hz, 1H), 5.78 (s, 
1H), 3.56 (d, br, J = 5.0 Hz, 2H), 3.40 – 3.30 (m, covered by the solvent residue peak, 
2H), 2.92 (t, J = 6.0 Hz, 2H), 2.50 (dt, J = 9.0, 5.5 Hz, 1H), 2.35 (q, br, J = 18.0 Hz, 2H), 
2.27 – 2.18 (m, 1H), 2.12 (s, 1H), 1.32 (s, 3H), 1.22 (d, J = 8.5 Hz, 1H), 0.87 (s, 3H). 13C 
NMR (151 MHz, MeOD) δ 176.0, 172.3, 159.6, 157.2, 140.8, 131.0, 127.0, 112.8, 112.7, 
107.4, 58.4, 53.3, 45.4, 44.7, 41.8, 39.2, 32.3 (2 carbons), 26.5, 21.5. HRMS (ESI+, m/z) 
calculated for C20H27N2O5 [M + H]
+ 375.1920, found 375.1919. 




The compound was synthesized with an overall yield of 15% from 2–50and 5 mg 
material was obtained. The product was purified on HPLC (RP-C18 column), 1 %  15 
% B in 0  20 min (A: 0.1 M TEAA in water, B: acetonitrile).  
1H NMR (500 MHz, MeOD) δ 7.69 (d, J = 9.0 Hz, 1H), 6.47 (d, J = 9.0 Hz, 1H), 3.28 (t, 
J = 6.5 Hz, 2H), 2.89 (t, J = 6.5 Hz, 2H). 13C NMR (126 MHz, MeOD) δ 173.7, 172.2, 
160.2, 131.3, 113.0, 109.0, 106.4, 40.6, 37.1. HRMS (ESI+, m/z) calculated for 
C10H13N2O5 [M + H]
+ 241.0824, found 241.0801. 
 
6.4  Synthetic protocols for compounds in Chapter 4 
6.4.1  Synthesis of compound 4–1 and 4–2 
For the synthesis of natural c-di-GMP, see ref [330]. The synthesis of endo-S-c-
di-GMP is outlined in Scheme 4–1 in Section 4.1.1, and the detailed procedure was 
described below.  
2’-OTBS, N-acetyl guanosine-3’-dicyanoethylphosphorothioate (4–4) 
 
Standard guanosine phosphoramidite 4–3 (1.03 g, 1.09 mmol) and cyanoethyl 
alcohol (0.40 mL 5.5 mmol) were dissolved in anhydrous acetonitrile (15 mL) at RT 
under argon and stirred for 15 min. After the addition of imidazolium perchlorate [351] 
(0.70 g, 4.0 mmol), the reaction mixture was stirred for 6 h at RT. Beacauge reagent (3H-
1,2-benzodithiole-3-one 1,1-dioxide,  0.55 g, 2.8 mmol) was then added, and the reaction 
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mixture was stirred for an extra 1 h before an aqueous solution of Na2S2O3 (1 M, 30 mL) 
was poured into the reaction vessel to quench the reaction and CH2Cl2 (30 mL) was 
added. The two layers were immediately separated and the organic layer was collected. 
The aqueous layer was then extracted with CH2Cl2 (50 mL x 2) and the combined organic 
layer was concentrated with a rotary evaporator to dryness.  
The crude material was re-dissolved in CH2 l2 (20 mL), and dichloroacetic acid 
(1.00 mL, 12.2 mmol) was added dropwise over 5 min to form a red/orange solution. 
After stirring for 10 min at RT, an aqueous solution of NaHCO3 (saturated solution, 30 
mL) was poured into the reaction mixture to quench the reaction. The two layers were 
separated and the organic layer was collected. The aqueous layer was then extracted with 
CH2Cl2 (50 mL x 2) and the combined organic layer was concentrated at a reduced 
pressure. The crude product was immediately purified with a silica-gel (40 g, 400-mesh) 
column with gradient elution (2–10 % MeOH in CH2Cl2, Rf = 0.45, 10 % MeOH in 
CH2Cl2). Product (60 % from phosphoramidite 4–3) was collected as a pale yellow 
glacial solid.  
1H NMR (500 MHz, CDCl3) δ 12.33 (s, 1H), 9.96 (s, br, 1H), 7.89 (s, 1H), 5.76 (d, J = 
7.0 Hz, 1H), 5.12 (dd, J = 10.5, 4.5 Hz, 1H), 5.04 (d, J = 5.0 Hz, 1H), 4.87 (d, J = 5.0 Hz, 
1H), 4.40 – 4.22 (m, 4H), 3.99 (d, J = 12.5 Hz, 1H), 3.90 – 3.71 (m, 1H), 2.95 – 2.71 (m, 
4H), 2.31 (s, 3H), 0.73 (s, 9H), –0.09 (s, 3H), –0.28 (s, 3H). 31P NMR (202 MHz, CDCl3) 
δ 67.7. 13C NMR (126 MHz, CDCl3) δ 173.0, 155.6, 147.9, 139.5, 122.4, 116.8, 89.3, 
84.6, 78.9, 73.5, 63.0, 61.9, 53.6, 31.0, 25.6, 24.5, 19.7, 18.0, –4.7, –5.2. ESI+/MS for 
[C24H37N7O8PSSi]






A solution containing guanosine phosphothioate 4–4 (0.27 g, 0.42 mmol) and 
phosphoramidite 4–3 (0.59 g, 0.63 mmol) in anhydrous acetonitrile (15 mL) was stirred 
at RT under argon for 15 min. After the addition of imidazolium perchlo ate (0.35 g, 2.0 
mmol), the reaction mixture was stirred for 6 h at RT. t-BuOOH (70 % aqueous solution, 
0.50 mL, 3.9 mmol) was then added, and the reaction mixture was stirred for an extra 10 
min before an aqueous solution of Na2S2O3 (1 M, 30 mL) was poured into the reaction 
vessel to quench the reaction and CH2 l2 (30 mL) was added. The two layers were 
immediately separated and the organic layer was collected. The aqueous layer was then 
extracted with CH2Cl2 (50 mL x 2) and the combined organic layer was concentrated 
with a rotary evaporator to dryness.  
The crude material was re-dissolved in CH2 l2 (20 mL), and dichloroacetic acid 
(0.50 mL, 6.1 mmol) was added dropwise over 5 min to form a red/orange solution. Af er 
stirring for 10 min at RT, an aqueous solution of NaHCO3 (saturated solution, 30 mL) 
was poured into the reaction mixture to quench the reaction. The two layers were 
separated and the organic layer was collected. The aqueous layer was then extracted with 
CH2Cl2 (50 mL x 3) and the combined organic layer was concentrated at a reduced 
pressure. The crude product was passed through a short silica-gel olumn (10 g) with 
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elution of 2:1 acetone: hexane (100 mL) to remove the byproduct. The desir d product 
could be eluted with 1:10 MeOH: CH2Cl2 (Rf = 0.25) and then dried thoroughly under 
high vacuum.  
A mixture of the crude material, methyltriphenoxyphosphonium iodide (0.95 g, 
2.10 mmol) and 2,6-lutidine (1.00 mL, 8.61 mmol) was dissolved in anhydrous DMF (10 
mL) under argon. The reaction was stirred for 1 h at RT before an aqueous solution of 
Na2S2O3 (1 M, 30 mL) and CH2Cl2 (30 mL) was poured into the reaction mixture. The 
two layers were separated and the organic layer was collected. The aqueous layer was 
then extracted with CH2Cl2 (50 mL x 3) and the combined organic layer was concentrated 
at a reduced pressure. The crude product was immediately purified with a silica-gel (40 
g) column with gradient elution (1–8 % MeOH in CH2Cl2, Rf = 0.30, 5 % MeOH in 
CH2Cl2). 0.42 g product (61 % from intermediate 4–4) was collected as a pale yellow 
glacial solid. 
1H NMR (500 MHz, CDCl3) δ 12.28 (s, 1H), 12.15 (s, 1H), 10.75 (d, J = 7.0 Hz, 2H), 
7.84 (s, 1H), 7.72 (s, 1H), 5.76 (dd, J = 22.0, 7.0 Hz, 2H), 5.41 – 5.15 (m, 2H), 5.15 – 
4.89 (m, 2H), 4.74 – 4.49 (m, 2H), 4.49 – 4.12 (m, 8H), 3.62 (dd, J = 10.5, 8.0 Hz, 1H), 
3.46 (dd, J = 10.5, 5.0 Hz, 1H), 2.84 – 2.69 (m, 6H), 2.24 (d, J = 2.5 Hz, 6H), 0.74 (s, 
9H), 0.73 (s, 9H), –0.05 (s, 3H), –0.06 (s, 3H), –0.23 (s, 3H), –0.29 (s, 3H). 31P NMR 
(202 MHz, CDCl3) δ 67.9, –2.9.
 13C NMR (126 MHz, CDCl3) δ 173.1, 155.9, 155.7, 
148.5, 148.1, 139.7, 138.8, 122.8, 122.3, 116.9, 116.7, 89.3, 88.8, 82.5, 81.4, 79.7, 72.8, 
71.9, 67.8, 63.3, 63.0, 29.7, 25.6, 24.3, 19.8, 18.0, 5.5, –4.57, –4.79, –5.15, –5.18. 
ESI+/MS for [C45H67IN13O15P2SSi2]




Endo-S-c-di-GMP (4–2, as a triethylammonium salt) 
 
5’-Iodo guanosine phosphothioate 4–5 (50 mg, 0.038 mmol) was stirred with 
ammonia (30 % NH4OH in water, 5 mL) at RT for 24 h. The solvent was removed with a 
rotary evaporator and the crude material was thoroughly dried under high vacuum. 
Anhydrous pyridine (1.0 mL) and NEt3
.3HF (0.25 g, 1.6 mmol; caution! the chemical is 
highly toxic) were added carefully into the plastic reaction vessel, and the mixture was 
stirred vigorously at 50 °C for 6 h. Upon the immediate addition of acetone (20 mL), a 
white precipitate formed. The solid was filtered by a powder funnel with a piece of 
cotton, and was washed with acetone (5 mL x 4). The collected crude pro uct was then 
re-dissolved in water (10 mL), purified by HPLC (Nacalai tesque 5C18-MS II column), 
concentrated at a reduced pressure, and washed with acetone (2 mL x 5) to remove the 
excess of TEAA (triethylammonium acetate) buffer. 16 mg product was collected as a 
white solid (59 % from 4–5).  
1H NMR (500 MHz, D2O, with water suppression) δ 8.25 (s, 1H), 8.10 (s, 1H), 6.12 (s, 
1H), 6.05 (d, J = 4.5 Hz, 1H), 5.22 – 5.02 (m, 3H), 4.87 (d, J = 5.0 Hz, 1H), 4.59 – 4.53 
(m, 2H), 4.50 (d, J = 12.5 Hz, 1H), 4.24 (d, J = 12.5 Hz, 1H), 3.42 (ddd, J = 13.0, 12.5, 
7.5 Hz, 1H), 3.30 (q, J = 7.5 Hz, 12H), 3.22 (ddd, J = 14.0, 12.0, 3.0 Hz, 1H), 1.38 (t, J = 
7.5 Hz, 18H). 31P NMR (202 MHz, D2O) δ 19.9, –0.4.
 13C NMR (151 MHz, D2O) δ 158.9 
 
(2 carbons), 153.9, 153.8, 151.6, 150.9,
79.6, 74.3, 73.5, 72.0, 70.8, 62.4, 46.7, 31.4, 8.2.
calculated 705.0647, found 
 
6.4.2  Cleavage of c-di-
The RocR enzymatic reaction was scaled up 
total volume of 0.50 mL, and other conditions remained the same as indicated in Section 
6.6.2. At three time points: 30 min, 2 h and 18 h, 
the reaction was stopped by adding a final concentration of 5 mM EDTA and cooling on 
ice. RocR was then removed by running through a size exclusion column. The samples 
were subsequently stored at 
Figure 6–3. HPLC analysis of cleavage of endo
11 % B, 0  16 min (A: 100 mM TEAA buffer in water; B: acetonitrile), RT. 
 138.1, 137.1, 116.5 (2 carbons), 89.2, 88.0, 81.1, 
ESI–/MS for [C20
705.0620. 
GMP and endo-S-c-di-GMP by RocR 
to 500 µM endo-S
aliquots of the reaction were taken and 
–20 °C until HPLC analysis (Figure 6–3). 










The HPLC chromatography (Figure 6–3) clearly showed that endo-S-c-di-GMP 
(at 15.5 min) was converted to a product (at 20.3 min) almost quantitatively after 18 h. 
Mass spectrometry and NMR analysis both indicated that 5’-pGSpG was the product 
(terminal phosphothioates usually give a 31PNMR signal at 16–17 ppm [352,353], 
whereas the endo-sulfur phosphothioates have signals around 20 ppm [354]. Additionally 
terminal phosphates (dianionic) have 31PNMR peaks around 1 ppm (see NMR data for 
pGpG (4–7)), whereas phosphodiesters (monoanionic) have 31PNMR signals around –1 
pm [333]. The 31PNMR of the product of the RocR cleavage reaction has peaks at –0.5 
and 20.3 ppm (characteristic of a phosphodiester and a terminal phosphothioate 
respectively); therefore we conclude that cleavage of endo-S-c-di-GMP exclusively 
occurred at the natural phosphate site.  
5’-pGSpG (4–6) 
1H NMR (600 MHz, D2O) δ 7.82 (s, 1H), 7.78 (s, 1H), 6.00 (d, J = 3.0 Hz, 1H), 5.63 (d, J
= 5.0 Hz, 1H), 5.33 (td, J = 7.5, 3.5 Hz, 1H), 5.13 (ddd, J = 11.0, 7.0, 5.0 Hz, 1H), 4.62 – 
4.51 (m, 2H), 4.47 – 4.37 (m, 1H), 4.20 (ddd, J = 11.5, 4.5, 2.5 Hz, 1H), 4.12 (dt, J = 
11.0, 5.5 Hz, 1H), 4.06 (dt, J = 6.0, 4.5 Hz, 1H), 3.08 (q, J = 7.5 Hz, 9H), 2.60 (ddd, J = 
20.5, 14.5, 5.5 Hz, 2H), 1.15 (t, J = 7.5 Hz, 15H). 31P NMR (162 MHz, D2O) δ 20.3, –
0.5. ESI–/MS for [C20H23N10O13P2S]
–: calculated 705.0647 [M–H3O]
–, found 705.0622. 
pGpG bis(triethylammonium) salt (4–7) 
1H NMR (600 MHz, D2O) δ 7.93 (s, 1H), 7.86 (s, 1H), 5.74 (d, J = 5.5 Hz, 1H), 5.69 (d, J
= 5.5 Hz, 1H), 4.48 – 4.33 (m, 1H), 4.30 (s, 1H), 4.21 (s, 1H), 4.13 (dt, J = 11.5, 3.0 Hz, 
1H), 4.05 (dt, J = 11.5, 4.0 Hz, 1H), 3.99 – 3.77 (m, 2H), 3.07 (q, J = 7.5 Hz, 12H), 1.15 
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(t, J = 7.5 Hz, 18H). 31P NMR (243 MHz, D2O) δ 1.1, –0.6. ESI
–/MS for 
[C20H25N10O15P2]
–: calculated 707.0982, found 707.0989. 
 
6.4.3 Syntheses of compounds 4–52 and 4–53 
Jones’ strategy for the synthesis of c-di-GMP [330] was adopted for the synthesis 
of c-di-GMP analogs containing natural phosphate linkages, 4–52 and 4–53. Crude 
materials were used for the steps up until intermediate 6–14before the first purification 
was done (Scheme 6–4). 2.0 g of starting phosphoramidite 6–11 was used. After mono-
cyanoethyl protected 6–14 was obtained, the solvent was removed from the reaction 
mixture by high-vacuum to yield a sticky yellow solid. This crude material was 
transferred to a centrifuge tube and was sequentially washed with EtOAc (50 mL x 2), 
MeOH (50 mL x 3) and centrifuged each time. The EtOAc layer was extracted with H2O 
(25 mL x 2), and the aqueous layer combined with the MeOH layer and ws concentrated 
and subjected to HPLC purification. HPLC condition: 10  25% B, 0  20 min (A: 0.1 
M TEAA in water; B: acetonitrile). The product was identified by ESI-MS (negative 
mode) before the global deprotection step. Procedures for global deprotection, using 
ammonium hydroxide, and HPLC purification of the final compound were similar to 





Scheme 6–4. Synthesis of compounds 4–52 (R1 = Me) and 4–53 (R1 = F). Modified 
conditions from ref [330] were used: a) pyridinium trifluoroacetate, H2O, then t-BuNH2; 
b) dichloroacetic acid, then quenched with pyridine; c) compound 6–11; d) t-BuOOH; e) 
dichloroacetic acid, then quenched with pyridine; f) 5,5-dimethyl-2-oxo-2-chloro-1,3,2-
dioxaphosphinane (DMOCP); g) I2, H2O, then HPLC purification; h) ammonia, then 
HPLC purification.  
 
2’,2’-di-OMe c-di-GMP bis(triethylammonium) salt (4-52) 
 
1H NMR (500 MHz, D2O) δ 7.93 (s, 2H), 5.88 (d, J = 6.0 Hz, 2H), 4.81 (td, J = 8.5, 4.5 
Hz, 2H), 4.44 (t, J = 5.5 Hz, 2H), 4.33 (d, J = 3.0 Hz, 2H), 3.81 (dd, J = 13.0, 2.5 Hz, 2H), 
3.76 (dd, J = 13.0, 3.5 Hz, 2H), 3.39 (s, 6H), 3.10 (q, J = 7.5 Hz, 12H), 1.18 (t, J = 7.5 Hz, 
18H). 31P NMR (202 MHz, D2O) δ 0.1.
 13C NMR (126 MHz, D2O) δ 158.7, 153.7, 151.3, 
138.0, 116.6, 86.0, 85.0, 81.2, 72.1, 61.1, 58.1, 46.6, 8.1. ESI–/MS for [C22H27N10O14P2]
–: 




C-di-dGMP bis(triethylammonium) salt (4-53) 
 
1H NMR (400 MHz, D2O) δ 7.96 (s, 2H), 6.21 (s, 2H), 5.07 – 4.86 (m, 1H), 4.15 (s, 2H), 
4.00 (dd, J = 40.0, 10.5 Hz, 3H), 3.06 (q, J = 7.5 Hz, 12H), 2.99 – 2.77 (m, 2H), 2.63 (dt, 
J = 14.0, 7.0 Hz, 2H), 1.14 (t, J = 7.5 Hz, 18H). 31P NMR (161 MHz, D2O) δ –0.5. ESI
–
/MS for [C20H23N10O12P2]
–: calculated 657.0978, found 657.0998. 
 
6.4.4  Solid support synthesis (compounds 4–54 to 4–57) 
Sulfonylethyl-ODMT CPG (10 µmol/g) was prepared following literature [344] 
(see Scheme 6–1, credit: Andrew Shurer). The solid support was loaded (0.1 g) into the 
synthesis column (Figure 6–2b) and sealed tightly. A DNA/RNA synthesizer was used 
for making the dinucleotide and was set up as described in Section 6.1.4 (Figure 6–2). 
Two cycles of standard 1.0 µmol RNA program (DMT-off) were performed with an 
interruption before the oxidation step during the first cycle and the oxidation step was 
done manually, using a solution of Beacauge reagent (1 mg/mL in anhydrous acetonitrile, 
1 mL) for 30 min using the apparatus shown in Figure 6–4. A white precipitate might be 
observed in the syringes in the sulfurization step, and after the reaction was finished, the 
synthesis column was put back on to the DNA/RNA synthesizer for the est of the 
synthesis cycles.  
 
Figure 6–4. Sulfurization of the phosphonate on CPG beads. An empty syringe and 
another one with 1 mL Beacauge reagent (1 mg/mL in anhydrous acetonitrile) were 
attached on each side of the synthesis column. The liquid was passed through the column 
by pushing and pulling the two syringes simultaneously. This liquid transfer was repeated 
three times during the 30 min. 
  
When the two synthesis cycles 
with anhydrous acetonitrile for another 60 s on the DNA/RNA synthesizer before the 
CPG beads in the synthesis column 
DNA/RNA synthesizer can handle four synthesis columns simulta
24 columns were synthesized for each analog. The argon
in a round-bottom flask (theoretically contained 24 
were then further dried under the high vacuum for 5 h while ge
DMF (10 mL) was transferred to the flask containing the dried CPG beads with a 
cannula, followed by a rapid transfer
2.10 mmol) and 2,6-lutidine (1
reaction was stirred for 1 h at RT before 
was poured into the reaction 
3) and methanol (10 mL x 3) in a Buchner funnel befor  transferred into
flask and stirred with ammonia (30 % NH
The reaction mixture was then filtered and rinsed with H
 
were completed, the synthesis column was washed 
were dried by blowing through 
neously
-dried CPG beads were collected 
µmol nucleotides). The CPG beads 
ntly stirring. Anhydrous 
 of methyltriphenoxyphosphonium iodide
.00 mL, 8.61 mmol) under the protection of argon
an aqueous solution of Na2S2O
mixture. The CPG beads were washed with H
4OH in water, 15 mL) at 40 °C for overnight. 
2O (10 mL x 3). The combined 
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with argon. The 
 and a total of 
 (0.95 g, 
. The 
3 (1 M, 30 mL) 
2O (10 mL x 
 a round-bottom 
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filtrate was concentrated and for analogs 4–54, 4–55 and 4–57 the crude products were 
directly subjected to HPLC purification. For the procedure of OTBS group deprotection 
of analog 4–56 and HPLC conditions refer to the preparation of compound 4–2. The 
factions collected from HPLC were concentrated at a reduced pressure, and washed with 
acetone (2 mL x 5) to remove the excess of TEAA (triethylammonium acetate) buffer. 3–
14 mg product of compounds 4–54 to 4–57 was collected as a white solid (estimated 
yields of 18–83 % were obtained, based on the estimated loading of the CPG beads). 
2’,2’-difluoro-endo-S-c-di-GMP bis(triethylammonium) salt (4-54) 
 
1H NMR (500 MHz, D2O, water suppression, 50 °C) δ 8.28 (s, 1H), 8.15 (s, 1H), 6.51 (d, 
J = 19.0 Hz, 1H), 6.42 (d, J = 19.0 Hz, 1H), 5.98 (dd, J = 52.0, 3.5 Hz, 1H), 5.80 (dd, J = 
52.0 3.5 Hz, 1H), 5.50 (tdd, J = 13.0, 8.5, 5.0 Hz, 1H), 5.35 (dt, J = 22.5, 9.0 Hz, 1H), 
4.63 (d, J = 12.5 Hz, 1H), 4.33 (d, J = 11.0 Hz, 1H), 3.69 (dt, J = 13.5, 5.0 Hz, 1H), 3.30 
(t, J = 11.0 Hz, 1H). 31P NMR (202 MHz, D2O, 50 °C) δ 19.3, –0.5. ESI
–/MS for 
[C20H21F2N10O11P2S]
–: calculated 709.0561, found 709.0596. 




1H NMR (500 MHz, D2O, 50 °C) δ 8.31 (s, 1H), 8.18 (s, 1H), 6.30 (s, 1H), 6.19 (d, J = 
4.5 Hz, 1H), 5.35 (dt, J = 10.0, 5.0 Hz, 1H), 5.21 (td, J = 9.0, 5.0 Hz, 1H), 4.91 (t, J = 4.5 
Hz, 1H), 4.66 – 4.52 (m, 4H), 4.39 – 4.23 (m, 1H), 3.87 (s, 3H), 3.76 (s, 3H), 3.52 (ddd, J 
= 14.0, 11.5, 7.5 Hz, 1H), 3.38 (q, J = 7.5 Hz, 12H), 3.32 (ddd, J = 14.0, 11.5, 3.0 Hz, 
1H), 1.47 (t, J = 7.5 Hz, 18H). 31P NMR (202 MHz, D2O, 50 °C) δ 18.9, –0.7. 
13C NMR 
(126 MHz, D2O, 50 °C) δ 159.9 (2 carbons), 154.9, 154.8, 152.6, 152.0, 139.1, 138.2, 
117.6 (2 carbons), 88.1, 87.7, 83.7, 82.3, 81.8, 80.8, 74.1, 71.3, 71.2, 63.3, 59.9, 47.9, 
32.4, 9.30. ESI–/MS for [C22H27N10O13P2S]
–: calculated 733.0960, found 733.0981. 
2’,2’-OMe-OH-endo-S-c-di-GMP (4-56) 
 
1H NMR (500 MHz, D2O, water suppression, 50 °C) δ 8.32 (s, 1H), 8.18 (s, 1H), 6.29 (s, 
1H), 6.12 (d, J = 4.5 Hz, 1H), 5.35 – 5.06 (m, 3H), 4.74 – 4.48 (m, 3H), 4.31 (d, J = 13.0 
Hz, 1H), 3.84 (d, J = 3.0 Hz, 3H), 3.50 (ddd, J = 13.5, 11.5, 7.5 Hz, 1H), 3.35 – 3.17 (m, 
1H). 31P NMR (202 MHz, D2O, 50 °C) δ 19.1, –0.2. ESI
–/MS for [C21H25N10O13P2S]
–: 
calculated 719.0804, found 719.0793. 




1H NMR (500 MHz, D2O, water suppression, 50 °C) δ 8.26 (s, 1H), 8.23 (s, 1H), 6.65 – 
6.43 (m, 2H), 5.41 (s, 2H), 4.69 – 4.48 (m, 2H), 4.46 – 4.27 (m, 2H), 3.42 (q, J = 7.5 Hz, 
6H), 3.33 (dd, J = 13.5, 5.5 Hz, 2H), 3.23 (ddd, J = 20.5, 13.5, 6.0 Hz, 2H), 3.02 (dt, J = 
13.5, 6.0 Hz, 1H), 2.92 (ddd, J = 11.0, 5.5, 5.0 Hz, 1H), 1.51 (t, J = 7.5 Hz, 9H). 31P 
NMR (202 MHz, D2O, 50 °C) δ 19.7, –0.3. ESI
–/MS for [C20H23N10O11P2S]
–: calculated 
673.0749, found 673.0702. 
 
6.5  Computational details 
All of the calculations were performed with the Gaussian 03/09 program [298].  
6.5.1   Ring-opening reaction 
For ring-opening reaction in Chapter 2 (Scheme 2–8), density functional B3LYP 
[355,356] was used to locate all the transition structures and intermediates. Frequency 
calculations at the same level have been performed to confirm each stationary point to be 
either a minimum or a transition structure. 6-31G basis set is applied for all elements. The 
reported energies (Table 6–1) are zero-point energy-corrected electronic energies (∆E0 
K), enthalpies (∆H298 K) and free energies (∆G298 K).  
 
Table 6–1. The computed energies and other thermal parameters for the ring-ope ing 
reaction (in Hartree).[a] 
Structures Eele E0 K H298 K G298 K 
2–32 –547.920343986 –547.681748 –547.668910 –547.718623 
TS-a –547.879565801 –547.643849 –547.631576 –547.679279 
2–36 –547.960483826 –547.720075 –547.707858 –547.755868 
TS-b –547.864745024 –547.629002 –547.616869 –547.664266 
2–37 –547.938092690 –547.697860 –547.685563 –547.733836 
[a] For the Cartesian coordinates of the computed structures, see the Supporting 




6.5.2  Calculation of the radii (volumes) of c-di-GMP polymorphism 
Hartree-Fock method and Onsager’s model (Gaussian keyword: SCRF = dipole) 
in the self-consistent reaction field (SCRF) were used to calculate the radius of the solute 
cavity (Gaussian keyword: volume; parameters: H2O dielectric constant ε = 78.4, a0 = 
1000 Å). The 3-21G basis set was used for atom C, N, O, and H, and 6-31G(d) basis set 
was used for atom P, S and K.  
According to Stokes-Einstein equation, D = k T / (6 π η R), where k is the 
Boltzmann constant, T is the temperature, η is the solvent viscosity and R is the radius of 
the molecular sphere. The diffusion constants in solution phase are inversely proportional 
to the radii of the particles. The diffusion constant of monomeric c-di-GMP and endo-S-
c-di-GMP were measured with previous reported method [227,316]. The diffusion 
constants for other c-di-GMP aggregation states can be predicted from the calculated 
radii. Due to the low symmetry of endo-S-c-di-GMP aggregates, the radii calculation 
requires higher computing resource. However, we assume that the ratios of different 
aggregates of endo-S-c-di-GMP are similar to that of c-di-GMP. Thus we applied the 
ratio of calculated radii for c-di-GMP aggregates, and the measur d monomeric endo-S-
c-di-GMP diffusion constant to predict other diffusion constants for endo-S-c-di-GMP 
aggregates. The results of the calculation were summarized in the Tabl  6–2 (See 
Supporting Information of ref [357] for the Cartesian coordinates of the c-di-GMP 












constant (10-10 m/s2) 
c-di-GMP 
Monomeric c-di-GMP (closed) 6.41 C2 3.01a 
Monomeric c-di-GMP (open) 6.34 C2 -- 
Dimeric c-di-GMP 7.91 --b 2.45 
Tetrameric c-di-GMP 9.61 D4 2.01 




6.50 C1 2.55a 
Monomeric endo-S-c-di-GMP 
 (open) 
6.27 C1 -- 
Dimeric endo-S-c-di-GMP -- -- 2.07 
Tetrameric endo-S-c-di-GMP -- -- 1.70 
Octameric endo-S-c-di-GMP -- -- 1.37 
a) The diffusion constants of monomeric form of c-di-GMP and endo-S-c-di-GMP were 
measured from DOSY T1/T2 relaxation analysis with no metal cation added (average 
value; see Figure 4–2, 4–3 and Section 6.6.1 for detail); b) The dimeric c-di-GMP 
structure was adapted from x-ray crystal structure (PDB code: 315A) 
 
6.6  NMR experiments for T1/T2 relaxation analysis (DOSY) and NOE 
The Bruker AV III 600 MHz spectrometer was used to determine the diffusion 
constants and the NOE effect. The concentration of the samples was controlled at 3 mM 
in D2O (with or without K
+) using UV analysis (ε260 nm =21600). The samples with 100 
mM KCl was incubated at 90 °C for 5 min, cooled down to RT, and stored at 4 °C for 
overnight before use. Shigemi NMR tubes (D2O) were used for all experiments, in which 
0.30 mL sample solution was applied. A temperature control module was used for all 
experiments at 30.0 °C [316]. 
DOSY was measured with the stimulated echo pulse sequence (Bruker p lse 
program stebpgp1s19) using bipolar gradient pulses and watergate 3-9-19 to subpressed 
the solvent. Key aquisition parameters for the DOSY experiment include the big delta (∆) 
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at 0.10 s, the number of scans at 8, relaxation delay at 2.5 s, and the gradient strength was 
varied 32 times lineary from 5 to 95% . The gradient pulse length (small delta δ) within 
the range of 1.4–1.8 ms was optimized under the experiment condition upon the point 
that the region of 5.5–9.0 ppm showed a good decay for the major peaks. The data were 
processed with TopSpin 2.1 software with T1/T2 relaxation analysis. Exponantial function 
was applied for the raw data and the curve-fitting of the decays w s based on the area of 
the peaks.  
The condition of NOE experiment was referred to previous report [227], where a 
short mixing time (150 ms) was applied. The Figure 6–5 illustrates that the syn 
conformer of guanine H8 and anomeric H showed a significantly stronge  positive NOE 
(> 35 %) compared to anti conformer (< 8 %).  
 
 
Figure 6–5. The NOE of syn- and anti- guanosines.  
 
 
6.7  Biological assays 
6.7.1  Minimal inhibitory concentration (MIC) 
In Chapter 2, Staphylococcus aureus (Newman), Streptococcus agalactiae 
(2603V/R), and Bacillus subtilis (3160) were routinely grown in tryptic soy broth, Todd 
Hewitt broth and Luria Broth, respectively. For minimal inhibitory con entration 
determination, each of the strains was diluted to 5 x 105 cfu/mL and 98 µL was added to 
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2 µL of diluted compounds or known antibacterial agent (carbenicillin or platensimycin) 
at the indicated concentration in sterile 96-well plate. The plates w re shaken for 24 
hours at 37 ˚C in a humidified chamber. The MIC was determined as the lowest 
concentration at which no bacteria were observed to grow as determined by OD600 
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Figure 6–6. MIC determination for platensimycin analogs against a) S. aureus, b) S. 
agalactiae and c) B. subtilis.  
 
In Chapter 3, each of the strains of Bacillus subtilis (3160) and Escherichia coli 
K12 (1655) were grown in Luria Broth. The strains were diluted to 3 x 105 cfu/mL and 98 
µL was added to 2 µL of diluted compounds or known antibacterial agent (FAS inhibitors: 
platensimycin or cerulenin) at the indicated concentration in a sterile 96-well plate. When 
MDR inhibitor Phe-Arg β-naphthylamide dihydrochloride (PAβND) was added, 97 µL 
bacterial broth, 2 µL antibacterial solution and 1 µL MDR inhibitor solution was mixed in 
each well of a 96-well plate. The plates were shaken for 24 hours at 37 ˚C. The minimum 
inhibitory concentration (MIC) was determined as the lowest concentration at which no 
bacteria were observed to grow as determined by OD600. All experiments were performed 
in triplicate. The MIC testing against MRSA and VRE strains were done by Accugen 






















6.7.2 Enzymatic assays 
Alg44, RocR, and WspR were purified by histidine chromatography followed by 
Q-sepharose anion exchange column. Proteins were dialyzed into a 10 mM Tris, 100 mM 
NaCl solution. α-32P-c-di-GMP was generated from purified WspR as described in Lee et 
al.’s previous report [225]. For binding assay of Alg44, 5 µM protein was mixed with 1 
µM α-32P-c-di-GMP and indicated competitor (c-di-GMP or endo-S-c-di-GMP) in a 
buffer containing 10 mM Tris (pH 8.0), 100 mM KCl, and 5 mM MgCl2. This mixture 
was allowed to equilibrate for 10 min. The binding assay was analyzed using pulldown 
assay with Ni-NTA agarose beads [225]. For RocR and WspR enzymatic assays, 5 µM 
enzyme was added to 8 nM α-32P-c-di-GMP (for RocR) or 8 nM α-32P-GTP (for WspR) 
and 1 mM of the indicated competitor in reaction buffer (10 mM Tris pH 8.0, 100 mM 
NaCl, 5 mM MgCl2). 1 µL of sample were spotted on polyethyleneimine cellulose TLC 
plates at indicated times after addition of the enzyme. Samples were dried and separated 
using a mobile phase consisting of 1: 1.5 of saturated (NH4)2SO4 and 1.5 M KH2PO4. 
TLC plates were dried, exposed on a phosphorimager screen and visualized with a 
Fujifilm FLA-7000.  
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Appendix I. Kinetic study of the epimerization reaction 
Assuming the reaction pathway is as described in Scheme S1. 
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At the equilibrium point (> 1380 min),  
Let 0][])[]([][ ABAB ξξ =+=∞ , so, 0])[1(][ AA ξ−=∞ .  
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Using the initial condition: 0][ 0 ==tB ,  
)1(][][ /0
ξξ KteAB −−=   (S6) 
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Thus, 70 % of the equilibrium is reached in 6 h.   
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Appendix II. Reaction conditions for dynamic ring-closing metathesis 
Dynamic ring-closing metathesis (DRCM) was performed by combining the 
ruthenium catalyst and an epimerization base in the same flask. Other than Hoveyda-
Grubbs II catalyst, two other ruthenium catalysts, Grubbs I and Grubbs II catalyst 
(Figure S2), were also screened.  In the case of Grubbs I catalyst, no reaction occurred 
with the bis-alkene substrate 2–34 and the starting material was recovered. For Grubbs II 
catalyst, the yield of the reaction (23 %) was significantly lower than the reaction that 
was catalyzed by Hoveyda-Grubbs II catalyst (69 %). Significant side products (a 
complicated mixture) were also obtained when Grubbs II catalyst was used (Scheme S2). 
 
 
Figure S2. The structures of Grubbs I, Grubbs II and Hoveyda-Grubbs II catalyst.   
 
 
Scheme S2. The unsuccessful ring-closing metathesis reactions that were catalyzed by 
Grubbs I and Grubbs II catalyst. Reaction condition: 0.05 M cis-2–34: trans-2–34 (1: 




The rate-limiting step of the dynamic ring-closing metathesis (see Section 2.2.2) 
is the DBU catalyzed epimerization, with an apparent rate constant of 0.24 M–1min–1 (see 
Appendix I). Since the ruthenium catalyst is deactivated over time in the presence of 
alkenes [283,284] (t1/2 ~ 1 h under the experiment condition), the catalyst needs to be 
repeatedly added every other 3 h during the slow epimerization process. W  envisaged 
that a base with better epimerization ability would reduce the loading of the ruthenium 
catalyst. Ideally, if the epimerization equilibrium can be rapidly reached before the 
catalyst is deactivated, the ruthenium catalyst can be added at the beginning of the 
reaction (one time loading).  Therefore we screened other amine and alkoxide bases for 
the epimerization ability and the compatibility with Hoveyda-Grubbs II catalyst (Table 
S1). The epimerization reaction was performed with 30 mol% of various bases and a 
mixture of cis-2–34: trans-2–34 (1: 5.7) at 75 °C. To test the compatibility of the bases 
and the ruthenium catalyst, a simpler bis-alkene, diallyl dimethylmalonate was used with 
3 mol% Hoveyda-Grubbs catalyst and 30 mol% indicated base. No ring-closure product 
can form if the ruthenium catalyst is poisoned (Scheme S2). Among all the amine bases 
that are screened, 1,5,7-triazabicyclo[4.4.0]dec-5-ene, solid-supported and solution phase 
DBU (entry 7, 9 and 4, Table S1) had the best epimerization abilities. In the case of 
1,5,7-triazabicyclo[4.4.0]dec-5-ene, the epimerization reaction was significantly more 
rapid than the reactions catalyzed by other bases, and the reaction lmost reaches 
equilibrium after 1 h (at equilibrium, cis-2–34: trans-2–34 = 1.0: 1.2 in toluene). This 
amine, however, poisons the Hoveyda-Grubbs II catalyst, and is, therefore, not ideal for 
DRCM. Most of the amines or imines bearing an N–H moiety were not compatible with 
the ruthenium catalyst. Bulky tertiary amines, such as Hünig’s base (entry 2, Table S1) 
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and DBU are therefore most ideal for DRCM because they can epimerize ketone 
substrates and do not readily poison the ruthenium catalyst. Surprisingly, KOt-Bu (entry 
10, Table S1) was also compatible with Hoveyda-Grubbs II catalyst in protic solvent, t-
BuOH, and the epimerization ability was similar to DBU (entry 4 and 9, Table S1). 
 
Table S1. Epimerization of ketone 2–34 by various bases (the initial mixture of 2–34 





1 Et3N 1.0: 5.5 























10 KOt-Bu[c] 1.0: 4.2 
11 (no base) 1.0: 5.7 
[a] The reaction condition for the epimerization reaction: 30 mol% base and 0.05 M cis-
2–34: trans-2–34 (1: 5.7) was heated at 75 °C in (CH2Cl)2; [b] the concentration of 
substrate was 0.20 M; [c] the reaction was performed in t-BuOH.  
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 To test if the various bases in Table S1 can poison the ruthenium catalyst, a 
model reaction (Scheme S3) on a small scale was performed and monitored by TLC. In 
the absence of any added amine base, the reaction proceeded to completion, as judged by 
the disappearance of starting material and the appearance of a prduct. Initial TLC 
screening indicated that in the presence of Et3N, Hünig’s base, 7-methyl-1,5,7-
triazabicyclo[4.4.0]dec-5-ene , solid-support DBU and KOt-Bu (entries 1, 2, 6, 9 and 10 
in Table S1), the starting material was mostly consumed after 1 h, and the product band 
appeared on the TLC. For the bases DBU (solution phase) and 2,3,4,6,7,8-
hexahydropyrrolo[1,2-a]pyrimidine (entries 4 and 5 in Table S1), some starting material 
remained after 1 h, therefore we conclude that these two bases partially inhibited the 
ruthenium catalyst. For bases morpholine, 1,5,7-triazabicyclo[4.4.0]dec-5-ene and 
N,N,N',N'-tetramethylguanidine (entries 3, 7 and 8 in Table S1), no product band was 
observed and the starting material band remained on TLC after 1 h. Therefore, we 
conclude that these bases poisoned the catalyst.  
 
 





Appendix III. Introduction on pulsed gradient spin echo for DOSY experiment 
DOSY (Diffusion Ordered SpectroscopY) experiment is a NMR technique based 
on Pulsed Gradient Spin Echo (PGSE), a method for measuring translational diffusion 
rate of each component in a mixture of various aggregates [357]. PGSE NMR is 
commonly used to determine the size of oligomerization of biomolecules in aqueous 
solution [358]. 
In the magnetic spin vector model, the magnetization vector of the a oms 
precesses (Larmor precession) when they are applied a magnetic field. Because a 90° 
radiofrequency (RF) pulse is applied, the magnetization precession rotates from the z-axis 
to the x-y plane [359]. When a linear gradient field is applied at t1 long the z-axis of the 
NMR tube in DOSY experiment (G in a duration of δ, Figure S3a), the magnetic field 
strength of each point along the z-axis is different from the ot rs [359]; therefore the 
precession angles of the magnetization vector (Ω, Figure S3a) are shown as linear 
distribution along the z-axis (Figure S3b, S3c). After a period of time (∆), a second 
magnetic gradient field is applied to offset the previously generated precession (the 
precession is on a opposite direction due to the 180° RF pulse, see Figur S3a). If no 
translational diffusion occurs along the z-axis, the precession is completely cancelled out; 
therefore a maximum echo signal is obtained (Figure S3b). However, if the translation 
diffusion occurs, the spin precession cannot offset; therefore, the larger the diffusion, the 
poorer the spins are refocused and the smaller the echo signal is obtained [359].   
 
 
Figure S3. a) The Pulsed 
of the pulsed gradient (in duration 
Also shown are the magnetic
 
 
Gradient Spin Echo (PGSE) pulse sequence. G is the amplitude 

































































































































































































































 HPLC chromatography 
 
HPLC condition: A: 0.1 % TFA in H2O; B: 0.1 % TFA in acetronitrile. 1  20 min: 33 























































































HPLC condition: A: 0.1 % TFA in H2O; B: 0.1 % TFA in acetronitrile. 120 min: 33  







HPLC condition: 0.1 % TFA in H
63 % B.  
 




























HPLC condition: A: 100 mM TEAA buffer with 2% MeOH in water; B: acetonitrile; 0 






































































































































































1. Sintim HO, Al Smith J, Wang JX, Nakayama S, Yan L. Paradigm shift in discovering 
next-generation anti-infective agents: targeting quorum sensing, c-di-GMP signaling and 
biofilm formation in bacteria with small molecules. Fut. Med. Chem., 2(6), 1005-1035 
(2010). 
2. von Nussbaum F, Brands M, Hinzen B, Weigand S, Habich D. Antibacterial natural 
products in medicinal chemistry--exodus or revival? Angew. Chem. Int. Ed., 45(31), 
5072-5129 (2006). 
3. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century – a clinical super-
challenge. New Engl. J. Med., 360(5), 439-443 (2009). 
4. Lawrence C. Bubonic plague – extinct disease or present danger? Nurs. Mirror, 145(21), 
13-16 (1977). 
5. Hiramatsu K, Aritaka N, Hanaki Het al. Dissemination in Japanese hospitals of strains of 
Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet, 350(9092), 
1670-1673 (1997). 
6. Nicolau DP. Current challenges in the management of the infected patient. Curr. Opin. 
Infect. Dis., 24 Suppl 1, S1-10 (2011). 
7. van Rijen MM, Van Keulen PH, Kluytmans JA. Increase in a Dutch hospital of 
methicillin-resistant Staphylococcus aureus related to animal farming. Clin. Infect. Dis., 
46(2), 261-263 (2008). 
8. Levy SB. Antibacterial household products: cause for concern. Emerg. Infect. Dis., 7(3 
Suppl), 512-515 (2001). 
9. Henrichsen J. Typing of Streptococcus pneumoniae: past, present, and future. Am. J. 
Med., 107(1A), 50S-54S (1999). 
10. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature, 46, 
837 (1940). 
11. Miller CP, Bohnhoff M. Studies on the action of penicillin; development of penicilli 
resistance by gonococcus. Proc. Soc. Exp. Biol. Med., 60, 354-356 (1945). 
12. Plough HH. Penicillin resistance of Staphylococcus aureus and its clinical implications. 
Am. J. Clin. Pathol., 15, 446-451 (1945). 
13. Medeiros AA. Evolution and dissemination of beta-lactamases ccelerated by generations 
of beta-lactam antibiotics. Clin. Infect. Dis., 24 Suppl 1, S19-45 (1997). 
259 
 
14. Barber M. Methicillin-resistant staphylococci and hospital infection. Postgrad. Med. J., 
40, Suppl:178-181 (1964). 
15. Eriksen KR. Methicillin-resistance in Staphylococcus aureus apparently developed 
during treatment with methicillin. Acta Pathol. Microbiol. Scand., 61, 154-155 (1964). 
16. Finland M, Murray R, et al. Development of streptomycin resistance during treatment. J
Am. Med. Assoc., 132, 16-21 (1946). 
17. Klein M, Kimmelman LJ. Development of streptomycin resistance of the shigellae. J. 
Bacteriol., 51, 581 (1946). 
18. Colquhoun J, Weetch RS. Resistance to chloramphenicol developing duri treatment of 
typhoid fever. Lancet, 2(6639), 621-623 (1950). 
19. Rountree PM, Bulteau VG. Hospital infection with tetracycline-resistant haemolytic 
streptococci. Med. J. Aust., 2(11), 446-448 (1965). 
20. Turner GC. Tetracycline-resistant pneumococci in a general hospital. Lancet, 2(7321), 
1292-1295 (1963). 
21. Shlaes DM, Marino J, Jacobs MR. Infection caused by vancomycin-resistant 
Streptococcus sanguis II. Antimicrob. Agents. Chemother., 25(4), 527-528 (1984). 
22. Landy M, Larkum NW, Oswald EJ, Streightoff F. Increased synthesis of p-aminobenzoic 
acid associated with the development of sulfonamide resistance in Staphylococcus aureus. 
Science, 97(2516), 265-267 (1943). 
23. Clapper WE, Secrest RR, January HL. Clinical results and resistance of organisms 
remaining after treatment with erythromycin. Antibiot. Annu., 616-622 (1956). 
24. Galizzi A, Cacco G, Siccardi AG, Mazza G. Mode of action of p lymyxin B: 
physiological studies with Bacillus subtilis-resistant mutant. Antimicrob. Agents. 
Chemother., 8(3), 366-369 (1975). 
25. Raviglione MC, Boyle JF, Mariuz P, Pablos-Mendez A, Cortes H, Merlo A. 
Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care 
hospital. Antimicrob. Agents. Chemother., 34(11), 2050-2054 (1990). 
26. Tebas P, Martinez Ruiz R, Roman F et al. Early resistance to rifampin and ciprofloxacin 
in the treatment of right-sided Staphylococcus aureus endocarditis. J. Infect. Dis., 163(1), 
204-205 (1991). 
27. Ayliffe GA. Cephalosporinase and penicillinase activity of Gram-negative bacteria. J. 
Gen. Microbiol., 40(1), 119-126 (1965). 
28. Ezekiel DH, Hutchins JE. Mutations affecting RNA polymeras associated with 
rifampicin resistance in Escherichia coli. Nature, 220(5164), 276-277 (1968). 
260 
 
29. Lukas W. Analytical study of the treatment of 18 cases of chronic open pulmonary 
tuberculosis with secondary resistance to rifampicin. Respiration, 28, Suppl:70-83 (1971). 
30. Kohn J, Evans AJ. Group A streptococci resistant to clindamycin. Br. Med. J., 2(5706), 
423 (1970). 
31. Borges JS, Schleider M, Roberts RB. In vivo development of resistance to clindamycin 
by Staphylococcus aureus. Postgrad. Med. J., 58(1), 153-154 (1975). 
32. Sze EH, Osborne NG, Adelson MD, Granato P. Emergence of imipene-r sistant 
Pseudomonas aeruginosa during treatment of intra-abdominal infection in a patient with 
ovarian carcinoma. J. Natl. Med. Assoc., 80(10), 1133-1135 (1988). 
33. Krcmery V, Antal M, Menkyna R, Knothe H, Schafer V. Differential resistance of 
hospital Pseudomonas aeruginosa to ceftazidime, imipenem or aztreonam. J. Chemother., 
1(4 Suppl), 364-365 (1989). 
34. Schmitz FJ, Sadurski R, Stattfeld A, Kray A, Verhoef J, Fluit AC. Cross-resistance 
analyses and molecular typing of Staphylococcus aureus and Streptococcus spp. isolates 
resistant to quinupristin/dalfopristin. J Antimicrob. Chemother., 44(6), 847-849 (1999). 
35. Soltani M, Beighton D, Philpott-Howard J, Woodford N. Mechanisms of resistance to 
quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat, 
and hospital patients in Western Europe. Antimicrob. Agents Chemother., 44(2), 433-436 
(2000). 
36. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of 
Staphylococcus aureus. Lancet, 358(9277), 207-208 (2001). 
37. Richter E, Rusch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of 
Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 51(4), 1534-1536 (2007). 
38. Lewis JS, 2nd, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of 
daptomycin resistance inEnterococcus faecium during daptomycin therapy. Antimicrob. 
Agents Chemother., 49(4), 1664-1665 (2005). 
39. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-
lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother., 
39(6), 1211-1233 (1995). 
40. Fisher JF, Meroueh SO, Mobashery S. Bacterial resistance to b ta-lactam antibiotics: 
compelling opportunism, compelling opportunity. Chem. Rev., 105(2), 395-424 (2005). 
41. Finlay J, Miller L, Poupard JA. A review of the antimicrobial activity of clavulanate. J. 
Antimicrob. Chemother., 52(1), 18-23 (2003). 
261 
 
42. Schoonover LL, Occhipinti DJ, Rodvold KA, Danziger LH. Piperacillin/tazobactam: a 
new beta-lactam/beta-lactamase inhibitor combination. Ann. Pharmacother., 29(5), 501-
514 (1995). 
43. Benson JM, Nahata MC. Sulbactam/ampicillin, a new beta-lactamse inhibitor/beta-
lactam antibiotic combination. Drug Intell. Clin. Pharm., 22(7-8), 534-541 (1988). 
44. Imtiaz U, Billings EM, Knox JR, Mobashery S. A structure-based analysis of the 
inhibition of class A beta-lactamases by sulbactam. Biochemistry, 33(19), 5728-5738 
(1994). 
45. Henquell C, Sirot D, Chanal C et al. Frequency of inhibitor-resistant TEM beta-
lactamases in Escherichia coli isolates from urinary tract infections in France. J. 
Antimicrob. Chemother., 34(5), 707-714 (1994). 
46. Chaibi EB, Sirot D, Paul G, Labia R. Inhibitor-resistant TEM beta-lactamases: 
phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother., 43(4), 
447-458 (1999). 
47. Le Goffic F, Capmau ML, Tangy F, Baillarge M. Mechanism of action of 
aminoglycoside antibiotics. Binding studies of tobramycin and its 6'-N-acetyl derivative 
to the bacterial ribosome and its subunits. Eur. J. Biochem., 102(1), 73-81 (1979). 
48. Borovinskaya MA, Pai RD, Zhang Wet al. Structural basis for aminoglycoside inhibition 
of bacterial ribosome recycling. Nat. Struct. Mol. Biol., 14(8), 727-732 (2007). 
49. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside 
resistance genes and familial relationships of the aminoglycoside-modifying enzymes. 
Microbiol. Rev., 57(1), 138-163 (1993). 
50. Lai CJ, Weisblum B, Fahnestock SR, Nomura M. Alteration of 23 S ribosomal RNA and 
erythromycin-induced resistance to lincomycin and spiramycin in Staphylococcus aureus. 
J. Mol. Biol., 74(1), 67-72 (1973). 
51. Morales G, Picazo JJ, Baos E et al. Resistance to linezolid is mediated by the cfr gene in 
the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. 
Dis., 50(6), 821-825 (2010). 
52. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K. 
Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-
resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. 
Chemother., 42(2), 199-209 (1998). 
262 
 
53. Allen NE, Hobbs JN, Jr., Richardson JM, Riggin RM. Biosynthesis of m dified 
peptidoglycan precursors by vancomycin-resistant Enterococcus faecium. FEMS 
Microbiol. Lett., 77(1-3), 109-115 (1992). 
54. Billot-Klein D, Gutmann L, Sable S, Guittet E, van Heijenoort J. Modification of 
peptidoglycan precursors is a common feature of the low-level vancomycin-resistant 
VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species 
Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and 
Enterococcus gallinarum. J. Bacteriol., 176(8), 2398-2405 (1994). 
55. Park IS, Walsh CT. D-Alanyl-D-lactate and D-alanyl-D-alanine synthesis by D-alanyl-D-
alanine ligase from vancomycin-resistant Leuconostoc mesenteroides. Effects of a 
phenylalanine 261 to tyrosine mutation. J. Biol. Chem., 272(14), 9210-9214 (1997). 
56. Kuzin AP, Sun T, Jorczak-Baillass J, Healy VL, Walsh CT, Knox JR. Enzymes of 
vancomycin resistance: the structure of D-alanine-D-lactate ligase of naturally resistant 
Leuconostoc mesenteroides. Structure, 8(5), 463-470 (2000). 
57. Ma D, Cook DN, Alberti M, Pon NG, Nikaido H, Hearst JE. Genes acrA and acrB 
encode a stress-induced efflux system of Escherichia coli. Mol. Microbiol., 16(1), 45-55 
(1995). 
58. Husain F, Nikaido H. Substrate path in the AcrB multidrug efflux pump of Escherichia 
coli. Mol. Microbiol., 78(2), 320-330 (2010). 
59. Li XZ, Nikaido H, Poole K. Role of mexA-mexB-oprM in antibiotic efflux in 
Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 39(9), 1948-1953 (1995). 
60. Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-
resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system 
MexA-MexB-OprM. Antimicrob. Agents Chemother., 43(2), 287-291 (1999). 
61. Neyfakh AA, Borsch CM, Kaatz GW. Fluoroquinolone resistance protein NorA of 
Staphylococcus aureus i  a multidrug efflux transporter. Antimicrob. Agents Chemother., 
37(1), 128-129 (1993). 
62. Mallea M, Chevalier J, Eyraud A, Pages JM. Inhibitors of antibiotic efflux pump in 
resistant Enterobacter aerogenes trains. Biochem. Biophys. Res. Commun., 293(5), 
1370-1373 (2002). 
63. Shi WF, Jiang JP, Xu N, Huang ZM, Wang YY. Inhibitory effects of reserpine and 
carbonyl cyanide m-chlorophenylhydrazone on fluoroquinolone resistance of 
Acinetobacter baumannii. Chin. Med. J., 118(4), 340-343 (2005). 
263 
 
64. Saenz Y, Ruiz J, Zarazaga M, Teixido M, Torres C, Vila J. Effect of the efflux pump 
inhibitor Phe-Arg-beta-naphthylamide on the MIC values of the quinolones, tetracycline 
and chloramphenicol, in Escherichia coli isolates of different origin. J. Antimicrob. 
Chemother., 53(3), 544-545 (2004). 
65. Coban AY, Tanriverdi Cayci Y, Erturan Z, Durupinar B. Effects of efflux pump 
inhibitors phenyl-arginine-beta-naphthylamide and 1-(1-naphthylmethyl)-piperazine on 
the antimicrobial susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis 
patients. J. Chemother., 21(5), 592-594 (2009). 
66. Markham PN. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus 
pneumoniae by the multidrug efflux inhibitor reserpine. Antimicrob. Agents Chemother., 
43(4), 988-989 (1999). 
67. Schmitz FJ, Fluit AC, Luckefahr M et al. The effect of reserpine, an inhibitor of 
multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and 
moxifloxacin against clinical isolates of Staphylococcus aureus. J. Antimicrob. 
Chemother., 42(6), 807-810 (1998). 
68. Mullin S, Mani N, Grossman TH. Inhibition of antibiotic efflux in bacteria by the novel 
multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). Antimicrob. 
Agents Chemother., 48(11), 4171-4176 (2004). 
69. Debono M, Abbott BJ, Molloy RM et al. Enzymatic and chemical modifications of 
lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). 
J. Antibiot., 41(8), 1093-1105 (1988). 
70. Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J. 
Antimicrob. Chemother., 46(4), 523-526 (2000). 
71. Brickner SJ, Hutchinson DK, Barbachyn MR et al. Synthesis and antibacterial activity of 
U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential 
treatment of multidrug-resistant gram-positive bacterial infections. J. Med. Chem., 39(3), 
673-679 (1996). 
72. Barbachyn MR, Ford CW. Oxazolidinone structure-activity relationships leading to 
linezolid. Angew. Chem. Int. Ed., 42(18), 2010-2023 (2003). 
73. Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23 S rRNA 
identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal 
peptidyl transferase center. J. Mol. Biol., 294(1), 93-101 (1999). 
74. Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linezolid-resistant Enterococcus 
faecium isolated from a patient without prior exposure to an oxazolidinone: report from 
264 
 
the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis., 42(2), 
137-139 (2002). 
75. Jung D, Rozek A, Okon M, Hancock RE. Structural transitions as determinants of the 
action of the calcium-dependent antibiotic daptomycin. Chem. Biol., 11(7), 949-957 
(2004). 
76. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstei RA. Development of 
Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. 
Microbiol., 43(10), 5285-5287 (2005). 
77. Lee do K, Kim Y, Park KS, Yang JW, Kim K, Ha NJ. Antimicrobial activity of 
mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against 
vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005). 
J. Biochem. Mol. Biol., 40(6), 881-887 (2007). 
78. Wynn RL. FDA new drug approvals in 2004. Gen. Dent., 53(4), 246-248 (2005). 
79. Wynn RL. FDA new drug approvals in 2005. Gen. Dent., 54(4), 230-233 (2006). 
80. Wynn RL. FDA new drug approvals in 2006. Gen. Dent., 55(4), 275-279 (2007). 
81. Wynn RL. FDA new drug approvals in 2007. Gen. Dent., 56(6), 506-510 (2008). 
82. Wynn RL. FDA new drug approvals in 2008. Gen. Dent., 57(4), 300-304 (2009). 
83. Kaitin KI, Dimasi JA. Pharmaceutical innovation in the 21st century: new drug approvals 
in the first decade, 2000-2009. Clin. Pharmacol. Ther.,  (2010). 
84. Wynn RL. FDA new drug approvals in 2009. Gen. Dent., 58(4), 280-284 (2010). 
85. Champney WS, Rodgers WK. Retapamulin inhibition of translation and 50S ribosomal 
subunit formation in Staphylococcus aureus cells. Antimicrob. Agents Chemother., 51(9), 
3385-3387 (2007). 
86. Yan K, Madden L, Choudhry AE, Voigt CS, Copeland RA, Gontarek RR. Biochemi al 
characterization of the interactions of the novel pleuromutilin derivative retapamulin with 
bacterial ribosomes. Antimicrob. Agents Chemother., 50(11), 3875-3881 (2006). 
87. Campbell JW, Cronan JE, Jr. Bacterial fatty acid biosynthesis: targets for antibacterial 
drug discovery. Annu. Rev. Microbiol., 55, 305-332 (2001). 
88. Heath RJ, White SW, Rock CO. Lipid biosynthesis as a target for antibacterial agents. 
Prog. Lipid Res., 40, 467 (2001). 
89. Rock CO, Heath RJ. Fatty acid biosynthesis as a target for novel antibacterials. Curr. 
Opin. Investig. Drugs, 5, 146 (2004). 
90. Wright HT, Reynold KA. Antibacterial targets in fatty acid biosynthesis. Curr. Opin. 
Microbiol., 10, 447 (2007). 
265 
 
91. Zhang YM, White SW, Rock CO. Inhibiting bacterial fatty acid synthesis. J. Biol. Chem., 
281(26), 17541-17544 (2006). 
92. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. 
Science, 175(23), 720-731 (1972). 
93. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem., 71, 635-
700 (2002). 
94. The Global Plan to Stop TB, 2011-2015; World Health Organization (Geneva, 
Switzerland, 2010). 
95. Mediterranean E. The Global Tuberculosis Epidemic; Nov. 2010 - Fact Sheet; No. 7883-
02 (Kaiser Family Foundation, 2010). 
96. Schaefer AL, Val DL, Hanzelka BL, John E. Cronan J, Greenberg EP. Generation of cell-
to-cell signals in quorum sensing: Acyl homoserine lactone synthase activity of a purified 
Vibrio fischeri LuxI protein. Proc. Natl. Acad. Sci. USA, 93, 9505 (1996). 
97. Raetz CRH, Garrett TA, Reynolds CM et al. Kdo2-Lipid A of Escherichia coli, a defined 
endotoxin that activates macrophages via TLR-4 J. Lipid Res., 47, 1097 (2006). 
98. Pommerville JC. Alcamo's Fundamentals of Microbiology (Jones & Bartlett Learning, 
2010). 
99. Raetz CRH, Reynolds CM, Trent MS, Bishop RE. Lipid A modification systems in 
Gram-negative bacteria. Annu. Rev. Biochem., 76, 295 (2005). 
100. Daffé M, Reyrat JM. The mycobacterial cell envelope (ASM Press, 2008). 
101. Schweizer E, Hofmann J. Microbial type I fatty acid synthases (FAS): major players in a 
network of cellular FAS systems. Microbiol. Mol. Biol. Rev., 68(3), 501-517 (2004). 
102. Witkowski A, Ghosal A, Joshi AK, Witkowska HE, Asturias FJ, Smith S. Head-to-head 
coiled arrangement of the subunits of the animal fatty acid synthase. Chem. Biol., 11(12), 
1667-1676 (2004). 
103. Asturias FJ, Chadick JZ, Cheung IKet al. Structure and molecular organization of 
mammalian fatty acid synthase. Nat. Struct. Mol. Biol., 12(3), 225-232 (2005). 
104. Lomakin IB, Xiong Y, Steitz TA. The crystal structure of yeast fatty acid synthase, a 
cellular machine with eight active sites working together. C ll, 129, 319 (2007). 
105. Smith S, Witkowski A, Joshi AK. Structural and functional organization of the animal 
fatty acid synthase. Prog. Lipid Res., 42(4), 289-317 (2003). 
106. Lu YJ, Zhang YM, Rock CO. Product diversity and regulation of type II fatty acid 
synthases. Biochem. Cell Biol., 82(1), 145-155 (2004). 
266 
 
107. Kaneda T. Fatty acids of the genus Bacillus: an example of branched-chain preference. 
Bacteriol. Rev., 41(2), 391-418 (1977). 
108. Kuhajda FP, Jenner K, Wood FD et al. Fatty acid synthesis: a potential selective target 
for antineoplastic therapy. Proc. Natl. Acad. Sci. USA, 91(14), 6379-6383 (1994). 
109. Byers DM, Meighen EA. Inhibition of Vibrio harveyi bioluminescence by cerulenin: in 
vivo evidence for covalent modification of the reductase enzyme involved in aldehyde 
synthesis. J. Bacteriol., 171(7), 3866-3871 (1989). 
110. Wall L, Meighen E. Covalent reaction of cerulenin at the active site of acyl-CoA 
reductase of Photobacterium phosphoreum. Biochem. Cell. Biol., 67(2-3), 163-167 
(1989). 
111. Haapalainen AM, Merilainen G, Wierenga RK. The thiolase superfamily: condensing 
enzymes with diverse reaction specificities. Trends Biochem. Sci., 31(1), 64-71 (2006). 
112. Takayama K, Wang C, Besra GS. Pathway to synthesis and processing of mycolic acids 
in Mycobacterium tuberculosis. Clin. Microbiol. Rev., 18(1), 81-101 (2005). 
113. Cronan JE, Waldrop GL. Multi-subunit acetyl-CoA carboxylases. Prog. Lipid Res., 41, 
407 (2002). 
114. Lin T-W, Melgar MM, Kurth D et al. Structure-based inhibitor design of AccD5, an 
essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium 
tuberculosis. Proc. Natl. Acad. Sci. USA, 103, 3072 (2006). 
115. Joseph-McCarthy D, Parris K, Huang A et al. Use of Structure-based drug design 
approaches to obtain novel anthranilic acid acyl carrier protein synthase inhibitors. J. 
Med. Chem., 48, 7960 (2005). 
116. White SW, Zheng J, Zhang Y-M, Rock CO. The structural biology of the type II fatty 
acid biosynthesis. Annu. Rev. Biochem., 74, 791-831 (2005). 
117. Qiu X, Janson CA, Konstantinidis AK et al. Crystal structure of beta-ketoacyl-acyl 
carrier protein synthase III. A key condensing enzyme in bacterial fatty acid biosynthesis. 
J. Biol. Chem., 274(51), 36465-36471 (1999). 
118. Price AC, Rock CO, White SW. The 1.3-Angstrom-resolution crystal structure of beta-
ketoacyl-acyl carrier protein synthase II from Streptococcus pneumoniae. J. Bacteriol., 
185(14), 4136-4143 (2003). 
119. Wang J, Kodali S, Lee SH et al. Discovery of platencin, a dual FabF and FabH inhibitor 
with in vivo antibiotic properties. Proc. Natl. Acad. Sci. USA, 104(18), 7612-7616 (2007). 
120. Wang J, Soisson SM, Young K et al. Platensimycin is a selective FabF inhibitor with 
potent antibiotic properties. Nature, 441(7091), 358-361 (2006). 
267 
 
121. Machutta CA, Bommineni GR, Luckner SR et al. Slow onset inhibition of bacterial beta-
ketoacyl-acyl carrier protein synthases by thiolactomycin. J. Biol. Chem., 285(9), 6161-
6169 (2009). 
122. Patel MP, Liu WS, West J, Tew D, Meek TD, Thrall SH. Kinetic and chemical 
mechanisms of the fabG-encoded Streptococcus pneumoniae beta-ketoacyl-ACP 
reductase. Biochemistry, 44(50), 16753-16765 (2005). 
123. Price AC, Zhang YM, Rock CO, White SW. Cofactor-induced conformational 
rearrangements establish a catalytically competent active si e and a proton relay conduit 
in FabG. Structure, 12(3), 417-428 (2004). 
124. Silva RG, de Carvalho LP, Blanchard JS, Santos DS, Basso LA. Mycobacterium 
tuberculosis beta-ketoacyl-acyl carrier protein (ACP) reductase: kinetic and chemical 
mechanisms. Biochemistry, 45(43), 13064-13073 (2006). 
125. Wang H, Cronan JE. Functional replacement of the FabA and FabB proteins f 
Escherichia coli fatty acid synthesis by Enterococcus faecalis FabZ and FabF 
homologues. J. Biol. Chem., 279(33), 34489 (2004). 
126. Lu H, Tonge PJ. Mechanism and inhibition of the FabV enoyl-ACP reductase from 
Burkholderia mallei. Biochemistry, 49(6), 1281-1289 (2010). 
127. Heath RJ, Rock CO. A triclosan-resistant bacterial enzyme. Nature, 406, 145 (2000). 
128. Rozwarski DA, Vilcheze C, Sugantino M, Bittman R, Sacchettini JC. Crystal structure of 
the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and 
a C16 fatty acyl substrate. J. Biol. Chem., 274(22), 15582-15589 (1999). 
129. Parikh S, Moynihan DP, Xiao G, Tonge PJ. Roles of tyrosine 158 and lysi e 165 in the 
catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. 
Biochemistry, 38(41), 13623-13634 (1999). 
130. Rafi S, Novichenok P, Kolappan S et al. Structure of acyl carrier protein bound to FabI, 
the FASII enoyl reductase from Escherichia coli. J. Biol. Chem., 281(51), 39285-39293 
(2006). 
131. Lu Y-J, Zhang Y-M, Grimes KD, Qi J, Lee RE, Rock CO. Acyl-phosates initiate 
membrane phospholipid synthesis in Gram-positive pathogens. Molecular Cell, 23, 765 
(2006). 
132. Schujman GE, Mendoza Dd. Solving an old puzzle in phospholipid biosyntheis. Nat. 
Chem. Biol., 2(11), 573 (2006). 
133. Lambalot RH, Walsh CT. Cloning, overproduction, and characterization of the 
Escherichia coli holo-acyl carrier protein synthase. J. Biol. Chem., 270(42), 24658 (1995). 
268 
 
134. Chu M, Mierzwa R, Xu L et al. Structure elucidation of Sch 538415, a novel acyl carrier 
protein synthase inhibitor from a microorganism. Bioorg. Med. Chem. Lett., 13, 3827 
(2003). 
135. Gilbert AM, Kirisits M, Toy P et al. Anthranilate 4H-oxazol-5-ones: novel small 
molecule antibacterial acyl carrier protein synthase (AcpS) inhibitors. Bioorg. Med. 
Chem. Lett., 14, 37 (2004). 
136. Gronwald JW. Biochem. Soc. Trans., 22, 616 (1994). 
137. Zhang H, Tweel B, Tong L. Molecular basis for the inhibition of the carboxyltransferase 
domain of acetyl-coenzyme-A carboxylase by haloxyfop and diclofop. Proc. Natl. Acad. 
Sci. USA, 101(16), 5910 (2004). 
138. Fredenhagen A, Tamura SY, Kenny PTM, Komura H, Naya Y, Nakanishi K. Andrimid, a 
new peptide antibiotic produced by an intracellular bacterial symbiont isolated from a 
brown planthopper. J. Am. Chem. Soc., 109(14), 4409 (1987). 
139. Davies SG, Dixon DJ. Asymmetric syntheses of moiramide B and andrimid. J. Chem. 
Soc., Perkin Trans. 1, 2635 (1998). 
140. Freiberg C, Brunner NA, Schiffer G et al. Identification and characterization of the first 
class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J. 
Biol. Chem., 279(25), 26066 (2004). 
141. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu. Rev. Biochem., 64, 29 
(1995). 
142. Minnikin DE, Kremer L, Dover LG, Besra GS. The methyl-branched fortifications of 
Mycobacterium tuberculosis Chem. Biol., 9, 545 (2002). 
143. Lin T-W, Melgar MM, Kurth D et al. Structure-based inhibitor design of AccD5, an 
essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium 
tuberculosis. Proc. Natl. Acad. Sci. USA, 103, 3072 (2006). 
144. Lin T-W, Nguyen T, Kurth D et al. Structure-based inhibitor design of AccD5/AccD6, 
essential carboxyltransferases of Mycobacterium tuberculosis. FASEB J., 33, 839.834 
(2008). 
145. Kurth DG, Gago GM, Iglesia Adl et al. Accase 6 is the essential acetyl-CoA carboxylase 
involved in fatty acid and mycolic acid biosynthesis in mycobacteria. Microbiology, 155, 
2664 (2009). 
146. Liu W, Han C, Hua L, Chen K, Shen X, Jiang H. Characterization and inhibitor discovery 
of one novel malonyl-CoA: acyl carrier protein transacylase (MCAT) from Helicobacter 
pylori. FEBS Lett., 580(2), 697 (2006). 
269 
 
147. He X, Reynolds KA. Purification, characterization, and identifica on of novel inhibitors 
of the b-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus. 
Antimicrob. Agents Chemother., 46(5), 1310 (2002). 
148. He X, Reeve AM, Desai UR, Kellogg GE, Reynolds KA. 1,2-Dithiole-3-ones as potent 
inhibitors of the bacterial 3-ketoacyl acyl carrier protein sythase III (FabH). Antimicrob. 
Agents Chemother., 48(8), 3093 (2004). 
149. Lee JY, Jeong KW, Shin S, Lee JU, Kim Y. Antimicrobial natural p oducts as beta-
ketoacyl-acyl carrier protein synthase III inhibitors. Bioorg. Med. Chem., 17(15), 5408-
5413 (2009). 
150. Lee JY, Jeong KW, Lee JU, Kang DI, Kim Y. Novel E. coli beta-k toacyl-acyl carrier 
protein synthase III inhibitors as targeted antibiotics. Bioorg. Med. Chem., 17(4), 1506-
1513 (2009). 
151. Khandekar SS, Gentry DR, Aller GSV et al. Identification, substrate specificity, and 
inhibition of the Streptococcus pneumoniae b-ketoacyl-acyl carrier protein synthase III 
(FabH). J. Biol. Chem., 276(32), 30024 (2001). 
152. Nie Z, Perretta C, Lu J et al. Structure-based design, synthesis, and study of potent 
inhibitors of b-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. 
J. Med. Chem., 48, 1596 (2005). 
153. Young K, Jayasuriya H, Ondeyka JG et al. Discovery of FabH/FabF inhibitors from 
natural products. Antimicrob. Agents Chemother. , 50(2), 519 (2006). 
154. Matsumae A, Nomura S, Hata. T. Studies on cerulenin. IV. Biological characteristics of 
cerulenin. J. Antibiot. (Tokyo), 17, 1 (1964). 
155. Price AC, Choi K-H, Heath RJ, Li Z, White SW, Rock CO. Inhibition of b-ketoacyl-acyl 
carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. J. 
Biol. Chem., 276(9), 6551 (2001). 
156. Kodali S, Galgoci A, Young K et al. Determination of Selectivity and Efficacy of Fatty 
Acid Synthesis Inhibitors. J. Biol. Chem., 280, 1669 (2005). 
157. Oishi H, Noto T, Sasaki Het al. Thiolactomycin, a new antibiotic. I. Taxonomy of the 
producing organism, fermentation and biological properties. J. Antibiot. (Tokyo), 35, 391 
(1982). 
158. Noto T, Miyakawa S, Oishi H, Endo H, Okazaki. H. Thiolactomycin, a new antibiotic. III. 
In vitro antibacterial activity. J. Antibiot. (Tokyo), 35, 401 (1982). 
270 
 
159. Omura S, Iwai Y, Nakagawa Aet al. Thiotetromycin, a new antibiotic. Taxonomy, 
production, isolation, and physicochemical and biological properties. J. Antibiot. (Tokyo), 
36, 109 (1983). 
160. Zhang Y-M, Rock CO. Evaluation of epigallocatechin gallate and related plant 
polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid 
synthase. J. Biol. Chem., 279(30), 30994–31001 (2004). 
161. Kass LR. The antibacterial activity of 3-decynoyl-N-acetylcysteamine: inhibition in vivo 
of b-hydroxydecanoyl thioester dehydrase. J. Biol. Chem., 243(12), 3223-3228 (1968). 
162. Morisaki M, Bloch K. Inhibition of β-hydroxydecanoyl thioester dehydrase by some 
allenic acids and their thioesters. Bioorg. Chem., 1, 188-193 (1971). 
163. Sharma SK, Kapoor M, Ramya TNC et al. Identification, characterization, and inhibition 
of plasmodium falciparum beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ). J. 
Biol. Chem., 278(46), 45661–45671 (2003). 
164. Banerjee A, Dubnau E, Quemard A et al. ihA, a gene encoding a target for isoniazid and 
ethionamide in Mycobacterium tuberculosis. Science, 263, 227-230 (1994). 
165. Rosner JL. Susceptibilities of xyR regulon mutants of Escherichia coli and Salmonella 
typhimurium to isoniazid. Antimicrob. Agents Chemother., 37, 2251-2253 (1993). 
166. Rawat R, Whitty A, Tonge PJ. The isoniazid-NAD adduct is a low, tight-binding 
inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and 
drug resistance. Proc. Natl. Acad. Sci. USA, 100(24), 13881-13886 (2003). 
167. Baulard AR, Betts JC, Engohang-Ndong J et al. Activation of the pro-drug ethionamide 
is regulated in Mycobacteria. Proc. Natl. Acad. Sci. USA, 275(36), 28326-28331 (2000). 
168. Wang F, Langley R, Gulten Get al. Mechanism of thioamide drug action against 
tuberculosis and leprosy. J. Exp. Med., 204(1), 73-78 (2007). 
169. Heath RJ, Yu Y-T, Shapiro MA, Olson E, Rock CO. Broad-spectrum antimicrobial 
biocides target the FabI component of fatty acid synthesis. J. Biol. Chem., 273, 30316 
(1998). 
170. Sullivan TJ, Truglio JJ, Boyne ME et al. High affinity InhA inhibitors with activity 
against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol., 1(1), 43-
53 (2006). 
171. Baldock C, Boer G-Jd, Rafferty JB, Stuitje AR, Rice DW. Mechanism of action of 
diazaborines. Biochem. Pharm., 55, 1541-1549 (1998). 
271 
 
172. Davis MC, Franzblau SG, Martin AR. Synthesis and evaluation of benzodiazaborine 
compounds against M. tuberculosis H37Rv in vitro. Bioorg. Med. Chem. Lett., 8, 843-846 
(1998). 
173. Payne DJ, Miller WH, Berry V et al. Discovery of a novel and potent class of FabI-
directed antibacterial agents. Antimicrob. Agents Chemother., 46(10), 3118 (2002). 
174. Seefeld MA, Miller WH, Newlander KA et al. Indole naphthyridinones as inhibitors of 
bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem., 46, 1627 (2003). 
175. Moche M, Schneider G, Edwards P, Dehesh K, Lindqvist Y. Structure of the complex 
between the antibiotic cerulenin and Its target, b-ketoacyl-acyl carrier protein synthase. J. 
Biol. Chem., 274(10), 6031 (1999). 
176. Morisaki N, Funabashi H, Shimazawa R et al. Effect of side-chain structure on inhibition 
of yeast fatty-acid synthase by cerulenin analogues. Eur. J. Biochem., 211, 111 (1993). 
177. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and 
antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. USA, 97(7), 
3450 (2000). 
178. Schujman GE, Choi K-H, Altabe S, Rock CO, Mendoza Dd. Response of Bacillus 
subtilis to cerulenin and acquisition of resistance. J. Bacteriol., 183(10), 3032 (2001). 
179. Miyakawa S, Suzuki K, Noto T, Harada Y, Okazaki H. Thiolact mycin, a new antibitoic. 
IV. Biological properties and chemotherapeutic activity in mice. J. Antibiot. (Tokyo), 35, 
411 (1982). 
180. Vilcheze C, William R. Jacobs J. The mechanism of isoniazid killing: clarity through the 
scope of genetics. Annu. Rev. Microbiol., 61, 35-50 (2007). 
181. Mdluli K, Slayden RA, Zhu Y et al. Inhibition of a Mycobacterium tuberculosis -ketoacyl 
ACP synthase by isoniazid Science, 280, 1607-1610 (1998). 
182. Ghosh AK, Xi K. Total synthesis of (–)-platensimycin, a novel antibacteri l agent. J. Org. 
Chem., 74(3), 1163-1170 (2009). 
183. Argyrou A, Vetting MW, Aladegbami B, Blanchard JS. Mycobacterium tuberculosis 
dihydrofolate reductase is a target for isoniazid. Nat. Struct. Mol Biol.,13, 408-413 (2006). 
184. Rouse DA, Li Z, Bai G-H, Morris. SL. Characterization of the katG and inhA genes of 
isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents 
Chemother., 39(11), 2472–2477 (1995). 
185. Rozwarski DA, Grant GA, Barton DH, W. R. Jacobs J, Sacchettini JC. Modification of 




186. Baldock C, Rafferty JB, Sedelnikova SEet al. A mechanism of drug action revealed by 
structural studies of enoyl reductase. Science, 274, 2107-2110 (1996). 
187. Ward WHJ, Holdgate GA, Rowsell S et al. Kinetic and structural characteristics of the 
inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry, 38, 12514-
12525 (1999). 
188. DeBarber AE, Mdluli K, Bosman M, Bekker L-G, Clifton E.Barry I. Ethionamide 
activation and sensitivity in multidrugresistant Mycobacterium tuberculosis. Proc. Natl. 
Acad. Sci. USA, 97(17), 9677-9682 (2000). 
189. Lu H, Tonge PJ. Inhibitors of FabI, an enzyme drug target in the bact rial fatty acid 
biosynthesis pathway. Acc. Chem. Res., 41(1), 11-20 (2008). 
190. Roujeinikova A, Sedelnikova S, Boer G-Jd et al. Inhibitor binding studies on enoyl 
reductase reveal conformational changes related to substrate recognition. J. Biol. Chem., 
274, 30811-30817). 
191. Boer G-Jd, Pielage GJA, Nijkamp HJJ et al. Molecular genetic analysis of enoyl-acyl 
carrier protein reductase inhibition by diazoborine. Mol. Microbiol. , 31, 443-450 (1999). 
192. McMurry LM, Oethinger M, Levy SB. Overexpression of marA, soxS, or acrAB produces 
resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS 
Microbiol. Lett., 166, 305-309 (1998). 
193. Sivaraman S, Sullivan TJ, Johnson F et al. Inhibition of the bacterial enoyl reductase 
FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. 
J. Med. Chem., 47(3), 509-518 (2004). 
194. Altenbern RA. Cerulenin-inhibited cells of Staphylococcus aureus resume growth when 
supplemented with either a saturated or an unsaturated fatty acid. Antimicrob. Agents 
Chemother., 11, 574-576 (1977). 
195. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. Type II fatty acid 
synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature, 458, 83-
86 (2009). 
196. Stone G, Wood P, Dixon L, Keyhan M, Matin A. Tetracycline rapidly reaches all the 
constituent cells of uropathogenic Escherichia coli biofilms. Antimicrob. Agents 
Chemother., 46(8), 2458-2461 (2002). 
197. Jenal U. Cyclic di-guanosine-monophosphate comes of age: a novel secondary messenger 




198. Kulasakara H, Lee V, Brencic A et al. Analysis of Pseudomonas aeruginosa diguanylate 
cyclases and phosphodiesterases reveals a role for bis-(3'-5')-cyclic-GMP in virulence. 
Proc. Natl. Acad. Sci. USA, 103(8), 2839-2844 (2006). 
199. Ross P, Weinhouse H, Aloni Y et al. Regulation of cellulose synthesis in Acetobacter 
xylinum by cyclic diguanylic acid. Nature, 325(6101), 279-281 (1987). 
200. Hickman JW, Tifrea DF, Harwood CS. A chemosensory system that regulates biofilm 
formation through modulation of cyclic diguanylate levels. Proc. Natl. Acad. Sci. USA, 
102(40), 14422-14427 (2005). 
201. Chan C, Paul R, Samoray D et al. Structural basis of activity and allosteric control of 
diguanylate cyclase. Proc. Natl. Acad. Sci. USA, 101(49), 17084-17089 (2004). 
202. Galperin MY, Nikolskaya AN, Koonin EV. Novel domains of the prokaryotic two-
component signal transduction systems. FEMS Microbiol. Lett., 203(1), 11-21 (2001). 
203. Romling U, Gomelsky M, Galperin MY. C-di-GMP: the dawning of a novel bacterial 
signalling system. Mol. Microbiol., 57(3), 629-639 (2005). 
204. Amikam D, Benziman M. Cyclic diguanylic acid and cellulose synthesis in 
Agrobacterium tumefaciens. J Bacteriol., 171(12), 6649-6655 (1989). 
205. Mayer R, Ross P, Weinhouse H et al. Polypeptide composition of bacterial cyclic 
diguanylic acid-dependent cellulose synthase and the occurrence of immunologically 
crossreacting proteins in higher plants. Proc. Natl. Acad. Sci. USA, 88(12), 5472-5476 
(1991). 
206. Saxena IM, Brown RM, Jr. Identification of a second cellulose synthase gene (acsAII) in 
Acetobacter xylinum. J. Bacteriol., 177(18), 5276-5283 (1995). 
207. Weinhouse H, Sapir S, Amikam Det al. c-di-GMP-binding protein, a new factor 
regulating cellulose synthesis in Acetobacter xylinum. FEBS Lett., 416(2), 207-211 
(1997). 
208. Amikam D, Galperin MY. PilZ domain is part of the bacterial c-di-GMP binding protein. 
Bioinformatics, 22(1), 3-6 (2006). 
209. Alm RA, Bodero AJ, Free PD, Mattick JS. Identification of a novel gene, pilZ, essential 
for type 4 fimbrial biogenesis in Pseudomonas aeruginosa. J. Bacteriol., 178(1), 46-53 
(1996). 
210. Boehm A, Kaiser M, Li H et al. Second messenger-mediated adjustment of bacterial 
swimming velocity. Cell, 141(1), 107-116 (2010). 
274 
 
211. Pratt JT, Tamayo R, Tischler AD, Camilli A. PilZ domain proteins bind cyclic 
diguanylate and regulate diverse processes in Vibrio cholerae. J. Biol. Chem., 282(17), 
12860-12870 (2007). 
212. Sudarsan N, Lee ER, Weinberg Z et al. Riboswitches in eubacteria sense the second 
messenger cyclic di-GMP. Science, 321(5887), 411-413 (2008). 
213. Hengge R. Principles of c-di-GMP signaling in bacteria. Nat Rev. Microbiol., 7(4), 263-
273 (2009). 
214. Hecht GB, Newton A. Identification of a novel response regulator required for the 
swarmer-to-stalked-cell transition in Caulobacter crescentus. J. Bacteriol., 177(21), 6223-
6229 (1995). 
215. Duerig A, Abel S, Folcher M et al. Second messenger-mediated spatiotemporal control of 
protein degradation regulates bacterial cell cycle progression. Genes Dev., 23(1), 93-104 
(2009). 
216. Levi A, Folcher M, Jenal U, Shuman HA. Cyclic diguanylate signal ng proteins control 
intracellular growth of Legionella pneumophila. mBio, 2(1), doi:10.1128/mBio.00316-
00310 (2011). 
217. Lee ER, Baker JL, Weinberg Z, Sudarsan N, Breaker RR. An allosteric self-splicing 
ribozyme triggered by a bacterial second messenger. Science, 329(5993), 845-848 (2010). 
218. Pei JM, Grishin NV. GGDEF domain is homologous to adenylyl cyclase. Proteins, 42(2), 
210-216 (2001). 
219. Liu Y, Ruoho AE, Rao VD, Hurley JH. Catalytic mechanism of the ad nylyl and 
guanylyl cyclases: modeling and mutational analysis. Proc. Natl. Acad. Sci. USA, 94(25), 
13414-13419 (1997). 
220. Rao F, Yang Y, Qi Y, Liang ZX. Catalytic mechanism of cycli d -GMP-specific 
phosphodiesterase: a study of the EAL domain-containing RocR from Pseudomonas 
aeruginosa. J. Bacteriol., 190(10), 3622-3631 (2008). 
221. Merighi M, Lee VT, Hyodo M, Hayakawa Y, Lory S. The second messenger bis-(3'-5')-
cyclic-GMP and its PilZ domain-containing receptor Alg44 are required for alginate 
biosynthesis in Pseudomonas aeruginosa. Mol. Microbiol., 65(4), 876-895 (2007). 
222. Christen M, Christen B, Allan MG et al. DgrA is a member of a new family of cyclic 
diguanosine monophosphate receptors and controls flagellar motor function in 
Caulobacter crescentus. Proc. Natl. Acad. Sci. USA, 104(10), 4112-4117 (2007). 
275 
 
223. Ryjenkov DA, Simm R, Romling U, Gomelsky M. The PilZ domain is a receptor for the 
second messenger c-di-GMP: the PilZ domain protein YcgR controls motility in 
enterobacteria. J. Biol. Chem., 281(41), 30310-30314 (2006). 
224. Hickman JW, Harwood CS. Identification of FleQ from Pseudomonas aeruginosa as a c-
di-GMP-responsive transcription factor. Mol. Microbiol., 69(2), 376-389 (2008). 
225. Lee VT, Matewish JM, Kessler JL, Hyodo M, Hayakawa Y, Lory S. A cyclic-di-GMP 
receptor required for bacterial exopolysaccharide production. Mol Microbiol., 65(6), 
1474-1484 (2007). 
226. Zhang Z, Gaffney BL, Jones RA. c-di-GMP displays a monovalent mtal ion-dependent 
polymorphism. J. Am. Chem. Soc., 126(51), 16700-16701 (2004). 
227. Zhang Z, Kim S, Gaffney BL, Jones RA. Polymorphism of the signaling molecule c-di-
GMP. J. Am. Chem. Soc., 128(21), 7015-7024 (2006). 
228. Navarro MV, De N, Bae N, Wang Q, Sondermann H. Structural analysis of the GGDEF-
EAL domain-containing c-di-GMP receptor FimX. Structure, 17(8), 1104-1116 (2009). 
229. Ko J, Ryu KS, Kim H et al. Structure of PP4397 reveals the molecular basis for different 
c-di-GMP binding modes by Pilz domain proteins. J. Mol. Biol., 398(1), 97-110 (2010). 
230. Nakayama S, Kelsey I, Wang J, Sintim HO. Chem. Commun., ASAP (2011). 
231. Singh SB, Jayasuriya H, Herath KBet al. Isolation, enzyme-bound structure, and activity 
of platensimycin A1 from Streptomyces platensis. Tetrahedron Lett., 50(37), 5182-5185 
(2009). 
232. Singh SB, Ondeyka JG, Herath KB et al. Isolation, enzyme-bound structure and 
antibacterial activity of platencin A1 from Streptomyces platensis. Bioorg. Med. Chem. 
Lett., 19(16), 4756-4759 (2009). 
233. Singh SB, Jayasuriya H, Ondeyka JG et al. Isolation, structure, and absolute 
stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an 
antisense differential sensitivity strategy. J. Am. Chem. Soc., 128(36), 11916-11920 
(2006). 
234. Nicolaou KC, Li A, Edmonds DJ. Total synthesis of platensimycin. Angew. Chem. Int. 
Ed., 45(42), 7086-7090 (2006). 
235. Ghosh AK, Xi K. Enantioselective synthesis of (–)-platensimycin oxatetracyclic core by 
using an intramolecular Diels-Alder reaction. Org. Lett., 9(20), 4013-4016 (2007). 
236. Lalic G, Corey EJ. An effective enantioselective route to the platensimycin core. Org. 
Lett., 9(23), 4921-4923 (2007). 
276 
 
237. Li PF, Payette JN, Yamamoto H. Enantioselective route to platensimycin: An 
intramolecular robinson annulation approach. J. Am. Chem. Soc., 129(31), 9534-9535 
(2007). 
238. Nicolaou KC, Edmonds DJ, Li A, Tria GS. Asymmetric total syntheses of platensimycin. 
Angew. Chem. Int. Ed., 46(21), 3942-3945 (2007). 
239. Nicolaou KC, Tang YF, Wang JH. Formal synthesis of (+/–)-platensimycin. Chemical 
Communications, (19), 1922-1923 (2007). 
240. Tiefenbacher K, Mulzer J. Protecting-group-free formal synthesis of platensimycin. 
Angew. Chem. Int. Ed., 46(42), 8074-8075 (2007). 
241. Zou YF, Chen CH, Taylor CD, Foxman BM, Snider BB. Formal synthesis of (+/–)-
platensimycin. Org. Lett., 9(9), 1825-1828 (2007). 
242. Kim CH, Jang KP, Choi SY, Chung YK, Lee E. A carbonyl ylide cycloaddition approach 
to platensimycin. Angew. Chem. Int. Ed., 47(21), 4009-4011 (2008). 
243. Nicolaou KC, Pappo D, Tsang KY, Gibe R, Chen DYK. A chiral pool based synthesis of 
platensimycin. Angew. Chem. Int. Ed., 47(5), 944-946 (2008). 
244. McGrath NA, Bartlett ES, Sittihan S, Njardarson JT. A concise ring-expansion route to 
the compact core of platensimycin. Angew. Chem. Int. Ed., 48(45), 8543-8546 (2009). 
245. Nicolaou KC, Li A, Ellery SP, Edmonds DJ. Rhodium-catalyzed asymmetric enyne 
cycloisomerization of terminal alkynes and formal total synthesis of (–)-platensimycin. 
Angew. Chem. Int. Ed., 48(34), 6293-6295 (2009). 
246. Yun SY, Zheng JC, Lee D. Stereoelectronic effect for the selectivity in C-H Insertion of 
alkylidene carbenes and its application to the synthesis of platensimycin. J. Am. Chem. 
Soc., 131(24), 8413-8414 (2009). 
247. Austin KAB, Banwell MG, Willis AC. A formal total synthesis of platencin. Org. Lett., 
10(20), 4465-4468 (2008). 
248. Hayashida J, Rawal VH. Total synthesis of (+/–)-platencin. Angew. Chem. Int. Ed., 
47(23), 4373-4376 (2008). 
249. Nicolaou KC, Toh QY, Chen DYK. An expedient asymmetric synthesis of platencin. J. 
Am. Chem. Soc., 130(34), 11292-11293 (2008). 
250. Nicolaou KC, Tria GS, Edmonds DJ. Total synthesis of platencin. Angew. Chem. Int. Ed., 
47(9), 1780-1783 (2008). 
251. Tiefenbacher K, Mulzer J. Short formal synthesis of (–)-platencin. Angew. Chem. Int. Ed., 
47(33), 6199-6200 (2008). 
277 
 
252. Waalboer DCJ, Schaapman MC, van Delft FL, Rutjes FPJT. High-pressure entry into 
platencin. Angew. Chem. Int. Ed., 47(35), 6576-6578 (2008). 
253. Yun SY, Zheng JC, Lee D. Concise synthesis of the tricyclic core of platencin. Angew. 
Chem. Int. Ed., 47(33), 6201-6203 (2008). 
254. Ghosh AK, Xi K. A symmetry-based concise formal synthesis of platencin, a novel lead 
against "superbugs". Angew. Chem. Int. Ed., 48(29), 5372-5375 (2009). 
255. Nicolaou KC, Tria GS, Edmonds DJ, Kar M. Total syntheses of (+/–)-platencin and (–)-
platencin. J. Am. Chem. Soc., 131(43), 15909-15917 (2009). 
256. Tiefenbacher K, Mulzer J. A Nine-Step Total Synthesis of (–)-Platencin. J. Org. Chem., 
74(8), 2937-2941 (2009). 
257. Varseev GN, Maier ME. Formal Total Synthesis of Platencin. Angew. Chem. Int. Ed., 
48(20), 3685-3688 (2009). 
258. Smanski MJ, Peterson RM, Rajski SR, Shen B. Engineered Str ptomyces platensis 
Strains That Overproduce Antibiotics Platensimycin and Platencin. Antimicrob. Agents 
Chemother., 53(4), 1299-1304 (2009). 
259. Yu ZG, Smanski MJ, Peterson RM et al. Engineering of Streptomyces platensis MA7339 
for Overproduction of Platencin and Congeners. Org. Lett., 12(8), 1744-1747 (2010). 
260. Heretsch P, Giannis A. An efficient entry to amino-substituted resorcylic acid derivatives 
for the synthesis of platensimycin and analogues. Synthesis, (17), 2614-2616 (2007). 
261. Kaliappan KP, Ravikumar V. An expedient enantioselective strategy for the 
oxatetracyclic core of platensimycin. Org. Lett., 9(12), 2417-2419 (2007). 
262. Nicolaou KC, Lister T, Denton RM, Montero A, Edmonds DJ. Adamantaplatensimycin: a 
bioactive analogue of platensimycin. Angew. Chem. Int. Ed., 46(25), 4712-4714 (2007). 
263. Nicolaou KC, Tang Y, Wang J, Stepan AF, Li A, Montero A. Total synthesis and 
antibacterial properties of carbaplatensimycin. J. Am. Chem. Soc., 129(48), 14850-14851 
(2007). 
264. Nicolaou KC, Stepan AF, Lister T et al. Design, synthesis, and biological evaluation of 
platensimycin analogues with varying degrees of molecular complexity. J. Am. Chem. 
Soc., 130(39), 13110-13119 (2008). 
265. Yeung YY, Corey EJ. A simple, efficient, and enantiocontrolled synthesis of a near-
structural mimic of platensimycin. Org. Lett., 10(17), 3877-3878 (2008). 
266. Zhang CW, Ondeyka J, Zink DL, Burgess B, Wang J, Singh SB. Isolation, structure and 
fatty acid synthesis inhibitory activities of platensimycin B-1-B-3 from Streptomyces 
platensis. Chem. Comm., (40), 5034-5036 (2008). 
278 
 
267. Jang KP, Kim CH, Na SW et al. 7-Phenylplatensimycin and 11-methyl-7-
phenylplatensimycin: more potent analogs of platensimycin. Bioorg. Med. Chem. Lett., 
20(7), 2156-2158 (2009). 
268. Jang KP, Kim CH, Na SW, Kim H, Kang H, Lee E. Isoplatensimycin: Synthesis and 
biological evaluation. Bioorg. Med. Chem. Lett., 19(16), 4601-4602 (2009). 
269. Maras N, Anderluh PS, Urleb U, Kocevar M. Simple synthesis of 3-acetamido-beta-
resorcylic acids as potential FabF and FabH inhibitors without using protecting groups. 
Synlett., (3), 437-440 (2009). 
270. McNulty J, Nair JJ, Capretta A. A synthesis of sulfonamide analogs of platensimycin 
employing a palladium-mediated carbonylation strategy. Tetrahedron Lett., 50(28), 4087-
4091 (2009). 
271. Patra M, Gasser G, Pinto A et al. Synthesis and biological evaluation of chromium 
bioorganometallics based on the antibiotic platensimycin lead structure. Chem. Med. 
Chem., 4(11), 1930-1938 (2009). 
272. Shen HC, Ding FX, Singh SB et al. Synthesis and biological evaluation of platensimycin 
analogs. Bioorg. Med. Chem. Lett., 19(6), 1623-1627 (2009). 
273. Wang J, Lee V, Sintim HO. Efforts towards the identification of simpler platensimycin 
analogues – The total synthesis of oxazinidinyl platensimycin. Chem. Eur. J., 15, 2747 
(2009). 
274. Zhang C, Ondeyka J, Herath K et al. Platensimycin and platencin congeners from 
Streptomyces platensis. J. Nat. Prod., ASAP (2011). 
275. Barykina OV, Rossi KL, Rybak MJ, Snider BB. Synthesis and antibacterial properties of 
(–)-nor-platencin. Org. Lett., 11(22), 5334-5337 (2009). 
276. Tiefenbacher K, Gollner A, Mulzer J. Syntheses and Antibacterial P operties of iso-
Platencin, Cl-iso-Platencin and Cl-Platencin: Identification of a New Lead Structure. 
Chem. Eur. J. , ASAP (2010). 
277. Zhang CW, Ondeyka J, Guan ZQ et al. Isolation, structure and biological activities of 
platensimycin B-4 from Streptomyces platensis. J. Antibiotics, 62(12), 699-702 (2009). 
278. Wright HT, Reynolds KA. Antibacterial targets in fatty acid biosynthesis. Curr. Opin. 
Microbiol., 10(5), 447-453 (2007). 
279. Tiefenbacher K, Mulzer J. Synthesis of platensimycin. Angew. Chem. Int. Ed., 47(14), 
2548-2555 (2008). 
280. Nicolaou KC, Chen JS, Edmonds DJ, Estrada AA. Recent advances in th  chemistry and 
biology of naturally occurring antibiotics. Angew. Chem. Int. Ed., 48(4), 660-719 (2009). 
279 
 
281. Lu X, You Q. Recent advances on platensimycin: a potential antimicrobial agent. Curr. 
Med. Chem., 17(12), 1139-1155 (2010). 
282. Palanichamy K, Kaliappan KP. Discovery and syntheses of "superbug challengers"-
platensimycin and platencin. Chem. Asian J., 5(4), 668-703 (2010). 
283. Hong SH, Sanders DP, Lee CW, Grubbs RH. Prevention of undesirabl isomerization 
during olefin metathesis. J. Am. Chem. Soc., 127, 17160 (2005). 
284. Hong SH, Wenzel AG, Salguero TT, Day MW, Grubbs RH. Decomposition of 
Ruthenium Olefin Metathesis Catalysts. J. Am. Chem. Soc., 129, 7961 (2007). 
285. Cherest M, Felkin H, Prudent N. Torsional strain involving partial bonds. 
Stereochemistry of lithium aluminium hydride reduction of some simple open-chain 
ketones. Tetrahedron Lett., 18, 2199-2200 (1968). 
286. Cherest M, Felkin H. Torsional strain involving partial bonds. Steric course of reaction 
between allyl magnesium bromide and 4-t-butyl-cyclohexanone. Tetrahedron Lett., 18, 
2205-2206 (1968). 
287. Mengel A, Reiser O. Around and beyond Cram's rule. Chem. Rev., 99(5), 1191-1223 
(1999). 
288. Mehta G, Khan FA. Electronic control of Pi-facial selectivities in nucleophilic additions 
to 7-norbornanones. J Am. Chem. Soc., 112(16), 6140-6142 (1990). 
289. Mehta G, Khan FA, Ganguly B, Chandrasekhar J. Importance of orbital and electrostatic 
interactions in determining Pi-facial selectivities in nucleophilic additions to 
endosubstituted bicyclo[2.2.2]octan-2-ones. Chem. Comm., (23), 1711-1712 (1992). 
290. Hahn JM, Lenoble WJ. Strongly enhanced stereoselectivity in the reduction of 5-
substituted adamantanones by substitution of C5 by positive nitrogen. J. Am. Chem. Soc., 
114(5), 1916-1917 (1992). 
291. Halterman RL, McEvoy MA. Diastereoselectivity in the reduction of sterically unbiased 
2,2-diarylcyclopentanones. J Am. Chem. Soc., 112(18), 6690-6695 (1990). 
292. Cieplak AS. Stereochemistry of nucleophilic-addition to cyclohexanone - the importance 
of 2-electron stabilizing interactions. J. Am. Chem. Soc., 103(15), 4540-4552 (1981). 
293. Cieplak AS, Tait BD, Johnson CR. Reversal of Pi-facial diastereoselection upon 
electronegative substitution of the substrate and the reagent. J. Am. Chem. Soc., 111(22), 
8447-8462 (1989). 
294. The reductive amination was conducted in the polar protic solvent, MeOH; therefore 
dipole minimization might not play as great a role in product distribution. 
280 
 
295. Wang J, Sintim HO. Dialkylamino-2,4-dihydroxybenzoic Acids as Easily Synthesized 
Analogues of Platensimycin and Platencin with Comparable Antibacteri l Properties. 
Chem. Eur. J., 17(12), 3352-3357 (2011). 
296. Alhamadsheh MM, Musayev F, Komissarov AAet al. Alkyl-CoA disulfides as inhibitors 
and mechanistic probes for FabH enzymes. Chem. Biol., 14(5), 513-524 (2007). 
297. Yu EW, Aires JR, Nikaido H. AcrB multidrug efflux pump of Escherichia coli: 
composite substrate-binding cavity of exceptional flexibility generates its extremely wide 
substrate specificity. J. Bacteriol., 185(19), 5657-5664 (2003). 
298. Gaussian 09, Revision A02. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; 
Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. 
A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; 
Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; 
Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; J. A. Montgomery, 
J.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; 
Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. 
C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; 
Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; 
Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; 
Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; 
Dapprich, S.; Daniels, A. D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, 
D. J.; Gaussian, Inc., Wallingford CT, 2009.  
299. Kumagai Y, Matsuo J, Hayakawa Y, Rikihisa Y. Cyclic di-GMP signaling regulates 
invasion by Ehrlichia chaffeensis of human monocytes. J. Bacteriol., 192(16), 4122-4133 
(2010). 
300. Egli M, Gessner RV, Williams LD et al. Atomic-resolution structure of the cellulose 
synthase regulator cyclic diguanylic acid. Proc. Natl. Acad. Sci. USA, 87(8), 3235-3239 
(1990). 
301. Xu Y, Kool ET. Chemical and enzymatic properties of bridging 5'-S-phosphorothioester 
linkages in DNA. Nucleic Acids Res., 26(13), 3159-3164 (1998). 
302. Smietana M, Kool ET. Efficient and simple solid-phase synthesis of short cyclic 
oligodeoxynucleotides bearing a phosphorothioate linkage. Angew. Chem. Int. Ed. Engl., 
41(19), 3704-3707; 3523 (2002). 
303. Rybakov VN, Rivkin MI, Kumarev VP. Nucleic Acids Res., 9, 189-201 (1981). 
304. Chladek S, Nagyvary J. . Am. Soc. Chem., 94, 2079-2084 (1972). 
281 
 
305. Cosstick R, Vyle JS. Nucleic Acids Res., 18, 829-835 (1990). 
306. Mag M, Lüking S, Engels JW. Nucleic Acids Res., 19, 1437-1441 (1991). 
307. Vyle JS, Connolly B, Kemp D, Cosstick R. Biochemistry, 31, 3012-3018 (1992). 
308. Kuimelis RG, McLaughlin LW. Cleavage properties of an oligonucleotide containing a 
bridged internucleotide 5'-phosphorothioate RNA linkage. Nucleic Acids Res., 23(23), 
4753-4760 (1995). 
309. Kuimelis RG, McLaughlin LW. Ribozyme-mediated cleavage of a substrate analogue 
containing an internucleotide-bridging 5'-phosphorothioate: evidence for the single-metal 
model. Biochemistry, 35(16), 5308-5317 (1996). 
310. Weinstein LB, Earnshaw DI, Cosstick R, Cech TR. J. Am. Soc. Chem., 118, 10341–
10350 (1996). 
311. Liu X, Reese CB. Tetrahedron Lett., 37, 925–928 (1996). 
312. Krasteva PV, Fong JC, Shikuma NJ et al. Vibrio cholerae VpsT regulates matrix 
production and motility by directly sensing cyclic di-GMP. Science, 327(5967), 866-868 
(2010). 
313. De N, Navarro MV, Raghavan RV, Sondermann H. Determinants for he activation and 
autoinhibition of the diguanylate cyclase response regulator WspR. J. Mol. Biol., 393(3), 
619-633 (2009). 
314. Ando I. Temperature effect of 1H NMR chemical shifts of poly(vinyl chloride). Die 
Makromolekulare Chemie, 179, 2663-2665 (1978). 
315. Zhao J, Veliath E, Kim S, Gaffney BL, Jones RA. Thiophosphate analogs of c-di-GMP: 
impact on polymorphism. Nucleosides Nucleotides Nucleic Acids, 28(5), 352-378 (2009). 
316. Larsson A, Carlsson C, Jonsson M, Albinsson B. Characterization of the binding of the 
fluorescent dyes Yo and Yoyo to DNA by polarized-light spectrosopy. J. Am. Chem. 
Soc., 116(19), 8459-8465 (1994). 
317. Netzel TL, Nafisi K, Zhao M, Lenhard JR, Johnson I. Base-content d pendence of 
emission enhancements, quantum yields, and lifetimes for cyanine dyes bound to double-
strand DNA: Photophysical properties of monomeric and bichromophoric DNA stains. J. 
Phys.Chem., 99(51), 17936-17947 (1995). 
318. Beyhan S, Bilecen K, Salama SR, Casper-Lindley C, Yildiz FH. Regulation of rugosity 
and biofilm formation in Vibrio cholerae: comparison of VpsT and VpsR regulons and 
epistasis analysis of vpsT, vpsR, and hapR. J. Bacteriol., 189(2), 388-402 (2007). 
319. Chan C, Paul R, Samoray D et al. Structural basis of activity and allosteric control of 
diguanylate cyclase. Proc. Natl. Acad. Sci. USA, 101(49), 17084-17089 (2004). 
282 
 
320. Tchigvintsev A, Xu X, Singer Aet al. Structural insight into the mechanism of c-di-GMP 
hydrolysis by EAL domain phosphodiesterases. J. Mol. Biol., 402(3), 524-538). 
321. Hickman JW, Tifrea DF, Harwood CS. A chemosensory system that regulates biofilm 
formation through modulation of cyclic diguanylate levels. Proc. Natl. Acad. Sci. USA, 
102(40), 14422-14427 (2005). 
322. Remminghorst U, Rehm BH. Alg44, a unique protein required for alginate biosynthesis 
in Pseudomonas aeruginosa. FEBS Lett., 580(16), 3883-3888 (2006). 
323. Kulasekara HD, Ventre I, Kulasekara BR, Lazdunski A, Filloux A, Lory S. A novel two-
component system controls the expression of Pseudomonas aeruginosa fimbrial cup 
genes. Mol. Microbiol., 55(2), 368-380 (2005). 
324. Kotaka M, Dutta S, Lee HC et al. Expression, purification and preliminary 
crystallographic analysis of Pseudomonas aeruginosa RocR protein. Acta Crystallogr. 
Sect. F Struct. Biol. Cryst. Commun., 65(Pt 10), 1035-1038 (2009). 
325. Rao F, Qi Y, Chong HS et al. The functional role of a conserved loop in EAL domain-
based cyclic di-GMP-specific phosphodiesterase. J. Bacteriol., 191(15), 4722-4731 
(2009). 
326. Bloomfield V, Crothers D, Tinoco I. Nucleic Acids. (University Science Books, 
California, 1999). 
327. Egli M, Gessner RV, Williams LD et al. Atomic-resolution structure of the cellulose 
synthase regulator cyclic diguanylic acid. Proc. Natl. Acad. Sci. USA, 87(8), 3235-3239 
(1990). 
328. Williams AA, Darwanto A, Theruvathu JA, Burdzy A, Neidigh JW, Sowers LC. Impact 
of sugar pucker on base pair and mispair stability. Biochemistry, 48(50), 11994-12004 
(2009). 
329. Gaffney BL, Veliath E, Zhao J, Jones RA. One-flask syntheses of c-di-GMP and the 
[Rp,Rp] and [Rp,Sp] thiophosphate analogues. Org. Lett., 12(14), 3269-3271 (2010). 
330. Hsu CYJ, Dennis D, Jones RA. Synthesis and physical characteriztion of bis-3'-5'-cyclic. 
Nucleosides & Nucleotides, 4(3), 377-389 (1985). 
331. Ross P, Mayer R, Weinhouse H et al. The cyclic diguanylic acid regulatory system of 
cellulose synthesis in Acetobacter xylinum. Chemical synthesis and biological activity of 
cyclic nucleotide dimer, trimer, and phosphothioate derivatives. J. Biol. Chem., 265(31), 
18933-18943 (1990). 
332. Hyodo M, Hayakawa Y. An improved method for synthesizing cyclic bis(3'-5')diguanylic 
acid (c-di-GMP). Bull. Chem. Soc. Jpn., 77, 2089-2093 (2004). 
283 
 
333. Kiburu I, Shurer A, Yan L, Sintim HO. A simple solid-phase synthesis of the ubiquitous 
bacterial signaling molecule, c-di-GMP and analogues. Mol. Biosyst., 4(6), 518-520 
(2008). 
334. Zahringer F, Massa C, Schirmer T. Efficient enzymatic production of the bacterial second 
messenger c-di-GMP by the diguanylate cyclase YdeH from E. coli. Appl. Biochem. 
Biotechnol., 163(1), 71-79 (2010). 
335. Ching SM, Tan WJ, Chua KL, Lam Y. Synthesis of cyclic di-nucleotidic acids as 
potential inhibitors targeting diguanylate cyclase. Bioorg. Med. Chem., 18(18), 6657-
6665 (2010). 
336. lyer RP, Egan W, Regan JB, Beaucage SL. 3H-1,2-Benzodithiole-3-one 1,1-dioxide as an 
improved sulfurizing reagent in  the solid-phase synthesis of oligodeoxyribonucleide 
phosphorothioates J. Am. Chem. Soc., 112(3), 1254-1255 (1990). 
337. Wender PA, D'Angelo N, Elitzin VI et al. Function-oriented synthesis: studies aimed at 
the synthesis and mode of action of alpha-alkyldaphnane analogues. Org. Lett., 9(9), 
1829-1832 (2007). 
338. Ii K, Ichikawa S, Al-Dabbagh B, Bouhss A, Matsuda A. Function-oriented synthesis of 
simplified caprazamycins: discovery of oxazolidine-containing uridine derivatives as 
antibacterial agents against drug-resistant bacteria. J. Med. Chem., 53(9), 3793-3813 
(2010). 
339. Nakai Y, Tepp WH, Dickerson TJ, Johnson EA, Janda KD. Function-orieted synthesis 
applied to the anti-botulinum natural product toosendanin. Bioorg. Med. Chem., 17(3), 
1152-1157 (2009). 
340. Wender PA, Verma VA. The design, synthesis, and evaluation of C7 diversified 
bryostatin analogs reveal a hot spot for PKC affinity. Org. Lett., 10(15), 3331-3334 
(2008). 
341. Wender PA, Verma VA, Paxton TJ, Pillow TH. Function-oriented synthesis, step 
economy, and drug design. Acc. Chem. Res., 41(1), 40-49 (2008). 
342. Mooberry SL, Hilinski MK, Clark EA, Wender PA. Function-oriented synthesis: 
biological evaluation of laulimalide analogues derived from a last step cross metathesis 
diversification strategy. Mol. Pharm., 5(5), 829-838 (2008). 
343. Patnaik S, Kumar P, Garg BS, Gandhi RP, Gupta KC. Photomodulation of PS-modified 
oligonucleotides containing azobenzene substituent at pre-selected positions in phosphate 
backbone. Bioorg. Med. Chem., 15(24), 7840-7849 (2007). 
284 
 
344. Di Bussolo V, Fiasella A, Romano MR, Favero L, Pineschi M, Crotti P. Stereoselective 
synthesis of 2,3-unsaturated-aza-O-glycosides via new diastereoi omeric N-Cbz-imino 
glycal-derived allyl epoxides. Org. Lett., 9(22), 4479-4482 (2007). 
345. Meyer DS, Schreiber SL. Acceleration of the Dess-Martin oxidation by water. J. Org. 
Chem. , 59, 7549-7552 (1994). 
346. Sapountzis I, Dube H, Lewis R, Gommermann N, Knochel P. Synthesis of functionalized 
nitroarylmagnesium halides via an iodine-magnesium exchange. J. Org. Chem., 70(7), 
2445-2454 (2005). 
347. Gani D, Young DW. JCS Perkin Trans. 1, 1355-1362 (1985). 
348. Corey EJ, Kim CU. J. Am. Chem. Soc., 94, 7586-7587 (1972). 
349. de Richter RK, Bonato M, Follet M, Kamenka JM. J. Org. Chem., 55, 2855-2860 (1990). 
350. Hayakawa Y, Kawai R, Hirata A et al. Acid/azole complexes as highly effective 
promoters in the synthesis of DNA and RNA oligomers via the phosphoramidite method. 
J. Am. Chem. Soc., 123(34), 8165-8176 (2001). 
351. Brear P, Freeman GR, Shankey MC, Trmcic M, Hodgson DR. Aqueous methods for the 
preparation of 5'-substituted guanosine derivatives. Chem. Commun., (33), 4980-4981 
(2009). 
352. Zhang B, Cui Z, Sun L. Synthesis of 5'-deoxy-5'-thioguanosine-5'-monophosphorothioate 
and its incorporation into RNA 5'-termini. Org. Lett., 3(2), 275-278 (2001). 
353. Smietana M, Kool ET. Efficient and simple solid-phase synthesis of short cyclic 
oligodeoxynucleotides bearing a phosphorothioate linkage. Angew. Chem. Int. Ed., 
41(19), 3704-3707; 3523 (2002). 
354. Becke AD. J. Chem. Phys., 98, 5648-5652 (1993). 
355. Lee C, Yang W, Parr RG. Phys. Rev. B, 37, 785-789 (1988). 
356. Wang J, Zhou J, Nakayama S et al. Conservative change to the phosphate moiety of c-di-
GMP remarkably affects its polymorphism and binding abilities to DGC, PDE and PilZ 
proteins. Unpublished work. 
357. Keresztes I, Williard PG. Diffusion-ordered NMR spectroscopy (DOSY) of THF solvated 
n-butyllithium aggregates. J. Am. Chem. Soc. 122, 10228-10229 (2000). 
358. Altieri AS, Hinton DP, Byrd RA. Association of biomolecular systems via pulsed-field 
gradient NMR self-diffusion measurements. J. Am. Chem. Soc. 117, 7566-7567 (1995). 
359 Cohen Y, Avram L, Frish L. Diffusion NMR spectroscopy in supramolecular and 
combinatorial chemistry: An old parameter - New insights." Angew. Chem. Int. Ed. 44, 
520-554 (2005). 
